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ABSTRACT 
Ryan R. Gordon 
A systems genetics analysis of metastatic mammary cancer development in mice fed 
varying levels of dietary fat 
(Under the direction of Daniel Pomp) 
 
High dietary fat intake and/or obesity may increase the risk of susceptibility to certain 
forms of cancer. To study the interactions of dietary fat, obesity, and metastatic mammary 
cancer, a population of F2 mice cosegregating obesity quantitative trait loci (QTL) and the 
MMTV-PyMT transgene was created. The mice were fed either a very high-fat or a matched-
control-fat diet, and evaluated for growth, body composition, age at mammary tumor onset, 
tumor progression, and pulmonary metastases development. Single nucleotide polymorphism 
(SNP) genotyping across the genome facilitated analyses of QTL and QTL by diet interaction 
effects. To further investigate the complex genetic architecture that modifies mammary 
cancer and metastasis, expression profiles of axillary tumors were characterized with the 
Illumina Mouse-6 whole genome sentrix arrays. Using a systems-based analysis pipeline 
developed in R, we conducted a genome-wide expression QTL (eQTL) analysis was 
conducted. In addition, network and pathway QTL analyses for mammary tumors that have 
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developed in the presence of varying degrees of obesity, and during exposure to high or 
normal fat diets.  
Results demonstrated that mice fed a high-fat diet are not only more likely to 
experience decreased mammary cancer latency but they also have increased tumor growth 
and occurrence of pulmonary metastases over an equivalent time. We identified 25 modifier 
loci for mammary cancer and pulmonary metastasis, likely representing 13 unique loci after 
accounting for pleiotropy, as well as novel QTL x diet interactions at a majority of these loci. 
Transciptome mapping revealed several candidate genes potentially underlying both tumor 
and metastasis QTL. These candidates were subsequently prioritized using multiple analytic 
approaches, including but not limited too causality testing, copy number variation analysis 
and database evaluations. 
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INTRODUCTION 
Significance 
According to National Institute of Health statistics for the US, breast cancer is the 
most common cancer type and accounts for the second leading cause of cancer-related deaths 
in women, excluding skin cancers (National-Cancer-Institute 2005). Although breast cancer 
is thought to be a disease that primarily affects women, about 1% of all breast cancer cases 
diagnosed occur in men. It has been estimated that in 2009, 192,370 women and 1,990 men 
in the United States will be diagnosed with some form of breast cancer and that over 40,170 
women and 450 men will die of this disease (American-Cancer-Society 2009), typically from 
secondary metastatic disease (Sporn 1996). The treatment and research of this disease costs 
the United States on average $8.1 billion a year (National Cancer Institute 2007). 
Additionally, this disease has a significant global impact, as indicated by the estimate that 
each year breast cancer causes 502,000 deaths worldwide (World-Health-Organiziation 
2006).  
Breast cancer is an extremely complex disease contributed to by a combination of 
environmental and genetic pressures. A substantial amount of effort has been expended in the 
attempt to identify the associated risk factors of breast cancer; however, the majority of 
underlying mechanisms that result in this altered disease state still remain unclear. While 
some successful attempts to understand the genetic predisposition to mammary cancer have 
been achieved (i.e., identifying small-to-low effect familial risk factors), support for 
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interactions between environmental components, such as dietary fat, and cancer have been 
less fruitful. The purpose of this work was to test the hypothesis that mice predisposed to 
mammary tumor development and challenged with either high or normal levels of dietary fat 
will experience variability in the pathogenesis of mammary cancer as a result of variations in 
genetic predisposition, gene expression, and somatic mutations. 
 
Breast cancer and metastasis paradigm 
The majority of breast cancer cases begin as aberrant cellular growths in the ducts or 
lobules of the mammary glands (American-Cancer-Society 2009). Multiple factors that alter 
breast cancer risk exist including, but are not limited to, diet (Murtaugh et al. 2008), breast 
feeding (Huo et al. 2008), age at first pregnancy, parity, and family history (Zografos et al. 
2004). Differential susceptibility to breast cancer is thought to be mediated by three different 
classes of cancer modifiers: rare high-penetrance cancer-associated alleles, rare genomic 
mutations that confer intermediate risk, or common low penetrance polygenes (Turnbull and 
Rahman 2008). While mutations in genes like BRCA1, BRAC2, TRP53 and PTEN can result 
in increased breast cancer risk (King et al. 2003; Rohan et al. 2006; Song et al. 2006; Walsh 
et al. 2006), these inherited alleles contribute to only about 15-20% of all breast cancers 
(Balmain et al. 2003), suggesting that a polygenic etiology is responsible for the majority of 
breast cancer cases. In most cancer cases the primary tumor is considered nonfatal and can be 
readily treated by its surgical removal. However, in many instances as tumor growth 
progresses, abnormal cells invade the lymphatic system or other vasculature and spread 
(metastasize) to distant sites in the body, such as the brain, bones, and lungs. These 
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secondary cancers are far more difficult to treat and typically result in mortality (Murphy 
2001). 
 The ability of a tumor to metastasize is an inefficient process (Chambers et al. 2002) 
mediated by a series of steps which ultimately allow the carcinogenic cells to escape and 
survive beyond the site of the primary tumor. As a tumor grows its energy requirements 
increase along with its need for additional vasculature (Lunt et al. 2009). The process of 
angiogenesis provides the tumor access to oxygen, nutrients and an outlet to eliminate waste 
products (Carmeliet and Jain 2000). This newly formed vasculature in turn, provides a route 
for metastatic cells to escape the primary tumor and pass into the general circulation 
(Carmeliet and Jain 2000). Additionally, the disruption of the cell-to-cell adhesion properties 
of the tissue surrounding the tumor, via secreted proteases, may allow the cancer cells to 
intravasate into the lymphatic or circulatory systems (Bogenrieder and Herlyn 2003; 
Kroemer and Pouyssegur 2008). Circulation is a harsh environment and most cancer cells 
undergo anoikis once they become detached from the extracellular matrix (Steeg 2006). 
Therefore, it is critical for metastasizing cells to protect themselves against programmed cell 
death until they are able to enter an arrested state. Alterations in gene expression of the 
metastatic cells may contribute to this process (Douma et al. 2004; Geiger and Peeper 2005; 
Howard et al. 2008; Zhan et al. 2004); however, the complete anti-anoikis mechanisms are 
not yet known.  
 Multiple mechanisms exist by which metastatic cells can escape from circulation. 
One possibility is for the cells to arrest themselves by becoming lodged in capillaries that are 
too small to pass through (Steeg 2006). These cells may also non-specifically bind to 
coagulation factors such as fibrinogen and fibrin, which increases the likelihood that they 
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will become lodged (Chambers et al. 2002). Additionally, the carcinogenic cells may take an 
active role in their arrest by secreting tumor-derived endothelial-cell adhesion molecules, 
which allow the cells to bind to the interior surface of the vessels (Glinskii et al. 2005). Once 
arrested the cells can extravasate the endothelium and begin their attempts to colonize at new 
locations (Miles et al. 2008). The ability to survive in a new tissue/organ environment 
requires that the surrounding conditions are optimal for growth, the cells are able to protect 
themselves from apoptosis, and that the cells are able to stimulate angiogenesis (Chambers et 
al. 2002).         
 
 
Figure 1.1: Schemata of the stages of the metastatic process (Lunt et al. 2009) 
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From a genetic standpoint, three contrasting paradigms for metastatic cancer currently 
exist: progression, initiation, and the predisposition models. The progression model suggests 
that the cancer’s ability to metastasize is a rare occurrence during the cancer’s progression in 
a population of cells due to random mutations and epigenetic alterations (Nowell 1976). The 
initiation model, which was derived from expression profiling, follows the belief that 
mutations that occur during early development of the primary tumor are responsible for 
metastatic potential (Ramaswamy et al. 2003). However, existing cancer data cannot be 
explained by either of these two models alone, and as a result a third model (predisposition) 
may be more appropriate (Threadgill 2005). The predisposition model explains that an 
individual’s susceptibility to metastatic cancer is a direct result of his/her genetic makeup. In 
layman’s terms, the cancer’s ability to spread to distant sites in the body is facilitated by 
inherited genes. While multiple genes that contribute to metastatic processes have been 
characterized (Nguyen and Massague 2007), these most likely only represent a small fraction 
of those involved in the metastatic cancer process. Additionally, an estimated 60-70% of 
patients have progressed to metastatic disease by the time of their diagnosis (Eccles et al. 
1994). Further elucidation of the genetic underpinnings influencing metastatic cancer is 
essential for decreasing cancer mortality. Therefore, in this dissertation further 
characterization of the genetic architecture altering the metastatic breast cancer processes 
will be performed. 
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Obesity and Mammary Cancer 
Obesity costs the U.S. ~75 billion dollars annually in associated health costs 
(Finkelstein et al. 2004). Obesity occurs when energy intake exceeds energy expenditure over 
a long period of time resulting in the storage of reserved energy as excessive adipose.  
According to the American Obesity Association (2005), 64.5 percent (about 127 million) of 
the adult American population is overweight or obese, and each year obesity contributes to 
an excess of 300,000 deaths in the US. Many of these deaths are through comorbidities, 
including those related to increased risk of cardiovascular disease, type II diabetes, and 
certain forms of cancer. Though many monogenic models of obesity exist in mice and in 
humans (see (Rankinen et al. 2006)), obesity is primarily a complex disease. As such, many 
factors may influence an individual’s risk of becoming obese, ranging from lifestyle (e.g. 
diet) to genetic predisposition, as well as interaction effects between genotype and 
environment.   
In the past few decades an increasing amount of attention has been spent trying to 
dissect the complex interaction occurring between obesity and cancer etiologies. Evidence 
suggests that a strong correlation exists between increasing levels of adiposity and increased 
risk for the development of breast cancer among postmenopausal women (Agnoli et al. 2009; 
Honda et al. 1998; Lahmann et al. 2004; Reeves et al. 2007). The evidence supporting a link 
between obesity and premenopausal breast cancer is less clear-cut. However, given the 
observation of Friedenreich et al. (2002) that postmenopausal breast cancer risk was highly 
associated with excess weight gain over a 20-yr period, excess body fat throughout one’s life 
appears to have negative breast health implications (Santen et al. 2007). This association 
appears to be further supported by findings that a link not only exists between obesity and 
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breast cancer in postmenopausal women, but also between weight gain over an extended 
period of time and the increased incidence of breast cancer as well (Feigleson et al. 2004). 
Changes in the concentrations of serum estrogen have been established to alter the 
risk for developing breast cancer (Hankinson et al. 1998; Kaaks et al. 2005), with higher 
levels typically associated with increased disease risk (Eliassen et al. 2006; Key et al. 2003). 
Links have been reported between increased adiposity and higher levels of estrogenic 
compounds among postmenopausal women (Lukanova et al. 2004; McTiernan et al. 2006). 
This increased production of estrogenic compounds is thought to be the result of aromatase 
conversion of androstenedione, produced in the adrenal gland, to estrone (Bray 2002). Given 
that this rate of estrone production is directly related to the size of the adipose deposits, it is 
potentially a significant source of estrogenic compounds, particularly in postmenopausal 
women (Bray 2002). This association between obesity and circulating estrogens has also 
been confirmed amongst postmenopausal breast cancer survivors as well, in which obesity 
was linked to higher levels of estrone and estradiol and, ultimately, to increased risk for a 
recurrence of cancer (Calle and Thun 2004; McTiernan et al. 2003).  
Not only has obesity been implicated in increasing one’s risk for breast cancer, 
excessive fat accumulation is also believed to lead to a poorer prognosis for survival. 
Individuals who are obese are more likely to have cancer that has progressed to more 
aggressive later stages at the time of diagnosis (Cui et al. 2002). This advanced stage of 
cancer is directly correlated to a decreased chance of survival (National-Cancer-Institute 
2005). Several large prospective studies have confirmed the link between a higher BMI, or 
higher waist-to-hip ratio, and increased breast cancer mortality (Borugian et al. 2003; Calle et 
al. 2003; Petrelli et al. 2002; Whiteman et al. 2005). These findings most likely occur, 
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partially because of the difficulty associated with and delay in detecting a tumor in obese 
women compared to women with less body fat (Oestreicher et al. 2002). This late diagnosis 
may lead to proliferation and progression of more advanced tumors and an overall greater 
tumor burden at the time of detection (Berclaz et al. 2004; Demirkan et al. 2007). 
Additionally, it has been observed that obese patients have a higher incidence of lymph node 
involvement as compared to patients of normal weight (Daniell 1988), reinforcing this link 
between obesity and metastatic cancer development. 
A mechanistic insight into the obesity and metastatic cancer development cancer 
paradigm may come directly from the adipocyte microenvironment. Inflammatory proteins, 
such as IL-6, produced in response to the inflammation associated with obesity help promote 
the angiogenic properties of a tumor by stimulating the production of vascular endothelial 
growth factor (VEGF). VEGF is an adipokine that is a well established promoter of the 
vasculariztion of mammary tumors (Rega et al. 2007). Leptin, another adipokine positively 
correlated with increased adipose stores appears to be a potent mediator of angiogenesis as 
well (Vona-Davis and Rose 2009). Whereas a reduction in the circulating levels of 
adiponectin, an adipokine negatively correlated with increasing adiposity (Weyer et al. 
2001), can have a negative impact of mammary tissue health. This negative impact is 
accomplished by promoting both tumor onset and tumor growth (Lam et al. 2009). 
Additionally, excess adipose tissue can result in an increase in the circulating levels of matrix 
metalloproteinase 2 and 9 (Bouloumie et al. 2001), both of which can contribute to the 
disruption of the cell-to-cell adhesion properties of the tissue surrounding a tumor. This 
disruption, as pointed out earlier, can allow the cancer cells to intravasate into the lymphatic 
or circulatory systems (Bogenrieder and Herlyn 2003; Kroemer and Pouyssegur 2008). 
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Ultimately, each one of these processes could individually or synergistically contribute to the 
increased mortality associated with the obese state. 
 
Dietary fat and breast cancer 
A complex relationship between diet and genetics underlies breast cancer 
susceptibility. Whereas genetic predisposition to mammary cancer has been confirmed by 
identification of multiple, small-to-low effect familial risk factors, the evidence connecting 
dietary components to cancer susceptibility has been limited and inconsistent. Links between 
diet and incidence of breast cancer have gained increasing attention (Key et al. 2004) and a 
broad spectrum of dietary components ranging from alcohol consumption (Lew et al. 2009; 
Terry et al. 2006) to fiber intake (Cade et al. 2007) have been investigated. To date the 
association between total dietary fat and breast cancer risk has produced conflicting results. 
While some studies have shown a positive association between fat intake and breast cancer 
(Cho et al. 2003; Lee et al. 2005; Thiebaut et al. 2007), others have failed to find such an 
association (Kim et al. 2006; Wakai et al. 2005). In mouse models this relationship seems to 
be much clearer, as observed in the original studies in this field by Tannenbaum (1942). 
Tannenbaum found that mice fed a high-fat diet experienced a higher frequency of mammary 
cancer as compared to the low-fat fed controls. This relationship has been subsequently 
confirmed many times in mice (e.g. (Cleary et al. 2004)), but the underlying mechanisms 
remain largely unknown.  Furthermore, given that it was recently estimated that 
approximately 34% of the total energy in the American diet is derived from fat (Kerver et al. 
2006), a strong need to clarify this relationship in an experimental model exists.  Therefore, 
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using the unique mouse population that we developed, further investigation of how dietary 
fat modulates cancer susceptibility and progression is proposed. 
 
Mouse models of breast cancer 
Mouse models have been used to gain a better understanding of the inherited genetic 
and environmental determinants for cancer risk in the human population (Callahan and Smith 
2000; Cavanna et al. 2007). The use of mouse models is mainly due to the striking 
similarities between biological and genetic processes related to cancer development and 
progression in humans and mice (e.g. (Lin et al. 2003)). Unlike in the human population, 
rigid control of all the environmental factors allowing for the systematic removal of external 
influences is possible (Balmain 2002). Additionally, evaluation of the environmental 
components of the breast cancer paradigm (i.e. diet) through selective inbreeding, which can 
provide us with a genetically homogenous research population, is possible. By utilizing 
inbred populations of mice, many other investigators have made substantial findings in the 
fields of breast cancer (Hennighausen 2000; Park et al. 2003; Thomas et al. 1996) and other 
polygenic diseases (Bower et al. 2006; Cheverud et al. 2004; Korstanje and DiPetrillo 2004; 
Liu et al. 2007a).  
Whereas mouse models can provide us with valuable information in regards to cancer 
processes, they have their limitations as well. A few essential differences between mouse 
models and humans are as follows; carcinogenic risk factors often differ among mice and 
humans, mouse tumors are commonly mesodermal sarcomas while tumors in humans are 
typically epithelial carcinomas, and the sites of spontaneous tumor formation can vary 
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(Anisimov et al. 2005).  However, in the case of breast cancer mice appear to develop cancer 
in the same general locations with a remarkably similar histopathological course as that 
observed in humans (Anisimov et al. 2005; Balmain and Harris 2000). Regardless of the 
limitations associated with using mice to investigate human diseases, mice remain an 
incredibly valuable resource in complex trait dissection. 
 
Quantitative trait analysis  
In complex genetic disorders, phenotypes alone do not allow us to dissect the 
underlying genetic problems, since typically phenotypes represent end-points that can 
potentially be reached in many ways (Gusella and MacDonald 2002). For essentially any 
disorder, phenotypes differ either qualitatively or quantitatively depending on the underlying 
genetic architecture (Gusella and MacDonald 2002). One specific technique for determining 
the genetic underpinnings for any given trait is the mapping of quantitative trait loci (QTL). 
QTL mapping has been described as the first step toward the identification of genes and 
casual polymorphisms for traits of importance in agriculture and human medicine (Seaton et 
al. 2002). This procedure utilizes an approach with no prior assumptions about the potential 
importance of specific genes or genetic regions. Instead, the results of the scan are used in an 
unbiased manner to identify chromosomal segments which are highly correlated with a 
particular phenotype. These regions, in turn, become the focus of more intensive follow-up 
analyses to uncover the underlying genes (Comuzzie and Allison 1998). The simplest and 
most efficient way to detect QTL is by using inbred-line crosses because the limited genetic 
variation within strain. Therefore, by crossing two inbred parental lines, the resulting 
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population will exhibit a fixed difference between every marker and trait locus. Thus, all 
linked loci in the F1 generation used to create the mapping population are in linkage 
disequilibrium (Slate 2005). In the subsequent F2 generation, QTL then represent genetic 
variation between the founder lines which are fixed for alternative alleles at the QTL (Seaton 
et al. 2002).   
The method of QTL mapping has proven to be an efficient platform for aiding in the 
process of understanding complex traits, including obesity and a variety of diet-related 
cancers. The usefulness of this method is particularly evident in the review by Dragani 
(2003), in which he describes the detection of over 100 QTL for a wide spectrum of cancer 
phenotypes. While QTL analysis is a beneficial tool for the dissection of complex traits, like 
any technology, associated limitations also exist. The successful completion of a QTL 
analysis requires large crosses consisting of hundreds and possibly thousands of animals, the 
tedious collection of relevant phenotypes, and the detection of informative loci spanning the 
entire genome (Singer et al. 2004). Yet, the most recognized limitation is the long and 
arduous processes involved in making the transition from a QTL to the underlying gene or 
genes of interest (Flint et al. 2005; Miles and Wayne 2008; Moore and Nagle 2000). 
Regardless of the limitations, when used as a starting point, this method still remains very 
useful for dissecting complex traits. Furthermore, with the advent of multiple promising 
analytic techniques, many of the aforementioned roadblocks may be circumvented. 
Therefore, we are proposing to utilize this QTL method as the foundation for our pursuit of 
the genetic architecture of metastatic mammary cancer.  
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Gene expression and eQTL 
Given that QTL analysis are compounded by a substantial roadblock in identifying 
the genes that underlie disease phenotypes, alternative approaches have been taken. Other 
methods such as in vivo selection, gene expression analysis and clinical verification have 
proven to be successful. In a particular experiment, a combination of these techniques was 
used in a mouse model to identify gene sets which predicted if mammary tumors would 
metastasize to the lung (Minn et al. 2005). The gene sets were then evaluated in humans and 
found to be clinically correlated with the development of lung metastasis when expressed in 
the primary tumor (Minn et al. 2005). Ultimately revealing multiple lung metastasis signature 
genes which appear to enhance metastatic growth within breast and the lung, along with a 
subset of metastatic genes that were rarely expressed in the primary tumors but were strongly 
selected for once they reached the lungs (Minn et al. 2005). Successful attempts have been 
made using these methods, but they tend to be labor-intensive and costly relative to their 
ultimate yield. Additionally, While QTL analysis and differential expression can reveal 
pathways, candidate regions and genes potentially linked to disease phenotypes, these 
methods are both independent assessments of the paradigm. As such, it is difficult to infer a 
relationship between the results of the two methods.   
 However, A relatively new approach has been developed with the potential to bridge 
this disconnect by treating the expression of each transcript identified through microarray 
analysis as a quantitative trait. The traits can then be tested for associations with genotypic 
data to develop what is known as an expression QTL (eQTL) (Jansen and Nap 2001; Schadt 
et al. 2003a).  In general, these eQTL are identified in an identical manner as traditional 
QTL. However, because the traits tested are actual transcripts and not endpoint phenotypes 
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(e.g. body weight, body fat, tumor size), the difficult task of assigning an actual gene to the 
QTL is less of an issue. When running an eQTL analysis two distinct classes of loci are 
detected. The first class is loci that map within close proximity to the actual physical location 
of the expressed gene (cis-acting), and the second class is loci which map independently of 
the expressed genes physical location (trans-acting) (Pomp et al. 2008). While trans-acting 
eQTL represent loci controlled by unknown regulators, cis-acting eQTL exhibit self-
regulation (Alberts et al. 2005). Therefore, by comparing or overlaying these cis-acting 
eQTL with locations of traditional phenotypic QTL detected in the same mapping 
population, the potential exists to significantly enrich for candidate genes that are both 
positional and functional in nature (Wang et al. 2007b). The field of research on metastatic 
breast cancer has produced only a few experiments utilizing this multifaceted approach 
(Crawford et al. 2008). A multifaceted approach which combines the traditional technique of 
QTL mapping and the emerging method of eQTL mapping to increase understanding of the 
dietary fat metastatic breast cancer paradigm was utilized in our studies (see following 
chapters). 
 
Copy number variation (CNV) and Chromosomal aberrations 
 Recently a new source of genetic variation that can potentially impact on disease 
processes has been identified, known as copy number variants (CNV). CNV is described as 
segments of DNA that are over or under represented due to insertions/deletions occurring 
naturally over time or acutely due to tissue-specific somatic mutations (Feuk et al. 2006). 
Approximately 12% of the human genome has been estimated to be affected by CNV 
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(Beckmann et al. 2007) and this over/under representation of chromosomal segments can 
have profound influences on the expression of the gene within these afflicted regions. 
Multiple diseases such as Crohn’s disease (Fellermann et al. 2006), lupus (Yang et al. 2007), 
and HIV (Gonzalez et al. 2005) have already been linked in part to CNV. It is plausible that 
CNV may be linked to many common complex diseases such as cancers (Shelling and 
Ferguson 2007), yet currently our knowledge of this paradigm remains limited.  
Taking into account CNV is especially important when analyzing tumor tissue, given 
the substantial amount of evidence linking the accumulation of CNV to cancer pathogenesis 
(de Tayrac et al. 2009; Fridlyand et al. 2006; Reis-Filho et al. 2005; van Beers and Nederlof 
2006; Yusenko et al. 2009). CNV can be classified into two categories, those that are 
inherited (germ-line) and those that are acquired during the replication of cells (somatic). In 
humans, germ-line CNVs are detected across all tissues in both healthy and diseased 
individuals (Shlien and Malkin 2009). The presence of CNV in genomic regions encoding 
cancer modifiers can lead to increased risk for the development of cancer (Albertson et al. 
2003). Somatic CNV are acquired during DNA replication and are not found uniformly 
through out all tissue types, and their presence can impart a growth advantage to cells 
harboring them, resulting in disease (Greenman et al. 2007). Tsafrir et al. (2006) research 
suggests that as cancer progresses it is possible for tumors to continue acquiring somatic 
CNV, which could potentially alter their metastatic tendencies. To date few, if any, large 
association studies have used this combined approach in the characterization of complex 
diseases. Therefore, CNV will be examined within our population and its association with 
mammary cancer susceptibility and progression will be evaluated.  
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Model Review 
 As previously suggested, the use of animal models to dissect the genetic architecture 
of complex diseases has yielded valuable information. The proposed cross involves M16i and 
FVB, two phenotypically divergent mouse models which have been extensively 
characterized. The following section includes a brief review of the M16 model of obesity and 
a mammary cancer-focused review of the FVB transgenic cancer model. 
M16i an inbred obesity line 
One particular model of interest is the M16, which was derived from the ICR strain 
through 27 generations of selection for weight gain from 3 to 6 weeks of age (Hanrahan et al. 
1973). When fed the same diet, M16 mice will gain weight faster and reach a greater end-
weight than its control line (ICR). M16 mice also appear to be hyperglycemic when 
compared to its control (Allan et al. 2004). The inbred version of the M16, the M16i has been 
used in multiple QTL mapping projects. One project in particular was carried out by creating 
a large F2 intercross between the M16i and its control line (ICR), and this ultimately resulted 
in a large number of QTL being detected (Rocha et al. 2004a, b). Another large intercross 
study utilizing these M16 and ICR strains (Allan et al. 2005) yielded 95 QTL. Of the 95, 39 
QTL had effects on body weight and growth traits, 36 on traits influencing body 
composition, 12 related to energy intake, four linked to feed efficiency, and eight were 
associated with serum leptin, insulin and blood glucose. This strain of mice has also been 
investigated for the impact of environmental components on body size. For example, dietary 
fat was found to significantly increase body weight and adiposity (Allan et al. 2004). 
Recently, this mouse model was investigated for the environmental effect of exercise, which 
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was found to significantly reduce bodyweight after only 6 days of free access to a running 
wheel (Nehrenberg et al. 2009). 
FVB/NJ-TgN(MMTV-PyMT)634Mul 
A transgenic mouse model that has been a widely used to study breast cancer is the 
Polyoma Middle T Oncoprotein (PyMT) mouse. In this model the PyMT antigen is under the 
control of mouse mammary tumor virus LTR (MMTV) which restricts it to the mammary 
epithelium (Guy et al. 1992). Multifocal tumors develop in all mammary glands of females 
and are detectable by palpation at 60 d of age, and by 100 d of age, 85% of the animals 
develop pulmonary metastasis. Furthermore, male carriers of PyMT experience delayed 
tumor latency and overall decreased severity (both decreased tumor size and propensity to 
metastasize) in comparison to females (Lifsted et al. 1998). To verify that the PyMT mouse 
was an appropriate model for breast cancer investigation, given that PyMT does not naturally 
occur in humans, the progression patterns and morphology of their tumors were compared to 
those in humans and were found to be strikingly similar (Lin et al. 2003). Additionally, it has 
been observed that gene expression patterns detected in PyMT-induced tumors share 
common characteristics with those in humans that are associated with poor of survival (Lin et 
al. 2003).  
 The FVB/NJ-PyMT is a mouse model that has played an important role in the cancer 
field for increasing the understanding of mammary cancer and the metastatic processes 
involved. Le Voyer et al. (2000) attempted to assess the basis for the tumor acceleration they 
observed in the FVB/NJ-PyMT I/LnJ F2 population. First they ruled out the possibility that 
the observed change in tumor latency was a result of alterations in the expression of the 
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transgene using western blots. Then a QTL analysis of this backcross revealed two loci, 
Ampt1 and Ampt2, responsible for the tumor acceleration, located on Chromosomes 15 and, 
respectively. The researchers were also able to identify a suggestive locus on Chromosome 7. 
Le Voyer et al. (2001) evaluated the mammary tumors arising in an F1 hybrid 
background (I/LnJ x FVB/N-TgN) that resulted in earlier onset but reduced total tumor mass 
than in the parental strain using quantitative and molecular approaches. Their experiments 
ultimately led to the identification of three loci, designated Mmtg1-3, which are associated 
with tumor growth modification. Both Mmtg1 and 2 mapped to Chromosome 4 which was a 
region that had been previously associated with mammary tumorigenesis.  Mmtg3 mapped to 
the proximal portion of Chromosome 7; this was the same region in which this group had 
previously mapped a potential latency modifier gene. 
Work by Cozma et al. (2002) utilized an approach that combined genetics, genomics 
and bioinformatics to identify interesting candidate genes for the Ampt mammary tumor 
latency modifiers.  By utilizing public databases they were able to identify a large number of 
papers that found genes within the regions similar to those of Ampt1 and 2, Chromosomes 15 
and 9.  The literature search was then further reduced to identify gene pairs that were known 
to interact or to be in a common pathway relating to breast cancer. This literature search led 
to the identification of one particular gene pair of interest, c-Myc and Cdc25A, which was 
tested for tumor response by creating a double-transgenic (PyVT/Myc) mouse model. The 
double-transgenic model displayed early and more aggressive tumor growth, and the data 
collected suggested that c-Myc and Cdc25A are indeed Ampt1 and Ampt2, respectively. 
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Hunter et al. (2001) set out to identify the approximate genomic locations of 
metastasis efficiency genes as a preliminary step for high-resolution mapping and positional 
cloning of genes of interest.  They attempted to identify these phenotypically relevant loci by 
analyzing four different genetic mapping experiments utilizing three inbred strains that 
altered only the metastatic phenotype of the mammary tumor, and one backcross that altered 
tumor growth rate, tumor latency and metastatic efficiency. These analyses lead them to 
identify a significant locus of a metastasis suppressor on the proximal end of Chromosome 
19, designated Mtes1. Other suggestive loci were found on Chromosomes 6, 9, 13 and 17.  
Upon further investigation (Hunter et al. 2001), Mets1 was suggested to co-localize with the 
mouse orthologue of the human breast cancer metastasis suppressor gene, Brms1. 
Park et al. (2005) began to further investigate the underlying genetic components that 
are responsible for metastatic progression, more specifically the Mets1 locus. They 
indentified these genetic factors this by utilizing various methods. The first approached used 
was to determine candidate regions on Chromosome 19 through an evaluation of a multiple 
cross and mapping study previously cited (Hunter et al. 2001). The evaluation resulted in 
identification of five regions of interest in which the researchers were able to seek candidates 
genes, one of which was Sipa1, a gene associated with metastatic progression of human 
prostate cancer. By using bioinformatics and molecular techniques (such as RT-PCR and 
western blot analysis), the investigators were able to eliminate several candidates. However, 
biochemical analysis revealed a polymorphism of interest in Sipa1 and, when further 
evaluated, Sipa1 was considered a strong candidate for one of the genetic polymorphisms 
underlying the Mtes1 locus. When Sipa1 was evaluated in a human cohort, germline 
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polymorphisms of this gene were implicated in modifying the aggressiveness of breast cancer 
(Crawford et al. 2006). 
Recently the primary tumors collected from multiple recombinant inbred mouse 
strains, including those derived from FVB-PyMT, were used to generate expression profiles 
for metastatic signature genes (Yang et al. 2005). These expression profiles were 
subsequently used to identify relevant metastatic eQTL mapping to the three regions of 
interest on Chromosomes 7, 17 and 18 (Crawford et al. 2007). The locus on Chromosome 17 
was further investigated because it encompassed ribosomal RNA processing 1 homolog B 
(Rrp1b), a factor known to interact with Sipa1 and shown to be highly correlated with 
metastasis-predictive gene expression. Additional analyses revealed that Rrp1b may function 
as a modifier of tumor progression and as a metastasis and metastatic predictive marker for 
humans (Crawford et al. 2007). By combining the aforementioned gene expression results 
with additional analyses, Crawford et al. (2008) were able to generate a transcriptional 
network, the Diasporin Pathway, which may be able to predict the metastatic potential of 
tumor in both humans and mice. 
 
Summary 
In summary, breast cancer is a complex disease resulting from a combination of, and 
interaction between, environmental and genetic factors. It is thought that differential genetic 
susceptibility to breast cancer is mediated by three different types of cancer modifiers: rare 
high-penetrance cancer-associated alleles, rare intermediate penetrance mutations, or 
common low penetrance polygenes. While mutations in genes like BRCA1, BRCA2, TRP53 
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and PTEN can result in increased breast cancer risk, these inherited alleles contribute to only 
15-20% of all breast cancers, suggesting that a polygenic etiology is responsible for the other 
80-85% of breast cancer cases. However, the identity of most of these polygenes has yet to 
be revealed.  
While genetic factors clearly influence breast cancer susceptibility, environmental 
factors an equally important role as well. Links between diet and incidence of breast cancer 
have been reported for a broad spectrum of dietary components. In particular, dietary fat has 
received significant attention, although reports have reached conflicting results. Whereas 
some human studies have shown a positive association between fat intake and breast cancer, 
others have failed to replicate these findings. Given this lack of congruity and the large 
number of individuals afflicted with this disease, a need exists to clarify further the 
relationships between diet and cancer. Furthermore, whereas numerous studies have 
investigated genetic or dietary factors linked to breast cancer, few have focused on the gene x 
diet interactions that are likely to be major contributors to differential risk. Understanding 
how diet might influence expression and effects of these cancer predisposition loci is 
increasingly needed as such genes are identified and used in human diagnostics paradigms. 
With the current analytical techniques available, i.e. QTL/eQTL mapping and CNV analysis, 
it is possible to address these gaps in our knowledge of the genetic underpinnings of 
metastatic breast cancer.  Additionally, given their extensive use in the field of complex trait 
analysis, mouse models utilized in the subsequent research papers are aptly suited for 
investigating the etiology of metastatic breast cancer.  
Finally, in this dissertation the hypothesis that mice predisposed to mammary tumor 
development and challenged with either high or normal levels of dietary fat will experience 
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variability in the pathogenesis of mammary cancer as a result of variations in genetic 
predisposition, gene expression, and copy number variation, will be tested.  The overall goals 
of the dissertation are to characterize the effects of dietary fat on mammary cancer 
phenotypes and elucidate the genetic architecture underlying development, severity and 
metastatic potential of mammary cancer. In addition, the question of how dietary fat interacts 
with susceptibility genes will be assessed. 
 
  
CHAPTER II 
Genotype X Diet Interactions in Mice Predisposed to Mammary Cancer: I.                                
Body Weight and Fat 
 
Ryan Gordon, Kent W. Hunter, Peter Sørensen, Daniel Pomp 
Mamm Genome. (2008) March;19(3):163-78 
 
Abstract: 
High dietary fat intake and obesity may increase susceptibility to certain forms of 
cancer. To study the interactions of dietary fat, obesity and metastatic mammary cancer, we 
created a population of F2 mice cosegregating obesity QTL and the MMTV-PyMT transgene, 
we fed the F2 mice either a very high fat or a matched control fat diet, and we measured 
growth, body composition, age at mammary tumor onset, tumor number and severity, and 
formation of pulmonary metastases. SNP genotyping across the genome facilitated analyses 
of QTL and QTL x diet interaction effects. Here we describe development of the F2 
population (n=615) which resulted from a cross between the polygenic obesity model M16i 
and FVB/NJ-TgN (MMTV-PyMT)634Mul, effects of diet on growth and body composition, 
and QTL and QTL x Diet and/or gender interaction effects for growth and obesity-related 
phenotypes. We identified 38 QTL for body composition traits that were significant at the 
genome-wide 0.05 level, likely representing 9 distinct loci after accounting for pleiotropic 
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effects. QTL x diet and/or gender interactions were present at 15 of these QTL, indicating 
that such interactions play a significant role in defining the genetic architecture of complex 
traits such as body weight and obesity.  
 
Introduction: 
Obesity costs the U.S. ~75 billion dollars annually in associated health costs 
(Finkelstein et al. 2004).  It occurs when energy intake exceeds energy expenditure over a 
long period of time resulting in the storage of reserved energy as excessive adipose.  
According to the American Obesity Association (2005), 64.5 percent (about 127 million) of 
the adult American population is overweight or obese, and each year obesity causes in excess 
of 300,000 deaths in the US.  Many of these deaths are through comorbidities, including 
those related to increased risk of cardiovascular disease, type II diabetes, and certain forms of 
cancer.  Though many monogenic models of obesity exist in mice and in humans (see 
(Rankinen et al. 2006)), obesity is primarily a complex and polygenic trait. As such, there are 
many factors that can influence an individual’s risk of becoming obese, ranging from 
lifestyle (e.g. diet) to genetic predisposition, as well as interaction effects between genotype 
and environment.   
Substantial progress has been made in understanding the genetic underpinnings of 
obesity in mice, and well over 200 quantitative trait loci (QTL) have been mapped for 
various obesity-related phenotypes (Pomp 1997).  Furthermore, genetic variation in response 
to high-fat diet has been well characterized (e.g. (Taylor and Phillips 1997; West et al. 1994a; 
West et al. 1994b)).  However, while many QTL studies have focused on finding 
chromosomal regions controlling obesity in either normal or high fat diets, much less focus 
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has been placed on examination of QTL x diet interactions by feeding both normal and high 
levels of fat within the same segregating population (e.g. (Cheverud et al. 2004)).  
Links between dietary fat and breast cancer risk have been shown in a meta-analysis 
of epidemiologic research and migration studies from countries of low to high risk for breast 
cancer (Forman 2007).  High fat diet has been studied as a risk factor for mammary tumors in 
mice (e.g. (Cleary et al. 2004; Tannenbaum 1942)), and several genetic modifiers of 
mammary tumor development have been identified in various transgenic mouse models 
(Connelly et al. 2007; Le Voyer et al. 2000; Le Voyer et al. 2001; Liao et al. 2007; Rajkumar 
et al. 2007). However, no studies have reported on diet x QTL interaction effects on 
mammary tumor development and associated metastasis. Understanding how diet might 
influence expression and effects of cancer predisposition loci is increasingly important as 
such genes are identified and used in human diagnostics paradigms (Bild et al. 2006).  
Many patients afflicted with cancer experience cachexia, the loss of both adipose and 
muscle tissue (Tisdale 1997), and as the disease progresses so does the associated wasting 
(Dewys et al. 1980).  This in turn can have serious implications on cancer survivability, and 
some estimates suggest that cachexia is responsible for ~20% of cancer related deaths 
(Tisdale 2002). While many mediators of cachexia have been characterized (for a detailed 
review see (Baracos 2006)) the exact mechanisms of action, which are critical for developing 
treatments, are still not fully understood (Gordon et al. 2005). 
We developed a large F2 population originating from a cross between the polygenic 
obesity model M16i (Allan et al. 2005) and FVB/NJ-TgN(MMTV-PyMT)634Mul, a transgenic 
line that generates aggressive mammary tumors with subsequent pulmonary metastases (Guy 
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et al. 1992). Half the F2 mice harbored PyMT while half did not, and the F2 mice were fed 
either high fat or matched control diets. Overall, our objectives were to evaluate the 
phenotypic effects of dietary fat on growth, body composition and cancer traits and to map, 
in a coordinated fashion, chromosomal positions of predisposition genes (QTL) for obesity 
and cancer and their associated diet x QTL interactions. In this paper we describe the 
population, effects of diet on growth and body composition, and QTL and diet x QTL 
interaction effects for growth and obesity-related phenotypes. In a companion paper we focus 
on cancer phenotypes.  
Materials and Methods: 
Resource Populations: An F2 population (n=615) was generated by crossing M16i, a 
polygenic obesity line (Allan et al. 2005), and FVB/NJ-TgN(MMTV-PyMT)634Mul (PyMT), a 
line transgenic for the Polyoma Middle T Oncoprotein, leading to the development of 
mammary tumors and subsequent pulmonary metastasis (Guy et al. 1992). Since PyMT 
females have impaired reproduction, the initial cross was between M16i females and FVB 
males hemizygous for PyMT. In the F1, males hemizygous for PyMT were crossed to 
females without PyMT to generate the F2 population in four consecutive replicate breeding 
cycles (repeated mating of F1 pairs).  F2 litters were standardized at birth to 10 pups, 
maintaining as many females as possible. Individual mice were identified by toe-clipping at 
postnatal day (d) 12, and toe-clips were used for PCR analysis (Pomp 1991) to identify mice 
hemizygous for the PyMT transgene with the following primers: forward 5’-
AACGGCGGAGCGAGGAACTG-3’: reverse 5’-ATCGGGCTCAGCAACACAAG-3’.  
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F2 mice were weaned at 3 wk of age and randomly assigned, using a random number 
generator, within litter, sex and genotype (PyMT or no PyMT) to receive one of two 
synthetic purified diets at 4 wk of age. Mice designated “high” received a high fat diet 
(Research Diets D12451) that contained 45% of total calories from fat, 20% from protein and 
35% from carbohydrate.  Mice designated “control” received a matched control fat diet 
(Research Diets D12450B) that contained 10% of total calories from fat, 20% from protein 
and 70% from carbohydrates (Tables 1 and 2).  Mice had ad libitum access to feed and water.  
Prior to starting specialized diets all animals received ad libitum access to a standard rodent 
diet (Teklad 8604 Rodent Chow). Total numbers of F2 mice phenotyped within each of the 8 
subclasses ([PyMT, non-PyMT] X [High, Control] X [Male, Female]) are presented in Figure 
1. 
Data collection:  Body weight was measured for each mouse at 3, 6, and 9 wk of age 
and at sacrifice (~11 wk for females, ~14 wk for males).  Body composition was analyzed at 
7 wk of age using dual-energy X-ray absorptiometry (DEXA; GE Lunar PIXImus) while 
mice were anesthetized with Avertin (2,2,2 tribromoethanol, Aldrich), and again at sacrifice 
following CO2 exposure. Age of onset of mammary tumor development in the F2 population 
was evaluated in mice hemizygous for PyMT beginning at 4 wk of age.  Mammary glands 
for each individual were palpated three times a week until age of onset was determined.   
Tissue collection:  Mice were sacrificed at approximately 1200 hours, 3 hr after 
removal of food to increase the accuracy of DEXA measurements by minimizing the amount 
of chow within the stomach.  Blood was collected and the following tissues were dissected 
from all F2 mice and snap frozen in liquid nitrogen: liver, epididymal fat for males, 
perimetrial fat for females (except from females with PyMT due to logistical constraints 
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associated with collecting the mammary tumors), skeletal muscle, hypothalamus, pituitary 
and tail. For F2 mice with PyMT, additional tissues were collected, including one inguinal 
mammary tumor, one axillary mammary tumor, and one lobe of the lung (the other being 
fixed for evaluation of metastases). Liver weight was recorded for all mice, while weights of 
fat pads were recorded for all males and for females lacking PyMT. 
Statistical Analysis:  Proc Mixed from SAS (2002) was used to analyze data for 
effects of diet, PyMT and gender. Models for phenotypic traits measured prior to sacrifice (3, 
6 and 9 wk weights, 7 wk lean mass and percent fat) included fixed effects of diet, gender 
and presence of PyMT, interactions of diet x gender, diet x PyMT and gender x PyMT, and 
random effects of replicate and dam.  Traits measured at time of sacrifice (liver weight, fat 
pad weight, sacrifice weight, total fat, lean mass and percent fat) contained age at sacrifice 
(in days) as an additional covariate.  Liver and fat pad weights were also expressed as a 
percentage of body weight at sacrifice. Correlations (with Bonferroni corrected P-values) 
among all traits were evaluated using the MANOVA procedure within Proc GLM (SAS) 
adjusted for fixed effects of diet, PyMT and gender.  
Genotyping and Linkage Map:  A total of 384 SNPs were genotyped across 552 tail 
DNA samples using a service provider (Illumina, San Diego, CA). These SNPs were selected 
to be relatively evenly spaced across the genome, and because they were predicted to be fully 
informative between M16i and FVB based on previous genotyping in M16 (the progenitor of 
M16i) and FVB (Cervino et al. 2005). No information existed on polymorphisms between 
M16i and FVB for the X chromosome, so only the autosomes were genotyped. The 552 
DNA samples consisted of 2 representative M16i parents, 2 FVB, 2 F1, most F2 animals with 
PyMT (106 males, 158 females), the majority of non-PyMT F2 females (n=178), a large 
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number of non-PyMT F2 males (n=96), and 8 replicate samples (to verify genotyping 
accuracy). Remaining F2 mice (n=77), containing the least relevant phenotypic information, 
were not genotyped due to sample size constraints in the genotyping process.  Total numbers 
of F2 mice genotyped within each of the 8 subclasses are presented in Figure 1. 
Any SNPs found to have allele sharing between the genotyped M16i and FVB 
parental mice were discarded.  All remaining SNPs were tested for deviation from the 
expected 1:2:1 F2 genotypic distribution using chi-square analysis. This revealed 30 SNPs 
exhibiting segregation distortion, localized to three specific genomic regions (MMU1, 
MMU2, MMU3). In all cases the distortion was caused by under-representation of M16i 
alleles. Under the assumption that inbreeding was not complete in these regions for one or 
two of the parental M16i mice, we repeated the analysis after dropping data for these SNPs 
from F2 mice originating from specific M16i parents.  By this method segregation distortion 
was eliminated from the population with loss of only a small amount of data from the 
experiment. 
A linkage map was created using Map Manager QTXb20 (Manly et al. 2001).  
Linkage groups were evaluated for consistency with known physical locations from Ensembl. 
Surplus SNPs (redundant markers) that were in complete linkage disequilibrium were 
removed, yielding a final linkage map consisting of 124 SNPs with average marker spacing 
of 10-15 cM (Table 4). The cM position for the first (proximal) SNP on each chromosome 
was estimated based on its physical location (Build 34) using the formula Mb x 1.6 (Shifman 
et al. 2006). 
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QTL Analyses:  Phenotypic and genotypic data were merged to detect QTL with the 
web-based program QTL Express (Seaton et al. 2002) using the “F2 inbred/Co-dominant 
Marker Analysis” option. One QTL per chromosome was fitted using the genetic model for 
additive plus dominance effects.  Analyses included the additive and dominance effects, 
replicate, PyMT, gender and diet as fixed effects in the model as well as a QTL x diet 
interaction (interaction model).  An additional model was tested for each trait with identical 
components as above but without the interaction term (non-interaction model). To test 
whether QTL x diet interaction effects were significant, the sum of squares error and the 
degrees of freedom for the peak position for each QTL in both the interaction and non-
interaction models were calculated and used to estimate an F statistic.  If the interaction was 
not significant at p < 0.05, the QTL x diet interaction effect was removed from the model.  If 
an interaction was detected, then the mapping population was separated according to diet 
(animals fed either the high fat diet or matched control (lower) fat diet) and reanalyzed 
independently with using the non-interaction model to elucidate the cause of the interaction.  
Similar methods were used to test for gender x QTL interactions. 
Genome-wide significance thresholds for QTL effects were determined using 
permutation testing. A bootstrap procedure was used to estimate confidence intervals for 
QTL positions.  The percentage of phenotypic variation explained by each QTL was 
calculated as follows: [(residual variance of the reduced model) - (residual variance of the 
full model) / residual variance of the reduced model] x 100.  The nonparametric bootstrap 
method described by Lebreton et al., (1998) was used to test for pleiotropy among multiple 
linked QTL. 
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Results:   
F2 Phenotypic Evaluation: No significant differences were found in body weight at 
3 wk of age among groups destined to be fed different diets, or between PyMT genotype 
groups (Figure 2). Male pups were slightly heavier than female pups at weaning.  By 6 wk of 
age males were 29.5% (difference between the two means as a percentage of the lower mean) 
heavier than females (P<.0001), individuals on the high fat diet had a modest 3.6% increase 
in body weight compared to those fed the matched control fat diet (P<.0001), while PyMT 
genotype still had no effect.  At 9 wk of age males were 23.2% heavier than females 
(P<.0001), high fat diet led to a 5.3% (1.9 gram) increase in body weight (P<.0001), and the 
presence of PyMT was associated with a 3.5% increase in body weight (P<.001).  At 
sacrifice (approximately 11 wk for females and 14 wk for males),  there were 8.6% (3.3 
grams) and 8.0% (3.1 grams) increases in body weight for F2 mice fed high fat diet (P<.0001) 
and with PyMT (P<.0001), respectively. No interactions for body weight were detected at 3 
or 6 wk.  The only two way interaction detected for 9 wk weight was for sex x PyMT 
(P<.05), in which case females with PyMT weighed 6.1% (2.0 grams) more than females 
without PyMT, while PyMT only led to a 1.3% increase in male weight. The larger weight in 
animals with PyMT was most likely due to tumor mass.  A similar gender x PyMT 
interaction was detected for weight at sacrifice (P<.0001), whereby the PyMT effect was 
greater in females than in males (14.5% and 2.8% increases, respectively), as a result of 
greater tumor mass in females relative to males. 
 Lean mass and adiposity were evaluated at 7 wk of age to examine short-term dietary 
effects and obtain baseline measures for the PyMT mice near or just after onset of mammary 
tumors, but prior to significant tumor development.  Male mice had 27.8% (P<.0001) more 
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lean mass than females, whereas high-fat diet led to a modest 5.4% (P<.0001) increase 
(Figure 3). Presence of PyMT was associated with a slight (2.0%; P<.05) increase in lean 
mass (Figure 3).  Measurements of adiposity revealed that female mice had an 8.4% increase 
in body fat relative to males (P<.0001), while high-fat diet led to an increase of 6.4% relative 
to the control fat diet (P<.01, Figure 4). There were no effects of PyMT on body fat in either 
female or male F2 mice.  
The main effects of PyMT, diet and gender were all significant for lean mass 
measured at sacrifice (P<.0001, Figure 3).  A gender X PyMT interaction for lean mass at 
sacrifice was detected (P<.0001), in which PyMT males had a 2.6% increase and PyMT 
females had a much higher 28.5% increase in lean muscle mass relative to males and females 
without the transgene (Figure 3). For adiposity measurements at time of sacrifice, the main 
effects of diet (11.5% increase due to high fat; P<.0001) and PyMT (13.6% increase due to 
presence of PyMT; P<.0001) were significant (Figure 4).  A significant interaction was 
detected between gender and PyMT (P<.0001), whereby females with PyMT had 35.6% 
relatively less body fat percentage compared to females without PyMT, while males with 
PyMT had slightly increased body fat percentage relative to males without PyMT (Figure 4). 
To ensure that the decrease in percent body fat at sacrifice was not a product of the large 
increase in body weight associated with tumor development, total fat in grams at sacrifice 
was calculated. The main effects of diet (21.8% increase due to high; P<.0001) and gender 
(26.4% increase in males vs. females; P<.05) were significant (Figure 4).  A significant 
interaction was detected between gender and PyMT (P<.0001), whereby females with PyMT 
had 19.7% relatively less body fat compared to females without PyMT, while males with 
PyMT had slightly increased body fat relative to males without PyMT (Figure 4). 
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In addition to whole body composition, liver weight (all mice) and weights of the 
right epididymal (all males) or perimetrial (females without PyMT) fat pads were measured 
at sacrifice. Main effects for raw liver weight were all significant with the high fat diet, males 
and PyMT genotype all resulting in increased liver size (Figure 5). A significant gender x 
PyMT interaction was detected (P<.0001). Males and females with PyMT had livers that 
were 22.0% and 4.1% larger than mice of the same gender without PyMT. When livers were 
evaluated as a percentage of body weight, only the main effects of diet and PyMT were 
significant, with control fat diet and presence of PyMT both resulting in increased percent 
liver weight (Figure 5). Similarly to what was observed for raw liver weights, there was a 
significant gender x PyMT interaction effect (P<.05). 
A strong dietary effect was detected for raw weight of perimetrial fat pad in females 
without PyMT (45.9% larger on high-fat diet vs. control fat diet; P<.0001; Figure 5). A 
comparable diet effect was seen for epididymal fat pad weight in males (Figure 5) but no 
influence of PyMT genotype was found (fat pad weight was not measured in females 
harboring PyMT).  When fat pad weights were reanalyzed as percentage of body weight, 
strong dietary effects were still detected with higher values for mice fed the high fat diet 
(36.6% and 49.7% increase for high-fat vs. control fat diet in females and males respectively; 
P<.0001; Figure 5). No two way interactions were detected for fat pads measured as raw 
weights or as a percentage of body weight. 
High positive phenotypic correlations were detected among all the body weight traits, 
although those between weight at 3 wk of age and the other time periods were of smaller 
magnitude (Table 3).  Fatness measured at 7 wk of age and at sacrifice had a correlation of 
~0.5. Likewise, correlations among body fat (measured by DEXA) and the fat pad 
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measurements were strongly positive.  Correlations between body weight and fatness were 
positive and of moderate magnitude.  
QTL evaluation: A total of 38 significant QTL (P<.05 genome-wise) were detected 
in the F2 population (Table 5).  These 38 QTL can be separated into four different categories, 
those associated with body weight, liver weight, lean mass and adiposity. For body weight, 
18 QTL were identified across the four time points measured.  Two were identified for 
weight at 3 wk of age, six for weight at 6 wk of age, five for weight at 9 wk of age and five 
for weight at sacrifice.  QTL with the largest effects were mapped to MMU2, 9 and 11. All 
QTL effects were additive, with the M16i allele associated with increased body weight 
values.  
Four QTL were detected for liver measurements, three for raw liver weights and one 
for liver as a percentage of body weight. The QTL detected for raw liver weight mapped to 
MMU2, 9 and 10 explaining 6.5%, 6.4% and 5.0% of the residual variance, respectively. 
Each demonstrated additive effects and in all cases the M16i allele was associated with 
increased liver weight. One QTL detected for liver as a percentage of body weight mapped to 
MMU9 and the effect was relatively small.  This QTL exhibited an additive effect with the 
FVB allele associated with increased percent liver weight. 
Analysis of lean mass revealed 7 QTL, 4 for lean mass at 7 wk of age and 3 for lean 
mass at sacrifice.  The QTL at 7 wk mapped to MMU2, 6, 10 and 11, with the QTL on 
MMU2 explaining the largest percentage of residual variance (11.6%).  The QTL detected 
for lean mass at sacrifice mapped to MMU2, 10 and 11 with LOD scores of 4.9, 4.34 and 
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3.77 respectively.  Each QTL for lean mass exhibited an additive effect in which the FVB 
allele was associated with an increase in lean body mass relative to the M16i allele. 
Adiposity was measured as total body fat (as a percentage of body weight) at 7 wk of 
age and at sacrifice, total fat at sacrifice (as grams of adipose), while a fat pad weight (raw 
weight and as a percentage of body weight) was also measured at sacrifice. Three QTL were 
found for adiposity at 7 wk on MMU2, 9 and 11.  Four were detected for adiposity at 
sacrifice (2 for total fat and 2 for percent body fat) mapping to MMU2 and 9 in similar 
regions as those detected for 7 wk of age, with respective LOD scores of 4.97 and 4.5 for 
percent body fat and 10.65 and 5.43 for total fat. An additional two QTL were identified for 
fat pad measurements, one for raw fat pad weight and the other for fat pad as a percentage of 
body weight. Both fat pad weight QTL were located on the distal portion of MMU2 near the 
adiposity QTL, explaining 6.1% and 3.3% of the residual variance, respectively. Three of the 
QTL for adiposity (adiposity at 7 wk on MMU2 and 11 and raw fat pad weight on MMU2) 
were additive with the M16i allele leading to an increase in fat, two (fat pad as a percentage 
of body weight on MMU2 and adiposity at sacrifice on MMU2) were additive with the 
increasing allele inherited from FVB, while the remaining QTL (percent fat at 7 wk and total 
fat on MMU9 and percent fat at sacrifice on MMU2 and 9) exhibited dominance gene action. 
Pleiotropy: The close proximity of QTL peak positions detected among highly 
correlated phenotypes suggested that a single locus may be affecting multiple traits. Results 
of a formal pleiotropy test revealed that of the original 38 QTL detected in the F2 population, 
9 distinct loci were present.  Of these 9 loci, only two represented single traits (3 wk weight 
on MMU8 and 6 wk weight on MMU13, Table 5). The other 7 loci influences multiple 
phenotypes distributed across 5 different chromosomes (Figure 6).  Typically, adiposity QTL 
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clustered together, while the body weight QTL clustered with liver and lean mass QTL, 
mirroring patterns of phenotypic correlations. 
Diet and Gender X QTL Interactions: Given that PyMT leads to tumor 
development, we initially analyzed QTL for weight, lean mass and adiposity within PyMT 
subclasses to see if presence of tumors impacted QTL detection for body weight and 
composition. However, differential QTL did not appear to be present amongst PyMT 
genotypes, so all subsequent analyses of QTL x diet and QTL x gender interactions were 
performed across the full population. This revealed 17 QTL with significant interactions with 
diet and 7 QTL with significant gender interactions (Table 5). Interactions were identified for 
post 3 wk body weights and adiposity at seven weeks.  Of the 17 QTL x diet interactions, 10 
resulted from the detection of a significant QTL within one diet but not the other (8 of these 
had significant effects in control fat fed mice, while only 2 had a significant effect in high fat 
fed mice). The remaining QTL x diet interactions were caused by differential allelic effects 
within the two diets. Examples of two QTL with diet interactions were those found on 
chromosome 9 and 13 for body weight at 9 wk (Figure 7A and B), the first of which was 
caused by the presence of a significant QTL only in control mice, while the other was caused 
by the opposite scenario.  Of the 7 QTL x gender interactions, only one resulted from the 
detection of a significant QTL within one gender but not the other (Figure 7C), while the 
remaining 6 interactions resulted from differential allelic effects within the two genders. 
While 24 interactions were detected between QTL and either sex or diet, several of these 
likely represented the same locus due to pleiotropy, as evidenced by patterns of interactions 
for specific traits. For example, the pleiotropic QTL affecting lean mass at 7 wk and body 
weights at 9 wk and at sacrifice on MMU6 exhibited a QTL x diet interaction for each trait. 
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Discussion:   
Although the primary goal of these studies is to identify QTL and dietary fat x QTL 
interactions that influence mammary tumor development and subsequent metastatic activity, 
description of body weight and body composition phenotypes and QTL is important for 
several reasons. First, we show that the M16i x FVB/NJ-TgN (MMTV-PyMT)634Mul F2 
population exhibited a broad range of phenotypic variation for body weight and fatness, 
caused by both segregating QTL and response to feeding of high versus control fat diets. This 
demonstrates that the cross we developed would be informative for testing the relationships 
between obesity and cancer, as described in the companion paper (Gordon et al., Companion 
Paper).  Second, we have identified several novel findings, including specific QTL and QTL 
x diet and QTL x gender interactions that contribute to the growing knowledge base 
regarding polygenic control of body weight regulation. And third, with particular emphasis 
on traits measured at sacrifice, we have for the first time evaluated the effects of cancer on 
the genetic control of body weight and body composition, evaluated as QTL x PyMT 
interaction effects. 
We have previously performed QTL detection in a variety of crosses using the M16 
and M16i models of obesity (Allan et al. 2005; Rocha et al. 2004a, b; Yi et al. 2006). The 
present cross involves M16i and FVB, the latter being a seldom used line in QTL 
experimentation for traits related to energy balance. When comparing the present results with 
those published using M16 or M16i crosses, we found three QTL that had not been 
previously identified, explaining variation for adiposity at 7 wk of age and at sacrifice, and 
likely representing a single underlying gene on proximal MMU9 as indicated by pleiotropy 
testing. Independent studies using a variety of mouse crosses have found QTL for adiposity 
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in this region (see Table 1, (McDaniel et al. 2006)). There are several lines of evidence 
indicating that the MMU9 QTL identified in this M16i x FVB intercross could represent the 
Obq5 gene causing the QTL originally described by Taylor et al., (1999). First, the QTL have 
been mapped in close proximity to each other. Second, Obq5 and our MMU9 QTL for 
adiposity at sacrifice both have interactions with gender, with significantly greater 
phenotypic impact in females than in males. And third, Obq5 impacts gonadal fat to a lesser 
extent than other fat depots (Taylor et al. 1999), and in the current study the MMU9 QTL 
was significant for total body fat but not for gonadal fat pad as a percentage of body weight.  
Of the remaining QTL we detected, those with the biggest effects were located on the 
distal portion of Chromosome 2.  This region has been routinely implicated as having large 
effects on body composition in mice (Allan et al. 2005; Horvat et al. 2000; Ishikawa et al. 
2005; Jerez-Timaure et al. 2004; Rocha et al. 2004a, b). 
Effect of high-fat diets on body composition in mice is variable, some strains having 
relatively little response while others are strongly impacted (Surwit et al. 1995; Svenson et al. 
2007; West et al. 1992). In accordance with previous studies with the parental lines we used 
(FVB, (Yakar et al. 2006) and M16, (Allan et al. 2004)), we observed that M16 x FVB F2 
mice fed a high fat diet had modestly increased body weight and adiposity relative to those 
on the control fat diet.  Despite the presence of widespread genetic variation in dietary-
induced obesity, most QTL studies have been performed in the presence of either high or 
control fat diets, and thus only a few experiments have been suitably designed to analyze 
QTL x diet interaction effects. For example, Coulter et al., (2003) evaluated diet (high and 
low fat) x QTL interactions for Pgc-1α and Ucp1 levels in adipose, and detected scenarios in 
which QTL were found at a particular position in the presence of one diet but not the other. 
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This type of QTL x diet interaction was prevalent in the present study. Interestingly, we 
found that in the majority of cases a QTL for body weight or fat was detected in mice fed the 
control fat diet and not in those fed a high fat diet. This is essentially the opposite scenario to 
what was observed by Cheverud et al., (2004), who examined QTL in a set of LG x SM 
RIL’s fed either high or control fat diets.  
QTL x diet interactions are likely caused by differences in gene expression, either at 
the QTL itself or at a gene or genes regulating the QTL in trans, in response to the different 
diets. Diet-induced differential gene expression is a common phenomenon (e.g. (Jump and 
Clarke 1999; Kennedy et al. 2007)). QTL x gender interactions would likely be caused by 
similar mechanisms, where physiological changes between males and females lead to altered 
gene expression. Indeed, Yang et al., (2006) recently showed wide-spread sexually dimorphic 
gene expression across multiple tissues in mice. In the present study, several instances of 
QTL x gender interaction were detected. In the majority of cases, the interaction was caused 
by differential QTL effects within males and females, as opposed to finding a significant 
effect in one gender and not in the other. Such findings are not uncommon in QTL analysis 
for body weight and adiposity in mice (e.g. (Taylor et al. 1999)). 
Understanding QTL x diet and QTL x gender interactions is important not only for 
understanding the genetic architecture of complex traits, but also for several practical 
reasons. First, the presence of such interactions should impact experimental design for QTL 
detection and discovery. Failure to appropriately account for interactions could lead to 
reduced power and increased type-II errors. Second, these interactions have relevance for 
development and application of genomics-based diagnostic and therapeutic tools.  
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Presence of the PyMT transgene in F2 mice was associated with increased body 
weight when controlled for diet. Since this model of mammary tumor development is not 
previously thought to be associated with cachexia (Lifsted et al. 1998), the increase in body 
weight is likely due to the added weight of harbored tumors.  Relative liver weights were 
larger in F2 mice with PyMT, potentially due to the liver’s function in detoxification of blood 
in the presence of tumor induced toxins and potentially circulating tumor cells (Canning et al. 
2006).  
In contrast, presence of PyMT led to a reduction in body fat in female F2 mice.  It is 
possible that females with tumors consume less food and utilize energy stores in an increased 
manner.  Richardson and Davidson (Richardson and Davidson 2003) noted that humans with 
cancer can have increased energy demands and expenditures that can result in the loss of 
adipose tissue.  den Broeder et al., (2001) found that the presence of a solid tumor in children 
was associated with an increased basal metabolic rate. Although most studies on cachexia 
have concentrated on muscle wasting, Ryden and Arner (2007) recently provided a synopsis 
of studies focusing on the loss of adipose tissue, concluding that adipocyte lipolysis is an 
important factor in the cachexic process.  
The modest adipose-based cachexia we observed could also be a response to 
signaling factors secreted by the tumors (Bing et al. 2006), which in the case of mammary 
tumors are localized to areas with large quantities of adipose tissue. Speculatively, two 
possible candidates are lipid-mobilizing factor and zinc-α2-glycoprotien, both of which are 
involved in initiation of lipolysis of adipose tissue (Russell and Tisdale 2002; Russell et al. 
2004).  
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Despite the significant effects of PyMT increasing body weight, and decreasing body 
fat, in the F2 population, there were no significant QTL x PyMT interaction effects on any of 
the traits studied, including weight and adiposity at sacrifice when the mammary tumor load 
was highest. This indicates that there were no QTL underlying variation in body weight and 
adiposity whose effects (and presumably, expression) were caused and/or altered either 
directly by PyMT expression or indirectly by the presence of mammary tumors. 
 While substantial progress has been made in understanding the genetic underpinnings 
of obesity in mice (Pomp 2007), and genetic variation in response to high-fat diet has been 
well characterized (e.g. (Taylor and Phillips 1997; West et al. 1994a; West et al. 1994b)), 
QTL x diet interactions have received very little research attention. Here we have shown that 
such interactions contribute significantly to the genetic architecture of body weight 
regulation, and that QTL results must be interpreted within the specific dietary 
environment(s) placed on the experimental samples. As pointed out by Schadt et al., (2003b), 
transcriptional responses to dietary fat intake represent significant heterogeneity that clearly 
demonstrates the complexity of underlying traits such as obesity. These findings highlight the 
relevance of accurately modeling the environmental exposures of human populations when 
conducting mouse genetical studies.       
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Table 2.1: Nutritional Composition of the high fat and matched control fat diets* 
 
  
D12451 (High Fat)   D12450B (Control) 
 
 
gm% kcal% 
  
gm% kcal% 
Protein  24 20   19.2 20 
Carbohydrate  41 35   67.3 70 
Fat  24 45   4.3 10 
 
Total 
 100  Total  100 
 kcal/gm 4.73   kcal/gm 3.85  
Ingredients 
 
gm kcal 
  
gm kcal 
Casein, 80 Mesh  200 800   200 800 
L-Cystine  3 12   3 12 
Corn Starch  72.8 291   315 1260 
Maltodextrin 10  100 400   35 140 
Sucrose  172.8 691   350 1400 
Cellulose, BW200  50 0   50 0 
Soybean Oil  25 225   25 225 
Lard  177.5 1598   20 180 
Mineral Mix 
S10026 
 10 0   10 0 
DiCalcium 
Phosphate 
 13 0   13 0 
Calcium Carbonate  5.5 0   5.5 0 
Potassium Citrate, 
1 H20 
 16.5 0   16.5 0 
Vitamin Mix 
V10001 
 10 40   10 40 
Choline Bitartrate  2 0   2 0 
FD&C Red Dye 
#40 
 0.05 0 Yellow Dye #5 0.05 0 
 Total 858.15 4057  Total 1055.05 4057 
 
*Diets were formulated and by E. A. Ulman, Ph.D., Research Diets, Inc. (New Brunswick, NJ). 
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Table 2.2: Composition of vitamin and mineral mixes in the high fat and matched 
control fat diets* 
 
*The vitamin (V10001) and mineral mix (S10026) formulas were provided by Research Diets, Inc. 
(New Brunswick, NJ)  
 
 
 
 
Vitamin Mix V10001    Mineral Mix S10026   
Ingredient gm 10 gm  Ingredient gm 10 gm 
Vitamin A Palmitate  
500,000 IU/gm 0.8 4,000 IU  
Sodium Chloride 
39.3% Na, 60.7% Cl 259 
Na 1.0 gm 
Cl 1.6 gm 
Vitamin D3 
100,000 IU/gm 1.0 1,000 IU  
Magnesium Oxide 
60.3% Mg 41.9 
 
Mg 0.5 gm 
Vitamin E Acetate 
500 IU/gm 10.0 50 IU  
Magnesium Sulfate, 7 H2O 
9.87% Mg, 13.0% S 257.6 S 0.33 gm 
Menadione Sodium 
Bisulfite 
62.5%Menadione 0.08 0.5 mg  
Chromium K Sulfate, 12 
H2O 
10.4% Cr 1.925 Cr 2.0 mg 
Biotin, 1.0% 2.0 0.2 mg  Cupric Carbonate, 57.5% Cu 1.05 Cu 6.0 mg 
Cyancocobalamin, 0.1% 1.0 10 ug  Sodium Fluoride, 45.2% Fl 0.2 FI 0.9 mg 
Folic Acid 0.2 2 mg  Potassium Iodate, 59.3% I 0.035 I 0.2 mg 
Nicotinic Acid 3.0 30 mg  Ferric Citrate, 21.2% Fe 21.0 45. mg 
Calcium Pantothenate 1.6 16 mg  
Manganous Carbonate, 
47.8% Mn 12.25 59. mg 
Pyridoxine-HCl 0.7 7 mg  
Ammonium Molybdate, 4 
H2O, 54.3% Mo 0.3 Mo 1.6 mg 
Riboflavin 0.6 6 mg  Sodium Selenite, 45.7% Se 0.035 Se 0.16 mg 
Thiamin HCl 0.6 6 mg  Zinc Carbonate, 52.1% Zn 5.6 Zn 29. mg 
Sucrose 978.42   Sucrose 399.105  
Total 1000   Total 1000  
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Table 2.3: Phenotypic correlations (and associated significance values adjusted for 
multiple comparisons) for traits measured in the M16i x FVB/NJ-TgN (MMTV-PyMT) 
634Mul
 F2 population. Correlations are adjusted for the fixed effects of gender, diet and 
PyMT. 
 
a3W: 3 week weight, 6W: 6 week weight, 9W: 9 week weight, SW: weight at sacrifice, PF7: percent fat 
measured at 7 weeks of age, PFS: percent fat measured at sacrifice, FS: Fat measured in grams at 
sacrifice, FP: raw weight of fat pad measured at sacrifice, PFP: fat pad as a percent of body weight, 
LIV: raw weight of liver at sacrifice, PLIV: liver as a percent of body weight, LM7: lean body mass at 7 
weeks of age, LMS: lean body mass at sacrifice. 
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Table 2.4: List of 124 SNPs used in the final F2 linkage map with known physical 
locations (Mb) from Ensembl and estimated linkage (cM) positions. 
 
SNP Name Chr 
Mb 
Location 
 cM 
Location
a
 SNP Name Chr 
Mb 
Location 
cM 
Location
a
 
Rs6333200 1 6.2 3.9 rs3667341 8 131.5 74.0 
Rs3659806 1 23.4 11.7 mCV24465575 9 6.7 4.2 
Rs6401503 1 35.8 15.8 rs3665911 9 35.9 18.1 
rs3696088 1 41.1 20.5 rs3703593 9 62.3 30.0 
rs6181164 1 47.9 24.8 rs3714992 9 84.6 41.8 
rs4222426 1 72.7 34.1 mCV24631499 9 106.5 55.6 
mCV24377815 1 93.7 43.7 rs3692532 9 125.6 69.1 
rs6163037 1 115.8 47.1 mCV25374719 10 8.3 5.2 
rs6354736 1 128.2 52.0 rs3685588 10 10.7 14.1 
rs3666261 1 128.2 60.5 rs8244562 10 61.3 28.7 
rs3701630 1 159.8 67.1 rs3682523 10 69.4 39.5 
mCV22660045 1 170.7 75.1 rs6284148 10 109.3 49.3 
rs6208459 1 182.3 80.8 mCV24217147 10 117.5 57.5 
mCV23204820 1 189.8 91.8 rs6171719 10 128.2 67.4 
mCV25103560 2 2.9 1.8 rs3682937 11 4.6 2.9 
rs4223189 2 61.7 40.2 rs3090752 11 26.7 12.3 
rs3661811 2 93.0 51.7 rs8243015 11 51.9 26.5 
rs8281186 2 120.0 61.9 rs3148189 11 70.8 38.2 
rs3713952 2 146.4 73.2 rs3714299 11 92.9 51.0 
rs8260429 2 163.2 83.2 rs4229101 11 102.0 58.0 
mCV24846159 2 174.0 91.2 rs6192404 11 119.7 73.6 
rs6310525 2 180.7 99.3 rs3689412 12 11.2 7.0 
mCV25454657 3 7.1 4.4 rs3700857 12 50.7 18.7 
rs3162526 3 36.9 14.2 rs6320805 12 75.6 32.8 
rs6319642 3 56.1 23.7 rs3676085 12 88.6 44.5 
rs6217010 3 95.5 37.8 rs3654706 12 112.8 61.7 
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mCV24793263 3 113.4 45.7 rs3686663 13 4.8 3.0 
mCV23230498 3 133.9 59.6 mCV25144745 13 34.7 12.8 
rs6157773 3 160.5 75.4 rs6411274 13 46.7 21.5 
rs3693267 4 14.3 9.0 mCV22672997 13 70.2 32.9 
rs3684104 4 38.5 22.0 rs6316213 13 88.3 42.5 
mCV24089992 4 63.9 34.0 rs3711084 13 98.5 49.3 
rs3712721 4 90.3 44.0 Rs3659752 13 114.0 60.3 
rs3659850 4 110.3 51.7 rs6393665 14 11.0 6.9 
rs3663950 4 135.0 71.5 rs3693175 14 27.0 16.6 
rs3713685 4 147.3 79.5 rs4197422 14 49.5 26.7 
rs3671575 5 21.8 13.6 rs3701623 14 67.5 39.9 
rs6192958 5 48.1 29.3 rs3691209 14 98.8 49.8 
rs3657238 5 74.3 40.6 rs6256423 14 106.9 57.0 
mCV24416913 5 108.3 52.6 mCV25349597 15 10.3 6.4 
mCV23328629 5 119.0 63.0 rs6165881 15 51.6 19.9 
rs6377710 5 132.7 70.7 rs3667755 15 78.7 35.2 
rs4225605 5 145.8 86.3 rs3722990 15 92.2 46.3 
rs3710142 6 8.0 5.0 rs3722513 15 96.9 52.8 
rs3662661 6 44.1 17.3 rs4170126 16 32.2 20.1 
rs3699367 6 76.4 31.0 rs4206932 16 76.1 39.4 
rs4226142 6 95.2 40.2 rs4215932 16 88.8 44.7 
rs3722157 6 123.1 50.6 rs3693921 17 13.1 8.2 
rs3673059 6 136.4 59.7 rs6278687 17 43.4 19.1 
rs3677539 6 149.5 68.9 rs3712800 17 57.0 28.6 
rs3688686 7 0.0 0.0 rs3710803 17 73.5 42.4 
rs3023117 7 34.3 9.7 mCV23317493 17 84.4 54.5 
rs8255275 7 46.0 18.9 rs6377403 18 11.4 7.1 
rs3677657 7 68.5 31.0 rs3699816 18 39.5 17.9 
rs3713052 7 101.6 42.0 rs3713935 18 58.7 29.1 
rs4226910 7 122.3 54.8 rs3722524 18 68.9 38.6 
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rs3711570 8 3.6 2.2 rs8257628 19 4.0 2.5 
rs3665640 8 33.5 20.5 rs3694495 19 20.0 12.8 
rs3659789 8 55.7 30.4 rs3681148 19 30.7 23.3 
rs6296403 8 92.0 40.5 rs3703918 19 42.8 32.8 
rs3677807 8 106.0 52.6 rs6304326 19 53.4 42.6 
rs3671292 8 118.4 60.7 rs3694663 19 58.1 51.6 
 
 
a
 The cM position for the first (proximal) SNP on each chromosome was estimated based on its 
physical location (Build 34) using the formula Mb x 1.6 (Shifman et al. 2006) 
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Table 2.5: Descriptive statistics of QTL detected with genome-wide significance (P<.05). 
Chr Traita  QTL Peak (cM)b C.I.
c
 LODd Additivee Dominancef % Varg Interaction
h
 
2 LM7 47 42—54 14.02 1.43 -0.23 11.6 MC 
2 LIV 56 43—74 7.55 0.16 0.01 6.5  
2 3W 58 13—85 4.23 0.28 0.63 3.6  
2 LMS 66 10.5—71 4.99 1.20 0.82 4.8 BD 
2 6W 67 47—71 9.23 1.58 0.51 7.7  
2 9W 67 47—71 12.38 2.09 0.13 12.5 BD 
2 SW 68 55—72 13.55 2.93 0.48 11.5  
2 PFP 72 6.5—90.5 2.61 -0.19 0.03 3.3  
2 FP 73 60—76 5.01 0.13 0.01 6.1  
2 FS 70 63—73 10.65 -1.43 -.20 10.0 BS 
2 PFS 74 0—89 4.97 -0.18 -1.65 4.4  
2 PF7 75 65—82 6.88 1.35 -0.46 5.9  
6 6W 39 33—64 6.72 1.22 0.1 5.7 BS 
6 LM7 41 27—65 5.0 0.84 0.18 4.3 BD 
6 9W 44 35—58 5.88 1.34 -0.3 5.1 BD 
6 SW 45 32—70 4.01 1.46 -0.62 3.5 BD 
8 3W 50 21—58 4.24 0.4 0.31 3.6  
9 PF7 20 14—24 8.02 0.84 -1.74 6.8 MC 
9 FS 21 11—52 5.44 -0.49 -0.50 5.0 MC 
9 PFS 24 0—69 4.5 -0.29 0.55 4.0 F 
9 9W 47 24—53 6.81 1.56 0.33 5.8 MC, BS 
9 SW 47 21—54 6.08 1.96 0.52 5.3 MC, BS 
9 PLIV 48 38.5—60 3.77 -0.14 -0.12 3.3  
9 LIV 49 42—55 7.34 0.15 -0.02 6.4  
9 6W 51 20—55 5.1 1.17 0.01 4.3 MC, BS 
10 LMS 20 13—41 4.34 1.10 0.33 4.2  
10 9W 23 15—55 6.4 1.46 0.45 5.5 BD 
10 LIV 23 16—45 5.76 0.13 0.02 5.0  
10 LM7 31 13—45 5.06 0.79 0.34 4.4 MC 
10 6W 34 19—54 6.37 1.23 0.07 5.4  
10 SW 34 16—49 5.4 1.74 0.15 4.7  
11 LMS 27 16.5—52 3.77 1.03 -0.13 3.6 
 
11 LM7 35 23—42 5.87 0.64 -0.68 5.0 H 
11 SW 35 25—46 6.1 1.72 -0.63 5.3 
 
11 PF7 37 28—63 4.37 1.04 -0.19 3.8 MC 
11 9W 39 27—46 6.25 1.21 -0.81 5.4 MC 
11 6W 40 30—45 8.41 1.13 -1.08 7.1 
 
13 6W 0 0—61 3.74 0.84 -0.49 3.2 H, BS 
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Table 2.5 Continued  
a 3W: 3 week weight, 6W: 6 week weight, 9W: 9 week weight, SW: weight at sacrifice, PF7: percent 
fat measured at 7 weeks of age, PFS: percent fat measured at sacrifice, FS: Fat measured in grams 
at sacrifice, FP: raw weight of pad measured at sacrifice, PFP: fat pad as a percent of body weight, 
LIV: weight of liver at sacrifice, PLIV: Liver as a percent of body weight.  
b Approximate peak QTL position. cM positions are adjusted to the linkage map presented in Table 4. 
c 95% confidence interval for QTL peak (in cM).  
d If an interaction was detected then the LOD score for the total genetic model was reported.  If no 
interaction was detected then the LOD score for the genetic model without the interaction term was 
reported. 
e Additive effect; a positive value indicates that the increasing allele originates from M16i. 
f Dominance effect representing the heterozygous genotype in relation to the mean of the two 
homozygous genotypes: a positive value indicates that the heterozygote is larger than the mid-parent 
(mean of the parents). 
g Percentage of phenotypic variance accounted for by the QTL effect 
h Cause of the interaction. H: significant effect in high fat diet only, MC: significant effect in matched 
control fat diet only, BD: differential effects in high and matched control fat diets, F: significant effect 
in females only, BS: differential effects in females and males. 
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Figure 2.1: Numbers of animals phenotyped in each sub-group of the F2 Population. HF 
designates animals fed a high fat diet, whereas LF designates animals fed the matched 
control fat diet.  PyMT represents animals hemizygous for the PyMT transgene, while 
PyMT- represents individuals without the PyMT transgene.  Numbers in parentheses indicate 
the number of animals genotyped per sub-group. 
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 51 
 
A.          B. 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
Figure 2.2: Least-squares means for body weight traits by gender and diet. PyMT+ signifies 
that animals were hemizygous for the PyMT transgene, whereas PyMT- indicates animals 
that did not harbor the PyMT transgene. High designates animals fed a high fat diet, whereas 
Normal designates animals fed the matched control fat diet. A. Male and female body weight 
at 3 weeks of age. B. Female body weights at 6, 9 weeks of age and at sacrifice (~ 11 weeks). 
C. Male body weights at 6, 9 weeks of age and at sacrifice (~14 weeks).  All * indicate the p 
value associated with the dietary effect: (*) Significant at P<.05, (**) Significant at P<.01, 
(***) Significant at P<.001, and (****) Significant at P<.0001. 
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Figure 2.3: Least-squares means for lean mass measurements by gender and diet. PyMT+ 
signifies that animals were hemizygous for the PyMT transgene, whereas PyMT- indicates 
animals that did not harbor the PyMT transgene. High designates animals fed a high fat diet, 
whereas Normal designates animals fed the matched control fat diet. A. Female lean body 
mass at seven weeks of age and at sacrifice (~ 11 weeks). B. Male lean body mass at seven 
weeks of age and at sacrifice (~ 14 weeks). All * indicate the p value associated with the 
dietary effect: (*) Significant at P<.05, (***) Significant at P<.001, and (****) Significant at 
P<.0001.  
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Figure 2.4: Least-squares means for adiposity traits by gender and diet. PyMT+ signifies that 
animals were hemizygous for the PyMT transgene, whereas PyMT- indicates animals that 
did not harbor the PyMT transgene. High designates animals fed a high fat diet, whereas 
Normal designates animals fed the matched control fat diet. A. Female percent body fat at 
seven weeks of age and at sacrifice (~ 11 weeks). B. Male percent body fat at seven weeks of 
age and at sacrifice (~ 14 weeks).  C. Body fat measured in grams at sacrifice.  P values 
associated with the dietary effect: (*) Significant at P<.05, (**) Significant at P<.01, (***) 
Significant at P<.001, and (****) Significant at P<.0001.  
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Figure 2.5: Least-squares means for liver and fat pad tissue weights by gender and diet. 
PyMT+ signifiesthat animals were hemizygous for the PyMT transgene, whereas PyMT- 
indicates animals that did not harbor the PyMT transgene. High designates animals fed a high 
fat diet, whereas Normal designates animals fed the matched control fat diet. A. Female raw 
tissue weights. B. Male raw tissue weights. C. Female tissue as a percentage of body weight. 
D. Male tissue as a percentage of body weight.  P values associated with the dietary effect: 
(*) Significant at P<.05, (**) Significant at P<.01, (***) Significant at P<.001, and (****) 
Significant at P<.0001. 
 
 
 
 
Female Tissue Weights (raw)
0
0.5
1
1.5
2
2.5
Liver Pymt + Liver Pymt - Fat Pymt -
gr
am
s High
Normal
**** 
** 
Female Tissue (as a percent of body weight) 
0
1
2
3
4
5
6
Liver Pymt + Liver Pymt - Fat Pymt -
High
Normal
**** 
* 
**** 
Male Tissue (as a percent of body weight)
0
1
2
3
4
5
6
Liver Pymt + Liver Pymt - Fat Pymt + Fat Pymt -
High
Normal
**** **** 
* 
Male Tissue Weights (raw)
0
0.5
1
1.5
2
2.5
3
Liver Pymt + Liver Pymt - Fat Pymt + Fat Pymt -
gr
a
m
s High
Normal
**** **** 
** 
 55 
 
 
 
 
Figure 2.6: Chromosomal regions with QTL demonstrating pleiotropic effects.  The seven 
regions designated in red (on MMU2, 6, 9, 10 and 11) represent segments of these 
chromosomes in which a single locus that accounts for variation in multiple traits is located.  
The respective textboxes indicate the traits that each of the loci impact. Trait symbols are as 
follows: 3W: 3 week weight, 6W: 6 week weight, 9W: 9 week weight, SW: weight at 
sacrifice, PF7: percent fat measured at 7 weeks of age, PFS: percent fat measured at sacrifice, 
FP: raw weight of fat pad measured at sacrifice, PFP: fat pad as a percent of body weight, FS: 
fat in grams at sacrifice, LIV: raw weight of liver at sacrifice, PLIV: liver as a percent of 
body weight, LM7: lean body mass at 7 weeks of age, LMS: lean body mass at sacrifice. 
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Figure 2.7: Examples of significant QTL interactions.  Each figure includes graphical 
displays of the LOD curves that represent each component of the interaction. 
line is a representation of the resulting LOD curve when no interaction term is fitted in the 
model.  The red dashed line represents the LOD curve when an interaction is included into 
the model.  The remaining two lines represent the LOD cu
components (either male/female or high fat diet/matched control fat diet).  The threshold bar 
56 
 
 
rves of the two interaction 
 
 
 
The solid black 
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represents an average threshold across the measured phenotypes.  Additionally, the bar 
graphs represent the least-squares means of the trait of interest, for each allelic combination 
measured at the SNP marker closest to the QTL peak position (A allele: FVB; B allele: 
M16i).  A. QTL x diet interaction for 9 week weight on chromosome 9. B. QTL x diet 
interaction for 6 week weight on chromosome 13. C. QTL x gender interaction for percent 
body fat at sacrifice on chromosome 9. 
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Abstract: 
High dietary fat intake and obesity may increase the risk of susceptibility to certain 
forms of cancer. To study the interactions of dietary fat, obesity and metastatic mammary 
cancer, we created a population of F2 mice cosegregating obesity QTL and the MMTV-
PyMT transgene, we fed the F2 mice either a very high fat or a matched control fat diet, and 
we measured growth, body composition, age at mammary tumor onset, tumor number and 
severity, and formation of pulmonary metastases. SNP genotyping across the genome 
facilitated analyses of QTL and QTL x diet interaction effects. Here we describe effects of 
diet on mammary tumor and metastases phenotypes, mapping of tumor/metastasis modifier 
genes, and the interaction between dietary fat levels and effects of cancer modifiers. Results 
demonstrate that animals fed a high fat diet are not only more likely to experience decreased 
mammary cancer latency, but increased tumor growth and pulmonary metastases occurrence 
over an equivalent time. We identified 25 modifier loci for mammary cancer and pulmonary 
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metastasis, likely representing 13 unique loci after accounting for pleiotropy, and novel QTL 
x diet interactions at a majority of these loci. These findings highlight the importance of 
accurately modeling not only the human cancer characteristics in mice, but also the 
environmental exposures of human populations.       
Introduction: 
 According to National Institute of Health statistics, breast cancer is the most common 
cancer type and accounts for the second leading cause of cancer-related deaths in women, 
excluding skin cancers (National-Cancer-Institute 2005). Although breast cancer is thought 
to be a disease that primarily affects women, about 1% of all breast cancer cases diagnosed 
occur in men.  It has been estimated that in 2007, 178,480 women and 2,030 men in the 
United States will be diagnosed with some form of breast cancer and that over 40,460 women 
and 450 men will die of this disease (American Cancer Society, 2007), typically from 
secondary metastatic disease (Sporn 1996). Furthermore, it has been estimated that each year 
breast cancer causes 502,000 deaths worldwide (World-Health-Organiziation 2006).   
Differential susceptibility to breast cancer is thought to be mediated by two different 
types of cancer modifiers, either rare high-penetrance cancer-associated alleles or common 
low-penetrance polygenes (Balmain et al. 2003).  While mutations in genes like BRCA1, 
BRAC2, TRP53 and PTEN can result in increased breast cancer risk (King et al. 2003; Rohan 
et al. 2006; Song et al. 2006; Walsh et al. 2006), these inherited alleles contribute to only 
about 15-20% of all breast cancers (Balmain et al. 2003), suggesting that a polygenic 
etiology is responsible for the majority of breast cancer cases. 
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While genetics clearly influences breast cancer susceptibility, environmental factors 
play an equally important role.  Recently, links between diet and incidence of breast cancer 
have been reported (Key et al. 2004).  A broad spectrum of dietary components ranging from 
alcohol consumption (Terry et al. 2006) to fiber intake (Cade et al. 2007) has been 
investigated.  Dietary fat has received increased attention of late, although reports to date 
have reached conflicting results.  While some studies have shown a positive association 
between breast cancer and fat intake (Cho et al. 2003; Lee et al. 2005), others have failed to 
replicate these findings (Kim et al. 2006; Wakai et al. 2005). To clarify the relationship, we 
tested the hypothesis that mice predisposed to mammary cancer will show a positive 
association between mammary cancer development and dietary fat intake. 
Numerous studies have investigated genetic or dietary links to breast cancer but few 
have focused on the gene x diet interactions that are likely to be major contributors to 
differential risk. We utilized an F2 population of mice generated by intercrossing the 
FVB/NJ-TgN(MMTV-PyMT)634Mul (PyMT) model of mammary cancer with the M16i 
polygenic obesity model and evaluated mammary cancer phenotypes that developed when 
the mice were maintained on one of two diets that differed in the level of dietary fat ((Gordon 
et al. 2008b), companion paper). Our objectives were to evaluate the phenotypic effects of 
dietary fat on tumor latency, severity and metastasis and to identify quantitative trait loci 
(QTL) and diet x QTL interactions associated with mammary cancer phenotypes.    
Materials and Methods: 
Population development:  An F2 population (n = 615) was generated by crossing 
M16i (Allan et al. 2005) and PyMT (Guy et al. 1992) mice in four replicate breeding cycles 
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(full details are provided in Gordon et al companion paper). F2 mice were weaned at three 
weeks of age and randomly assigned, within litter, gender and genotype (PyMT or no PyMT) 
to receive one of two synthetic purified diets at four weeks of age. Mice had ad libitum 
access to water and their assigned feed, either a high fat diet (Research Diets D12451) 
containing 45% of total calories from fat, 20% from protein and 35% from carbohydrate or a 
matched control fat diet (Research Diets D12450B) containing 10% of total calories from fat, 
20% from protein and 70% from carbohydrate. Prior to starting specialized diets all animals 
received ad libitum access to a standard rodent diet (Teklad 8604 Rodent Chow). Mice were 
evaluated for body weight and body composition as previously described ((Gordon et al. 
2008b), companion paper). 
Tumor analysis/Tissue collection:  All F2 mice that were confirmed carriers of the 
PyMT transgene were evaluated, starting at four weeks of age, to determine the age of onset 
for mammary tumors (TOID).  All mammary glands from each individual were evaluated by 
palpation three times a week until tumor onset was determined, or until they were sacrificed 
at either 11 weeks (females) or 14 weeks (males were evaluated later because of slower 
development of cancer phenotypes). Upon dissection, total tumor number (TC) was recorded 
along with the combined weights of the inguinal tumors (TI) and the combined weights of 
the axillary tumors (TA).   Total tumor weight was calculated by the addition of the total 
axillary and inguinal tumor weights (TTW).  The following tissues were collected and snap 
frozen in liquid nitrogen: one inguinal and one axillary mammary tumor and one pulmonary 
lobe (the other being used for evaluation of metastasis). 
Metastatic analysis: The metastatic burden was evaluated under a dissecting 
microscope by counting the total number of metastases present on the lung surface (MET).  
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The density of pulmonary metastases was determined in histological sections (AMD).  One 
pulmonary lobe was fixed in 10% paraformaldehyde, embedded in paraffin, sectioned and 
stained with hemotoxylin-eosin.  Three coronal nonadjacent sections of the lung, each 
separated by 100 µm, were prepared from each animal.  The slides were examined using a 
Leica M420 Macroviewer with an Apozoom lens under 12x magnification.  Three fields 
were scored for each slide, for a total of nine fields per animal.  Pulmonary metastatic density 
was determined using a Leica Q500MC Image Analysis System, which aided in the 
elimination of alveolar space from the measurement of lung tissue area measurements to 
control for varying degrees of lung inflation at sacrifice.  The metastasis index was measured 
as the number of multicellular metastatic lesions observed per square micron of lung tissue 
(AMN). Average metastasis size was calculated based on the total area of metastatic tissue 
on the slide divided by the number of metastases observed.  All slides were read blind, and 
analyzed by a single operator to improve technical consistency.  
Statistical Analysis:  Proc Mixed REML in SAS (2002) was used to analyze all 
cancer phenotypes.  The model for all male and female cancer traits except TOID contained a 
fixed effect of diet, random effects of replicate and dam, and used age at sacrifice as a 
covariate (TOID was analyzed without this covariate).  Correlations (with Bonferroni 
corrected P-values) among traits were generated using the MANOVA procedure within Proc 
GLM in SAS (2002), with the fixed effect of diet. 
QTL Analysis:  As described previously ((Gordon et al. 2008b), companion paper), 
data were analyzed with the “F2 inbred/Co-dominant Marker Analysis” option of the web-
based program QTL Express (Seaton et al. 2002), fitting one QTL per chromosome with the 
genetic model for additive plus dominance effects. Given the dissimilarities in cancer 
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phenotypes between gender, males and females were evaluated as individual populations for 
all traits except TOID, which was also evaluated in a pooled gender population. In all 
analyses stratified by gender, the fixed effects of additive, dominance, replicate and diet as 
well as a QTL x diet interaction (interaction model) were included. In the pooled analyses the 
fixed effect of gender was included as well. An additional model was tested for each trait 
with identical fixed effects but without the interaction term (non-interaction model). To test 
whether QTL x diet interaction effects were significant, the sum of squares error and the 
degrees of freedom for the peak position for each QTL in both the interaction and non-
interaction models were calculated and used to estimate an F statistic.  If the interaction was 
not significant, the QTL x diet interaction effect was removed from the model.  If an 
interaction was detected, then the mapping population was separated according to diet 
(animals fed either the high fat or matched control (lower) fat diet) and reanalyzed 
independently using the non-interaction model to elucidate the cause of the interaction.  
Genome-wide significance and suggestive thresholds for QTL effects were determined using 
permutation testing with 1000 iterations (permutated experiment-wide and chromosome-
wide, respectively). A bootstrap procedure was used to estimate confidence intervals for QTL 
positions.  The nonparametric bootstrap method described by Lebreton et al., (1998) was 
used to test for pleiotropy among multiple linked QTL. 
Real Time PCR:  PyMT expression was evaluated for all axillary tumors collected 
from the F2 females using real time PCR to verify that differences observed in the 
phenotypes were not the result of varying levels of transgene expression.  PyMT cDNA was 
amplified using primers AACGGCGGAGCGAGGAACTG and 
ATCGGGCTCAGCAACACAAG (Operon) and Taq polymerase (Qiagen). The real time 
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PCR results were evaluated using both the Proc Mixed and Proc Corr procedures of SAS 
(2002). 
Results:  
Phenotypic evaluation: Females fed the high fat diet were found to have a 
significantly earlier onset of mammary tumors, by approximately 3 days, than females fed 
the matched control fat diet (Figure 1A; p < 0.001).  While results for the males also 
suggested an earlier onset of 2.4 days for high fat fed animals, this difference was not 
significant (Figure 1A). No significant dietary effect was detected in either the male or 
female populations for number of tumors (Figure 1B). The upper limit of tumor number that 
could be detected in mouse was ten, corresponding to the number of mammary pads. While 
many female mice had 10 tumors, the maximum we detected for any male was two.  
After tumors were counted in females, they were removed and separated according to 
inguinal or axillary regions.  Weights for these two regions were evaluated individually as 
well as together to form a total tumor weight.  Females fed the control fat diet had 33.3% (p 
< 0.0001) (difference between the two means as a percentage of the lower mean) and 26.8% 
(p < 0.01) lower tumor weights in axillary and inguinal regions, respectively compared to 
females fed the high fat diet. When combined, this led to a reduction of 31.1% (p < 0.001) for 
total tumor weight (Figure 1C). No significant dietary effects were detected for male axillary 
tumor weight; no tumors developed in the inguinal region in males.  In addition 20 females 
from replicate four were randomly selected to have their total tumor load measured for 
percent adipose in the tissue.  These results (Figure 1D) suggested that animals fed the high 
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fat diet not only have larger tumor loads but their tumors contained less adipose tissue 
compared to tumors collected from animals fed the control fat diet (Figure 1D). 
Less than half of females with PyMT (~42%) developed pulmonary metastases at the 
time of evaluation. Within these females, a 68.1% increase in initial surface count of 
metastases was observed in mice fed the high fat diet relative to mice fed the control fat diet 
(Figure 2; p < 0.05).  For metastasis traits measured in lung sections, significant dietary 
effects were detected for average number of metastases (47.1% increase for animals fed the 
high fat diet; p < 0.05) and average density of metastases (46.1% increase for animals fed the 
high fat diet; p < 0.05) (Figure 2). 
The correlation analysis of the female cancer traits (Table 1) was consistent with 
expectations. All measurements for tumor weights were highly correlated with each other 
and traits measuring metastasis had strong positive correlations. Additionally, the 
correlations among tumor weights and metastasis traits were all moderately positive, while 
tumor onset and tumor count were either weakly or not correlated with the other traits.  
However, the analysis of correlations among the cancer traits and the body composition traits 
for this population did reveal some interesting results (Table 2).  Liver weight and lean mass 
at sacrifice were both highly correlated with tumor weights and a similar pattern was detected 
for body weight at sacrifice and tumor weights.  Also, percent body fat measured at sacrifice 
and tumor weights had moderately negative correlations.  In addition, the metastasis traits 
were positively correlated with both liver weight and sacrifice weight. 
We further partitioned correlations by diet. Few changes due to diet were observed 
(data not shown), although reduction in power limited to some extent the ability to identify 
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significant correlations. A few examples of possible alterations in phenotypic relationships 
when mice are raised on high fat diet versus control fat diet include those between fat traits 
and metastasis traits. The correlation between amount of body fat at sacrifice and metastasis 
was not significant in the high fat diet group, but was significantly (P<.05) positive in the 
low fat group. 
QTL evaluation: Two genome-wide significant QTL, mapping to Chr 1 and 9, were 
detected for tumor onset in days in the pooled population (Table 3).  Each of these QTL had 
relatively large effects as shown by their contributions to the residual variance of 10.4% and 
10.9%, respectively.  When the data were evaluated at the suggestive P < 0.05 level, 23 
additional QTL were detected (Table 3). Most of these QTL had high LOD scores (> 3.0), 
which likely did not reach genome-wide significance due to relatively small sample size. 
Given that we have shown that most, if not all, suggestive QTL for similar traits identified in 
our previous crosses were validated using chromosomal substitution lines (Lancaster et al. 
2005), we include and discuss all detected QTL herein.    
The QTL for tumor traits can be broken down into two categories, traits that are 
associated with the primary tumors and those that are associated with metastatic disease.  A 
total of 15 QTL were detected across all traits associated with the primary tumors.  Three 
QTL were detected for axillary tumor weight, located on Chr 9, 14 and 17.  Alleles 
increasing tumor weight originated with both the M16 (Chr 9) and FVB (Chr 14, 17) lines. 
One QTL was detected for inguinal tumor weight on Chr 5 and three for tumor count at 
sacrifice on Chr 1, 9, and 14.  The remaining eight QTL were all for TOID across seven 
different chromosomes (Table 3).  
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Analysis of our initial metastasis count at the time of sacrifice revealed four QTL in 
the female population that were located on Chr 1, 8, 11 and 19.  The FVB allele was 
associated with increased values for the QTL detected on Chr 1 and 19, whereas the M16i 
allele was associated with increased values for Chr 8 and 11.  The remaining metastatic QTL 
were detected for traits measured in a histological analysis of the formalin fixed lung of the 
PyMT positive females.  Two were detected for average metastasis number, on Chr 8 and 13, 
and two for average metastasis density in similar locations. In all four cases the allele 
associated with increased metastasis was inherited from FVB. 
Pleiotropy testing: The close proximity of QTL peak positions detected among highly 
correlated phenotypes suggested that a single locus may be affecting multiple traits. Results 
of a formal pleiotropy test revealed that of the original 25 QTL detected in the F2 population, 
13 distinct loci were present, with 6 pleiotropic loci representing many of the initial QTL 
detected (Table 3). For the most part, pleiotropic QTL influenced correlated traits within 
categories (e.g. tumor number/weight, or metastatic development). To determine if adiposity 
(companion paper) and female cancer phenotypes may be under joint control of a pleiotropy 
QTL, we first looked for overlap between QTL positions. Only 2 chromosomes (Chr 9 and 
11) had overlapping QTL, and tests for these indicated a lack of pleiotropy.  
Diet by QTL interactions: Testing for QTL x diet interactions was significant at 16 of 
the 25 cancer QTL identified (Table 3). Of these 16 interactions, four (for tumor onset, 
number of tumors at sacrifice and number of metastases at sacrifice) resulted from 
differential allelic effects within the two diets.  The remaining QTL x diet interactions were a 
result of the detection of a significant QTL within one diet but not the other. Three of these 
had significant effects in mice fed the control fat diet, while nine had a significant effect in 
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mice fed the high fat diet. These interactions were detected amongst all traits evaluated 
except inguinal tumor weight and total tumor weight.  Three examples of these interactions 
are depicted in Figure 4. The first two loci were located in close proximity to each other on 
Chr 8 for number of metastases at sacrifice and average metastasis density, resulting from the 
presence of a significant QTL only in mice fed high fat diet (Figure 4 A and B). The other 
locus displayed a similar interaction and was detected for the number of metastasis at 
sacrifice on Chr 19 (Figure 4C).  
PyMT evaluation: In order to verify that the QTL and phenotypic differences 
detected resulted from both dietary and genetic variations were not influenced by varying 
levels of the PyMT transgene, we utilized real time PCR to measure PyMT expression levels.  
Results revealed that there were no significant differences in PyMT expression in the 
mammary tumors of females on the high fat diet versus those on the control fat diet (data not 
shown). Furthermore, correlation analyses confirmed that PyMT expression was not 
correlated with any measured phenotypic trait (data not shown). 
Discussion:   
There is a complex relationship between diet and genetics of mammary cancer 
susceptibility. While genetic predisposition to mammary cancer has been confirmed by 
identification of multiple, small-to-low effect familial risk factors, the evidence linking 
dietary fat to cancer susceptibility is less consistent.  While results of some studies have 
suggested that there is no association between dietary fat intake and cancer development and 
progression (Salazar-Martinez et al. 2005; Smith-Warner et al. 2001), other studies have 
detected a positive association (Lee et al. 2005). To clarify the relationship, we tested the 
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hypothesis that mice predisposed to mammary cancer will show a positive association 
between mammary cancer development and dietary fat intake. 
Our results show that animals fed a high fat diet are not only more likely to develop 
mammary cancer at an earlier time, but their tumors grow larger over an equivalent time.  
Increased levels of circulating estrogen as a result of increased adipose stores have been 
shown to be positively associated with age of cancer onset (Bray 2002; Key et al. 2003). In 
the current studies, mice fed the high fat diet not only had increased adipose percentages 
(percent body fat at seven weeks), but earlier onset of mammary cancer. Increased levels of 
insulin-like growth factor I (IGF-I) also have been implicated in the onset of tumors due to its 
ability to stimulate the proliferation in the mammary epithelium and inhibit apoptosis (Shi et 
al. 2004; Stoll 1998). Similarly, it has been suggested that obesity is associated with adverse 
features at diagnosis including larger tumor size, advanced grade, and increased nodal 
involvement as a result of increased levels of insulin (Boyd 2003).  However, we did not 
detect a correlation between adiposity at seven weeks and cancer size or local progression. 
Nonetheless, we did observe a higher rate of metastasis in the high fat diet group than in the 
control fat diet cohort.  These results were similar to those found in a study by Senzaki et al., 
(Senzaki et al. 1998), in which fat intake was positively associated with xenograft growth and 
metastasis.  Consistent with these observations, Rose et al., (1991) found that animals fed a 
high fat diet were almost twice as likely to develop pulmonary metastasis. 
Increased tumor load in mice fed the high fat diet was not the result of tumors with 
higher levels of adipose, as shown by the fact that tumors in mice fed high fat actually had 
lower percent fat content. This implies that the tumor epithelium may be more aggressive as 
a result of consumption of a high fat diet. Furthermore, the decreased fat content in tumors of 
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females on a high fat diet suggests that paracrine action of adipocyte signaling hypothesized 
elsewhere may not play a significant role in obesity-associated mammary cancer morbidity 
(Schaffler et al. 2007). 
Genetic analysis of the F2 population supported detection of several modifiers, some 
of which have not been previously reported including a modifier of tumor onset on Chr 1.  
We also confirmed previously detected modifiers such as the locus located on Chr 9 for 
tumor onset, encompassing the region harboring Apmt2, a locus associated with the 
acceleration of tumor latency (Le Voyer et al. 2000).  In addition, the locus for tumor onset 
on Chr 7 appears to be in the same region as a previously detected suggestive locus for 
acceleration of tumor latency (Le Voyer et al. 2000), and a locus on Chr 17 to which we 
mapped a axillary tumor growth enhancer locus was recently implicated in harboring a tumor 
growth modifier (Lancaster et al. 2005). When our results were compared to the loci 
identified for metastasis by Hunter et al., (2001), it appears that the locus we identified on 
Chr 19 mapped to the same region as Mtes1.  Additionally, we mapped a modifier to Chr 13 
in a region previously implicated in metastasis (Hunter et al. 2001).  Of the remaining loci, 
those modifiers residing in two regions appear particularly interesting.  The first, located on 
Chr 1, is in close proximity to a locus detected for tumor onset suggesting that the modifier 
identified in this area represents the same underlying gene, which was supported by 
pleiotropy testing.  The second, on Chr 8, influences three of the different metastatic traits 
and, because of their similarities and the pleiotropic effects detected in this region, it is 
appears that they too are all regulated by a common underlying gene. 
Only a small number of the cancer modifiers detected were in similar locations to 
obesity QTL mapped in the same population ((Gordon et al. 2008b), companion paper), and 
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these do not appear to be due to pleiotropic loci. This may at first seem surprising, given the 
recent evidence that links obesity and cancer in humans (Hursting et al. 2007). Although this 
is just a single cross with limited power, it is possible that the obesity-cancer link has 
stronger environmental underpinnings relative to a genetic correlation. Our analyses were 
focused more on effects of dietary fat on cancer, and interaction between dietary fat and 
cancer modifiers. 
Our experimental design supported testing the hypothesis that animals fed a high fat 
diet would have more advanced cancer phenotypes as a result of underlying gene x diet 
interactions.  We found that 64% of all cancer modifiers detected had significant diet 
interactions, and of these interactions, nine were modifiers only detected in animals fed the 
high fat diet while three were detected in mice fed the control fat diet. These results implicate 
interactions of diet and modifier genes as a mechanism through which diet affects cancer. 
 As previously mentioned, the interaction detected with the Chr 19 locus controlling 
the number of metastasis counted at sacrifice mapped to almost an identical site as the Mtes1 
locus (Hunter et al. 2001). When we evaluated QTL for this trait without a diet interaction 
component it only yielded a suggestive modifier.  However, when gene x diet interaction was 
added to the model, the modifier became highly significant with the LOD score rising from 
2.56 to 4.21.  These results suggest that the high fat diet may modulate the effect of the Chr 
19 locus by increasing the development of pulmonary metastasis through the activity of this 
locus on a high fat diet.  The work reported by Park et al., (2005) suggests that the Sipa1 
gene is a strong candidate for the Mtes1 locus, which implies that a diet high in fat can alter 
the expression or activity of this gene.  Such an interaction is plausible as Sipa1 is correlated 
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to breast cancer metastasis (Crawford et al. 2006) and its binding partner Brd4 is implicated 
in the formation of subcutaneous fat (Houzelstein et al. 2002). 
Another interesting interaction we detected was between diet and the Chr 9 modifier 
for tumor onset.  The location of this modifier overlaps with the Ampt2 locus, previously 
identified as a modifier of tumor onset (Le Voyer et al. 2000). However, unlike the locus on 
Chr 19, we were unable to detect any modifier at this position without the gene x diet 
interaction included in the model; when the interaction was fitted we detected a significant 
modifier at this location.  When the two diets were evaluated separately, we observed that the 
LOD score in the high fat diet group was elevated above the pooled population, while the 
matched control fat diet suppressed detection of this modifier.  The potential identification of 
the Ampt2 locus as Myc, a gene shown to enhance tumor growth, suggests that a high fat diet 
could further enhance this gene’s ability to cause increased tumor latency 
 For a small number of the interactions detected, we found that the control fat diet was 
responsible for increasing the significance of the modifier. However, at each of these 
modifier locations the differences in the LOD scores observed for the high and control fat 
diet populations, when evaluated individually, were relative small. Given that the majority of 
the interactions resulted from the detection of a significant modifier within the population 
that was fed a high fat diet and not within those fed control fat diet, we can speculate that 
mice predisposed to mammary cancer show a positive association between mammary cancer 
development and dietary fat intake due to diet-induced alterations in gene expression either 
underlying the actual modifier or regulating the modifier.  How these alterations are 
manifested, e.g. through regulation of some global factors such as hormones (estrogen, IGF-
1, IGFBP-3 (Kaklamani et al. 1999)), requires further investigation. However, these findings 
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enforce the importance of accurately modeling not only the human cancer characteristics in 
mice, but also the environmental exposures of human populations 
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Table 3.1: Phenotypic correlations (and associated significance values) for female cancer 
traits measured in the M16i x FVB/NJ-TgN (MMTV-PyMT) 634Mul F2 population.  
Trait TC TA TI TTW METS  AMN AMD 
TOID -0.26 
<.01  
-0.23 
<.01  
-0.22 
<.05 
-0.25 
<.01 
-0.02 
NS 
-0.19 
NS 
-0.20 
NS 
TC 
  0.30  
<.001 
0.31  
<.001 
0.32  
<.001 
0.07  
NS 
0.04  
NS 
0.02  
NS 
TA 
    0.77  
<.0001 
0.97  
<.0001 
0.41  
<.01 
0.25  
<.05 
0.40  
<.0001 
TI 
  
    0.90  
<.0001 
0.34  
<.05 
0.21  
NS 
0.30  
<.001 
TTW 
  
      0.41  
<.01 
0.25  
<.05 
0.39  
<.001 
METS 
  
        0.59  
<.0001 
0.58  
<.0001 
AMN 
  
         0.67 
<.0001 
 
Correlations are adjusted for the fixed effect diet, and resulting P-values are adjusted for 
multiple comparisons. TOID: tumor onset measured in days, TC: number of tumors, TA: 
total weight of the axillary tumors, TI: total weight of the inguinal tumors, TTW: combined 
weight of axillary and inguinal tumors, METS: number of pulmonary metastasis counted at 
sacrifice, AMN: average metastasis number detected in internal sections, AMD: average 
metastatic density. 
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Table 3.2: Phenotypic correlations (and associated significance values) among female cancer 
and body composition traits measured in the M16i x FVB/NJ-TgN (MMTV-PyMT) 634Mul F2 
population. 
Trait TOID TC TA TI TTW METS  AMN AMD 
3W -0.26 
<.01 
0.08   
NS 
0.20  
<.05 
 0.12   
NS 
0.18   
NS 
-0.07 
NS 
0.13  
NS 
0.14  
NS 
6W 
 
-0.09 
NS  
0.16   
NS 
0.32 
<.001  
0.33 
<.05  
0.35 
<.001 
-0.09 
NS 
0.09  
NS 
0.10  
NS 
9W -0.35 
<.0001   
0.29 
<.001  
0.50  
<.0001 
0.44  
<.0001 
0.51 
<.0001 
0.11  
NS 
0.03  
NS 
0.29 
<.01 
SW -0.26 
<.001  
0.33 
<.0001  
0.79  
<.0001  
 0.73  
<.0001  
0.81  
<.0001 
0.23  
NS 
0.16  
NS 
0.37 
<.001 
PF7 -0.14  
NS 
-0.02 
NS 
0.11   
NS 
0.05    
NS 
0.10   
NS 
-0.22  
NS 
-0.07 
NS 
-0.06 
NS 
PFS 0.02   
NS  
-0.27 
<.01   
-0.51 
<.0001  
-0.58  
<.0001   
-0.57  
<.0001 
-0.28  
<.05 
-0.20 
NS 
-0.20 
NS 
FS -0.23 
<.01 
-.07    
NS 
-0.14 
NS 
-0.23 
<.01 
-0.18 
<.05 
-0.13 
NS 
0.00  
NS 
0.01  
NS 
LIV 
 
-0.29 
<.0001  
0.36 
<.0001  
 0.77  
<.0001 
 0.73  
<.0001  
0.80  
<.0001 
0.34 
<.05 
0.27 
<.05 
0.50 
<.001 
PLIV -0.27 
<.01 
0.33 
<.0001 
0.51  
<.0001 
0.51  
<.0001 
0.54  
<.0001 
0.29 
<.05 
0.48 
<.001 
0.50 
<.001 
LM7 -0.37 
<.0001  
0.24 
<.01 
0.27 
<.01  
0.21 
<.05 
0.26 
<.01 
0.04  
NS 
0.26 
<.05 
0.26 
<.01 
LMS -0.31 
<.001  
0.37 
<.0001  
0.89 
<.0001  
0.82 
<.0001  
0.91 
<.0001  
.034 
<.01 
.043 
<.001 
.042 
<.001 
 
Correlations are adjusted for the fixed effect diet, and resulting P-values are adjusted for 
multiple comparisons. TOID: tumor onset measured in days, TC: number of tumors, TA: 
total weight of the axillary tumors, TI: total weight of the inguinal tumors, TTW: combined 
weight of axillary and inguinal tumors, METS: number of pulmonary metastasis counted at 
sacrifice, AMN: average metastasis number detected in internal sections, AMD: average 
metastatic density, 3W: 3 week weight, 6W: 6 week weight, 9W: 9 week weight, SW: weight 
at sacrifice, PF7: percent fat measured at 7 weeks of age, PFS: percent fat measured at 
sacrifice, FP: raw weight of fat pad measured at sacrifice, PFP: fat pad as a percent of body 
weight, FS: fat in grams at sacrifice, LIV: raw weight of liver at sacrifice, PLIV: liver as a 
percent of body weight, LM7: lean body mass at 7 weeks of age, LMS: lean body mass at 
sacrifice. 
 76 
 
Table 3.3: QTL detected at the experiment-wide and chromosome wide .05 levels and their 
respective statistics by chromosome. 
Chr Traita  QTL Peak (cM)b C.I.
c
 Addd Dome Interactionf LOD Pleiotropy 
Groupg 
1 TOID-A 4 4—89.5 -0.03 -3.51 BD 4.62 1 
1 MET-F 7 4—93 4.64 -3.11 BD 3.78  
1 TOID-M 17 4—37 -1.37 -9.9  3.74 1 
1 TC-M 68 4—93 0.36 0.44 H 3.53  
1 TOID-F 69 4—90.5 0.31 -2.89  2.97 1 
5 TI-F 39.5 24.5—85.5 0.51 -0.15  3.86  
7 TOID-F 42 17—46 -1.49 -2.67  3.82  
8 TOID-A 21 13.5—56 -1.59 2.35  3.17  
8 AMD-F 31 12—69 0.28 -3.32 H 2.89 2 
8 AMN-F 31 8.5—70 0.03 -1.15 H 3.29 2 
8 MET-F 33 2—74 -3.48 -5.3 H 3.74 2 
9 TOID-F 56 4—69 1.2 -0.46 H 3 3 
9 TA-M 56 8—63 -0.27 -0.14  2.36 3 
9 TC-M 56 4—69 -0.42 0.07 H 3.53 3 
9 TOID-A 56 50—61.5 2.64 -0.91  4.86 3 
11 MET-F 14 5—73 -0.61 5.77 BD 3.17  
13 AMD-F 13 3—61 0.23 -2.49 H 3.09 4 
13 AMN-F 13 3—61 0.1 -0.88 H 3.49 4 
13 TOID-F 19 3—53.5 -2.1 -0.65  2.94 4 
14 TA-M 27 10—53.5 0.28 -0.16 MC 3.2 5 
14 TOID-F 40 7—57 0.65 -1.93 MC 3.07 5 
14 TC-F 52 7—57 -0.09 0.5 BD 2.8 5 
17 TA-F 42 8—47 0.17 1.18  2.63 6 
17 TOID-M 51 8—54 -2.39 3.6 MC 2.87 6 
19 MET-F 15.5 7.5—40.5 4.32 4.93 H 4.21  
 
Traits in bold were significant at the experiment wide level 
aTOID: tumor onset measured in days, TC: number of tumors, TA: total weight of the 
axillary tumors, TI: total weight of the inguinal tumors, MET: number of pulmonary 
metastasis counted at sacrifice, AMN: average metastasis number detected in internal 
sections, AMD: average metastatic density.  An (A) signifies the QTL was detected in the 
pooled population, an (F) signifies the QTL was detected in the female population, an (M) 
signifies the QTL was detected in the male population. 
bApproximate peak QTL position. cM positions are adjusted to the linkage map presented in 
Table 2 of Gordon et al. (companion paper). c95% confidence interval for QTL peak (in cM). 
dAdditive effect determined by QTL Express, a positive value indicates that the increasing 
allele originates from the FVB. eDominance effect representing the heterozygous genotype in 
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relation to the mean of the two homozygous genotypes: a positive value indicates that the 
heterozygote is larger than the mid-parent (mean of the parents). fCause of the interaction. H: 
significant effect in high fat diet only, MC: significant effect in matched control fat diet only, 
BD: differential effects in high and matched control fat diets. 
gPleiotropic groups represent QTL that likely represent a single locus, as determined using 
the method described by Leberton et al., (1998). A cell without a number indicates that 
pleiotropy was not detected.
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C.        D. 
 
 
 
 
 
 
 
 
Figure 3.1: Least-squares means for tumor traits by diet and gender. High designates animals 
fed a high fat diet, whereas Normal designates animals fed the matched control fat diet. (*) 
Significant at P<.05, (**) Significant at P<.01, (***) Significant at P<.001, and (****) 
Significant at P<.0001.  A. Mammary cancer latency.  B. Number of mammary tumors 
measured at the time of sacrifice.  C. Tumor weights measured in the female population. 
Tumor Ax: weight of axillary tumors, Tumor Ing: weight of inguinal tumors. Total tumor 
weight: collective weight of axillary tumor and inguinal tumor. D. Percent fat of tumors. 
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Figure 2. Least-squares means for metastatic traits when tested for dietary effects. High 
designates animals fed a high fat diet, whereas Normal designates animals fed the matched 
control fat diet. Mets: Surface metastatic burden determined at sacrifice, Avg # of Mets: 
average number of metastases per field of microscope view count, Avg Met Density: average 
metastases density calculated as the number of metastases per unit area of lung 
(number/square micron of lung x 1,000,000). 
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Figure 3.3:  Positions and confidence intervals for cancer QTL. QTL detected for cancer 
phenotypes (AMD: average metastasis density, AMN: average metastasis number, MET: 
number of metastasis observed at sacrifice, TA: axillary tumor weight, TC: total tumors 
counted at sacrifice, TI: inguinal tumor weight, TOID: Tumor onset in days) at both the 
chromosomal P<.05 (suggestive) or at experimental P<.05 (significant).  The presence of a 
A, F or M denotes that the QTL was detected in either the combined analysis, female analysis 
or the male analysis, respectively.  The confidence intervals are indicated by the thin black 
lines and the estimated peak position of each QTL are denoted by the colored ovals. Yellow 
ovals represent metastasis traits while red oval represent traits related to primary tumors. (*) 
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Figure 3.4:  QTL x Diet interactions for select female cancer traits.  Each figure includes 
graphical displays of the LOD curves that represent the individual components of the 
interaction. The solid black line is a representation of the resulting LOD curve when no 
interaction term is fitted in the model.  The red dashed line represents the LOD curve when 
an interaction is included into the model.  The remaining two lines represent the LOD curves 
of the two interaction components (high fat diet/matched control fat diet   The threshold bar 
represents an average suggestive threshold across the cancer phenotypes. Additionally, the 
bar graphs represent the least-squares means of the trait of interest, for each allelic 
combination measured at the SNP marker closest to the QTL peak position (A allele: FVB; B 
allele: M16i).  A.  LOD intervals for the QTL detected for metastasis number at the time of 
sacrifice, on MMU8.  B.  LOD intervals for the QTL detected for average metastasis density, 
on MMU8.C.  LOD intervals for the QTL detected for metastasis number at the time of 
sacrifice, on MMU19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
CHAPTER IV 
Dietary fat alters pulmonary metastasis of mammary cancers through cancer autonomous and 
non-autonomous changes in gene expression 
 
Michele La Merrill, Ryan R. Gordon, Kent W. Hunter, David W. Threadgill, Daniel Pomp 
 
Preface: 
The following chapter represents the work of a collaborative investigation between 
the laboratories of Daniel Pomp and David Threadgill.  While, the primary author of this 
chapter is Michele la Merrill it was included in this dissertation because it describes 
experiments critical to the subsequent chapter. Additionally, many of the 
experiments/analyses described here were carried out by myself or performed in 
collaboration with Michele la Merrill. I specifically had a hand in following component 
described in this chapter: Isolation of RNA from the axillary tumors and livers, microarray 
analysis, data processing and normalization of expression profiles, differential expression 
analysis, eQTL evaluation of Btn1a1, writing of methodologies and additional manuscript 
assistance.  
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Abstract: 
Metastasis virulence, a significant contributor to breast cancer prognosis, is 
influenced by environmental factors like diet. We previously demonstrated in an F2 mouse 
population generated from a cross between the M16i polygenic obese and MMTV-PyMT 
mammary cancer models that high fat diet (HFD) decreases mammary cancer latency and 
increases pulmonary metastases compared to a matched control diet (MCD). Genetic analysis 
detected eight modifier loci for pulmonary metastasis, and diet significantly interacted with 
all eight loci. Here, gene expression microarray analysis was performed on mammary cancers 
from these mice. Despite the substantial dietary impact on metastasis and its interaction with 
metastasis modifiers, HFD significantly altered the expression of only five genes in 
mammary tumors; four of which, including serum amyloid A (Saa), are downstream of the 
tumor suppressor PTEN. Conversely, HFD altered the expression of 211 hepatic genes in a 
set of tumor free F2 control mice. Independent of diet, pulmonary metastasis virulence 
correlates with mammary tumor expression of genes involved in endocrine cancers, 
inflammation, angiogenesis, and invasion. The most significant virulence-associated network 
harbored genes also found in human adipose or mammary tissue, and contained upregulated 
Vegfa as a central node. Additionally, expression of Btn1a1, a gene physically located near a 
putative cis-acting eQTL on Chromosome 13 and one of the metastasis modifiers, correlates 
with metastasis virulence.  These data support the existence of diet- dependent and 
independent cancer modifier networks underlying differential susceptibility to mammary 
cancer metastasis and suggest that diet influences cancer metastasis virulence through tumor 
autonomous and non-autonomous mechanisms. 
 
 85 
 
Introduction: 
 Breast cancer prognosis is largely determined by the level of metastasis and is 
influenced by non-genetic factors like diet, which is also a major contributor to obesity. A 
large prospective study of US women demonstrated that obese women in the highest quintile 
of body mass index (BMI) had twice the (Calle et al. 2003) death rate from breast cancer as 
did women in the lowest BMI quintile , possibly due to a higher risk for metastasis (Berclaz 
et al. 2004). The relationship between obesity and breast cancer risk has some genetic 
underpinnings; woman who have a family history of breast cancer are far more likely to 
develop breast cancer when obese rather than lean (Carpenter et al. 2003). Obesity can be 
linked to virulent breast cancer through both proliferative and inflammatory mechanisms 
(Lorincz and Sukumar 2006; Rose et al. 2004). For instance, adipocytes secrete the 
adipocytokine tumor necrosis factor (TNFa) and vascular endothelial growth factor (VEGF), 
which are both associated with breast cancer (Rose et al. 2004).  
Much of the current research on breast cancer metastasis demonstrates an important 
role of angiogenesis and invasion. VEGF family members are associated with poor prognosis 
largely because of their angiogenic potency (Mohammed et al. 2007). Studies of breast 
cancer metastatic invasion frequently include members of the matrix metallopeptidase 
(MMP) family, which remodel the primary tumor through intravasation and seed lung 
metastasis by mediating extravasation (Gupta et al. 2007; Minn et al. 2007). Several obesity-
modifying hormone pathways may interact in angiogenesis and invasion processes; for 
instance estradiol regulates MMP2 and tissue inhibitor of metalloproteinase 1 (TIMP1) 
(Nilsson et al. 2007). While there have been efforts to characterize the mechanistic events 
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driving metastasis and obesity-associated breast cancer, few have characterized the 
mechanistic relationships between obesity, breast cancer, and its metastasis. 
 In order to examine mechanisms underlying the interaction of obesity with breast 
cancer and its metastasis, we developed an obese mouse model of breast cancer metastasis 
(Gordon et al. 2008b). Mice from an F2 mouse population co-segregating obesity 
quantitative trait loci (QTL) and the MMTV-PyMT transgene had decreased mammary 
cancer latency and increased pulmonary metastases when fed a high fat diet (HFD) compared 
to those fed a matched control diet (MCD) (Gordon et al. 2008a). Genome-wide single 
nucleotide polymorphism (SNP) analyses reveled a strong genetic role in modifying 
susceptibility to pulmonary metastases, and diet significantly interacted with novel 
pulmonary metastasis QTL at all eight modifier loci detected (Gordon et al. 2008a). Here we 
examine relationships of dietary fat and the presence of metastasis on tumor gene expression 
signatures. Proliferation, inflammation, angiogenesis, and invasion processes were all 
significantly evident. For instance, pulmonary metastasis migration- associated serum 
amyloid A (Saa2) was upregulated in mammary tumors by HFD. Additionally, the milk 
component gene butyrophilin (Btn1a1) was identified on the metastasis virulence biomarker 
list, lies under a metastatic QTL that interacted with HFD, and mapped to an eQTL 7 cM 
away from its physical location on chromosome 13. These results suggest that Btn1a1 should 
be further examined as a biomarker of breast cancer metastasis risk among women 
consuming a high fat diet. 
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Materials and Methods: 
Husbandry and specimen collection: An F2 population was developed by mating 
M16i, a polygenic mouse model of obesity (Allan et al. 2004), with FVB/NJ-TgN(MMTV-
PyMT)634Mul (PyMT). PyMT is a mouse model of metastatic mammary cancer with primary 
tumor gene expression similar to the gene expression of luminal breast tumors (Guy et al. 
1992; Herschkowitz et al. 2007).  Full details of the generation and sampling of the F2 
population are provided in Gordon et al. (Gordon et al. 2008b). 
 Briefly, F2 female mice hemizygous for PyMT received one of two synthetic purified 
diets, either HFD (n = 76 mice, D12451, Research Diets, New Brunswick, NJ) containing 
45% of total calories from fat, 20% from protein and 35% from carbohydrate, or MCD (n = 
79 mice, D12450B, Research Diets) containing 10% of total calories from fat, 20% from 
protein and 70% from carbohydrates, at four weeks of age and thereafter ad libitum. Mice 
were palpated three times weekly beginning at four weeks of age. Pulmonary metastasis 
(MET) was evaluated on the whole lung superficially by counting the number of foci visible 
under a dissecting scope. Subsequently, three coronal nonadjacent sections of one lung lobe 
per animal were examined under 12x magnification; the number of multicellular metastatic 
lesions observed per square micron of non-alveolar lung tissue was defined as the average 
pulmonary metastatic density (AMD). Axillary mammary tumors were flash frozen for 
microarray analyses (n = 64 and 67 mice fed HFD and MCD, respectively). To validate that 
HFD had expected strong physiological effects, livers were collected from randomly selected 
PyMT negative, non-tumor bearing- F2 female sib-pairs fed opposing diets (n = 12 sib-pairs 
fed HFD, n = 12 sib-pairs fed MCD).  
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RNA isolation and microarray analyses: RNA from both axillary tumor and liver 
was isolated by TRIzol reagent (Invitrogen, Carlsbad, CA), and amplified using the 
Illumina® TotalPrep RNA Amplification kit, both according to manufacturer’s instructions 
(Ambion, Austin, TX). A solution containing 1.5 mg of highly purified biotinylated cRNA 
was applied to the Illumina Mouse 6 Sentrix array (version 1, Illumina, San Diego, CA) 
surface and hybridized at 55oC for 17.5 hours. Following the hybridization period arrays 
were placed in High Temperature Wash Buffer (Illumina) for 10 min, E1BC Buffer 
(Illumina) for 5 min, 100% ethanol for 10 min, E1BC Buffer (Illumina) for 2 min, Block E1 
Buffer for 10 min, and rocked with 2 mL of streptavidin-Cy3 (1 mg/mL in Block E1 Buffer, 
Illumina) for 10 min. Arrays were then washed in E1BC Buffer, dried, and evaluated on an 
Illumina Bead Scanner.  
Microarray data processing: Raw data containing ~ 46,000 probe sets were log 
transformed and then normalized using a combination of the Loess and Quantile methods 
available in the R-based Lumi evaluation program for Illumina expression data (Du et al. 
2008). Loess followed by Quantile normalization of identical pooled mammary tumor RNA 
ran across 11 chips produced a R2 value of 0.95. In order to eliminate transcripts that were 
not significantly expressed above the background signal, data were filtered at an Illumina 
detection score of 0.95 and above. 
Statistical analyses: Log transformed normalized data for all samples were run with 
1000 permutations at an FDR q- value, or Q < 0.05 in SAM software using two class-
unpaired analyses (Storey 2002; Tusher et al. 2001). We examined the effect of diet in 
tumors and livers by looking for significantly differential gene expression between HFD and 
MCD. To examine the relationship between metastasis virulence and gene expression in 
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primary cancers, we used a multi-tiered approach independent of diet. Samples were ordered 
such that 25% (n=33) of the total samples had no surface- or section- metastatic lesions and 
the longest tumor onset. These 33 samples were paired with 33 samples that had the most 
surface metastatic lesions detected (MET66), or with 33 samples that had the most sectional 
metastatic lesions detected (AMD66). Further analysis examined only those genes common 
to both MET66 and AMD66 with also known expression in human- mammary and/or 
adipose- tissues. 
Functional analyses: Significant genes and their fold change values that were 
generated in SAM were imported into Ingenuity Pathways Analysis (IPA) 6.5-1602 
(Redwood City, CA). RefSeq identifiers and their corresponding fold changes were mapped 
to corresponding gene objects in the IPA Knowledge Base (IPAKB). The curated IPAKB 
was used to generate functional analyses of significantly differential gene expression. IPAKB 
can also identify common pharmacological interactions through curation of Food & Drug 
Association data on approved pharmaceuticals, and of the National Institute of Health service 
ClinicalTrials.gov. The significance of functions and diseases to the gene set was determined 
by Fisher’s exact test to calculate the probability (p-value, or P) that each biological function 
and/or disease assigned to the gene set was due to chance alone.  
 
Candidate gene evaluation: Normalized expression profiles were analyzed with the 
F2 inbred/Co-dominant Marker Analysis option of the web-based program QTL Express 
(Seaton et al. 2002), fitting one expression QTL (eQTL) per chromosome.  The genetic 
model included the additive plus dominance effects and fitted replicate and diet as fixed 
 90 
 
effects. The resulting expression loci were classified in one of two categories, “cis” acting if 
they mapped within 10 cM of the physical location of the actual gene they represent; 
otherwise they were classified as “trans” acting. A genome-wide significance threshold for 
eQTL effects (LOD=3.5) was estimated using permutation testing with 1000 iterations 
(Churchill and Doerge 1994). 
Results: 
HFD alters expression of a limited repertoire of genes in mammary cancers: Genes 
differentially expressed between mammary primary cancers from mice fed HFD versus those 
from mice fed MCD were identified through comparison of microarray gene expression 
profiles. Despite the profound effect of diet on metastasis, only five genes were significantly 
upregulated in mammary cancers of mice fed HFD compared to those fed MCD, four of 
which were connected within a common network (Figure 1, Q = 0, Mon1a not shown). 
Reflective of their significant association with cancer (P < 0.001), the four genes of this 
network are downstream PTEN and/or TNF (Figure 1). 
 To determine if products of the genes associated with HFD correlate with existing 
therapies, we used the IPAKB to identify several pharmaceuticals that target products of 
HFD-induced genes. Hyperphosphorylation of eukaryotic translation initiation factor 4E 
binding protein 1 (EIF4EBP1) is induced by the breast cancer therapeutic paclitaxel 
(Greenberg and Zimmer 2005), and SCIO-469 blocks synthesis of TNFA, VEGF, and IL1B 
by inhibiting a MAPK14 complex that binds and phosphorylates EIF4EBP1 
(clinicaltrials.gov ID NCT00744432). Given Eif4ebp1 was upregulated by HFD in mammary 
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cancers, the efficacy of paclitaxel and SCIO-469 may be enhanced by combining therapy 
with dietary modifications reducing fat intake.  
HFD causes extensive changes in liver gene expression: To confirm the validity of 
the modest HFD effect on mammary cancer gene expression (i.e. to demonstrate that this was 
not due to microarray technical issues), we examined global gene expression of livers from 
wild-type F2 littermates of the MMTV-PyMT transgenic mice, because obesity resulting 
from HFD is closely associated with substantial liver transcriptional changes.(Li et al. 2008; 
Morgan et al. 2008) Livers from mice fed HFD were compared to livers from mice fed MCD 
and significant gene expression differences were identified (Q < 0.05). A total of 211 genes 
met this criterion, of which 116 were significantly downregulated and 95 were upregulated 
(Supplemental Table 1). As expected, HFD deregulated numerous biological and 
toxicological functions in liver including carbohydrate-, nucleic acid-, and lipid- metabolism 
(Supplemental Table 2, P < 0.05). Despite the non-transgenic status of these mice, diet was 
associated with hepatic expression changes of 36 genes that are significantly associated with 
cancer phenotypes (P < 0.01).  
Diet-independent transcriptional changes in primary cancers associated with 
metastasis: To investigate the relationship between gene expression in primary mammary 
cancers and metastasis, we identified genes with a Q < 0.05 by comparing global gene 
expression of primary cancers from mice with aggressive metastasis (MET66 and AMD66) 
to those from mice with no metastasis. A total of 478 genes met this criterion in MET66, of 
which 271 were significantly downregulated and 207 were upregulated (Supplemental Table 
3). A total of 212 genes met this criterion in AMD66, of which 140 were significantly 
downregulated and 72 were upregulated (Supplemental Table 4). Together, all significant 
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genes found in each MET66 and AMD66 (n = 690 genes) were examined in IPA for 
functional analyses. 
 The top three most significant function and disease classes of metastasis-associated 
genes were endocrine system disorders, metabolic disease and cancer (P < 0.05). 
Tumorigenesis (101 genes), neoplasia (98 genes), and cell death (94 genes) were the groups 
most populated by genes differentially regulated based upon metastasis (Supplemental Table 
5, P < 0.05). Many tissue remodeling activities, including the hematological system, were 
also significantly altered based upon metastasis (P < 0.05). However, only inflammation was 
evident among significant biological functions, diseases, and canonical pathways (e.g. 
glucocorticoid-, interferon-, and platelet derived growth factor- signaling canonical 
pathways, P < 0.05). 
Development of candidate transcriptional biomarkers of metastasis: Given the large 
number of genes involved in various processes of metastasis, we restricted our analysis to 
transcripts that might later serve as biomarkers of human breast cancer metastasis risk. First, 
a list of candidate metastasis virulence biomarkers was developed from the significant gene 
lists generated by AMD66 (n = 147 biomarker filter eligible genes) and MET66 (n = 420 
biomarker filter eligible genes) groups. The list of candidate biomarkers was developed by 
including only those genes whose expression occurs in mammary or adipose tissues of 
humans. Because AMD and MET are measurements of a similar phenotype, we further 
reduced the candidate biomarker list to those genes common to both gene sets (n = 128 
genes). This list of candidate biomarkers was then subjected to IPA Core Analysis using the 
IPAKB as the Reference Set to assess significance of functions, pathways, and toxicological 
analyses.  
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 Tumorigenesis (36 genes), cell death (36 genes), and neoplasia (35 genes) were the 
function- and disease- categories most populated in the candidate biomarker list 
(Supplemental Table 6). The top network includes upregulated Vegfa, whose product is 
implicated in many metastasis processes, including angiogenesis, and invasion (Figure 2, 
Supplemental Table 6).(Oshima et al. 2004) Other candidate metastasis virulence biomarkers 
are involved in angiogenesis of blood vessels (nine genes, P < 10-4) and angiogenesis-related 
processes including neovascularization (six genes, P < 10-4), as well as endothelial cell- 
migration (nine genes, P < 10-4) and proliferation (six genes, P < 0.01, Supplemental Table 
6). Further, molecules of the biomarker list were significantly associated with invasion (12 
molecules, P < 0.001) and its processes, such as chemotaxis (10 molecules, P < 0.01), and 
breast cancer cell migration (six genes, P < 10-4, Supplemental Table 6). The biomarker 
genes also associated with other diseases with an etiological basis in obesity, e.g. diabetes 
(15 genes, P < 10-6), hypertension (six genes, P < 0.01) and atherosclerosis (ten genes, P < 
10-6, Supplemental Table 6).   
 To determine if products of the candidate transcriptional biomarkers correlate with 
existing therapies, we used the IPAKB to identify those biomarkers whose expression 
changed in direction as predicted by their clinical target. Vegf and Vegfa are upregulated in 
the biomarker list, and the latter is also a drug target for endocrine-, epithelial-, and 
metastatic- cancers, including breast cancer. Another upregulated gene in the biomarker list, 
endothelin receptor type B (Ednrb), is inhibited by atrasentan. Atrasentan is in phase II and 
III trials to treat various cancers as well as endothelial dysfunction (clinicaltrials.gov ID 
NCT00046943). 
BTN1A1 as a candidate therapeutic target for metastasis: Milk fat component 
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Btn1a1 expression was significantly lower in primary cancers associated with metastasis 
compared to those without metastasis (P < 0.01). Similarly, a node just upstream of two 
genes upregulated by HFD in mammary tumors is butyric acid (Figure 1), another bioactive 
component of milk fat. Further, both Btn1a1 and butyric acid are implicated in breast cancer 
(De los Santos et al. 2007; Woelfle et al. 2003). To evaluate the plausibility of these 
correlations, the IPAKB path explorer tool was used to determine whether butyric acid and 
BTN1A1 are functionally related. Through a number of pathways, butyric acid and BTN1A1 
appear to be involved in a negative feedback loop (Figure 3A).  
 Given the non-invasive benefit of nipple aspirate as a potential biomarker of breast 
cancer metastasis risk, we confirmed the importance of BTN1A1 using eQTL analysis. We 
examined SNP markers across chromosome 13, and identified an eQTL on Chromosome 13 
near the Btn1a1 locus that regulates a significant amount of variation in Btn1a1 mRNA 
abundance, suggesting the presence of a cis-acting eQTL (Figure 3B, LOD = 7.39). Further, 
Btn1a1 colocalizes with a previously detected modifier for AMD that was only significant in 
mice fed HFD (Figure 3B) (Gordon et al. 2008a). 
Discussion: 
We previously demonstrated that diet plays a substantial role in tumor onset, tumor 
weight, and the extent of metastasis in an obese mouse model of breast cancer metastasis 
based on the MMTV-PyMT transgene (Gordon et al. 2008a). Yet the modest number of 
genes for which HFD significantly altered expression in primary tumors was unexpected 
given the strong HFD x QTL effects seen on mammary cancer metastasis phenotypes in this 
F2 mouse population (Gordon et al. 2008a). This result may be explained by: 1) the few but 
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highly significant transcript changes due to diet may have been sufficient to drive metastasis 
(Figure 1); 2) diet may have exerted its effects on metastasis through non-autonmous 
systemic changes in extra-mammary sites (Supplemental Table 2); and/or 3) HFD may have 
increased pulmonary metastasis through interaction between transcripts involved in the diet 
network (Figure 1) and transcripts involved in the metastasis networks (Supplemental Tables 
3-4). Although HFD may have changed the expression of few genes because of experimental 
design limitations, the effect of HFD on the liver transcriptome strongly indicates that the 
experimental design was adequate to detect diet effects.  
The expression of few genes in primary tumors change in response to diet: The 
upregulated diet-associated genes have an association with cancer (Figure 1, P < 0.001), 
perhaps because they are downstream from PTEN and/or TNF, both of which are implicated 
in advanced epithelial cancers and insulin resistance (Ikubo et al. 2008; Rosner et al. 2008). 
Further, upregulated Eif4ebp1 is joined with PTEN in the phosphatidylinositol 3-kinase 
(PI3K)/ thymoma viral proto-oncogene (AKT) canonical pathway, a pathway relevant to both 
obesity and cancer metastasis, through the regulation of glucose uptake, as well as cellular 
proliferation and survival (Gingras et al. 1998). Among genes for which HFD significantly 
altered their primary tumor expression, only Mon1a does not have an existing link with 
cancer. Although MON1A is poorly characterized, it is involved in macrophage iron loading 
(Wang et al. 2007a), and thus may interact with the hemoglobin complex, one member of 
which was also upregulated in mammary cancers by HFD. Notwithstanding these 
associations with cancer processes, the modest number of HFD-induced changes in 
mammary cancer gene expression was surprising given the robust effects of HFD on tumor- 
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latency, size, metastasis, and modifier interaction in this F2 population (Gordon et al. 2008a; 
Gordon et al. 2008b). 
Non-tumor-autonomous actions of diet may influences metastasis: Diet may have 
exerted its effects on metastasis through systemic changes in extra-mammary sites, such as 
the hepatic induction of the PI3K/AKT pathway genes associated with metastatic potential in 
the liver (P < 0.01, Supplemental Tables 1-2). PI3K/AKT hepatic signaling may have acted 
in concert with PI3K/AKT signaling in mammary tumors, given that in both tissues, the 
PI3K/AKT pathway was significantly altered by HFD (P < 0.05). A candidate PI3K signaling 
molecule driving such cancer non-autonomous action may be catenin beta 1 (Ctnnb1). 
Ctnnb1 was upregulated in livers from mice fed HFD compared to those fed LFD (P < 0.01), 
and is implicated in breast cancer and its invasion (Adam et al. 2001; Michaelson and Leder 
2001). Further, CTNNB1 binds N-myc downstream regulated gene 1 (NDRG1) (Tu et al. 
2007), which was upregulated by HFD in mammary tumors (Supplemental Table 2, Figure 
1). Cancer non-autonomous mechanisms may extend beyond the PI3K/AKT pathway. In 
liver from the non-transgenic F2 mice and elsewhere (Maxwell et al. 2003), HFD 
significantly upregulated hepatic ectonucleotide pyrophosphatase/ phosphodiesterase 2 
(Enpp2, P < 0.05), a cell membrane enzyme associated with invasion and metastasis 
(Supplemental Tables 1-2) (Nam et al. 2000). These observations strongly suggest that part 
of the effect of HFD on cancer metastasis may be through cancer non-autonomous 
mechanisms. 
Potential interactions between diet and metastasis networks: Saa2 and Saa3 were 
significantly downregulated in our previous functional genomic analysis of the PyMT model 
on FVB/J background compared to other strains of the PyMT model (Qiu et al. 2004). Yet 
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here Saa2 was upregulated by HFD, suggesting HFD and/or polygenic obesity can overturn 
the negative regulation of SAA family expression associated with this genetic mammary 
cancer model. Indeed, SAA2 varies according to the metastatic potential of mouse models of 
breast cancer and is part of a gene expression signature that distinguishes breast cancer 
patient outcomes across independent breast cancer datasets (Lukes et al. 2009).  
While the mechanism of SAA2 on metastasis has not yet been determined, the 
involvement of SAA2 in NFKB signaling in mammary epithelial cells has recently been 
demonstrated (Kho et al. 2008). Here, the second most significant network of the candidate 
panel of transcriptional biomarkers of metastasis has several up-regulated molecules in direct 
interaction with NFKB. Given the mechanism of SAA3 seeding metastasis in the pre-
metastatic lung is attributed to regulation of chemoattractant secretion and resulting NFKB-
mediated cell migration (Hiratsuka et al. 2008), diet-induced SAA2 may interact with the 
metastasis-induced NFKB pathway to increase metastatic virulence. 
Milk fat components are another compelling link between the influences of diet and 
metastasis on mammary tumor gene expression. We found significantly lower expression of 
Btn1a1, a major component of milk fat droplets, in our candidate panel of transcriptional 
biomarkers of metastasis (P < 0.01, Supplemental Tables 3-4). Consistent with this finding, 
decreased Btn1a1 expression was identified as part of the high virulent signature that 
previously characterized the effects of the MMTV-PyMT mammary cancer model (Qiu et al. 
2004), and has also been associated with metastatic breast cancer in humans (Woelfle et al. 
2003). Similarly, a node just upstream of two genes upregulated by HFD in mammary tumors 
is butyric acid (Figure 1), another bioactive component of milk fat. 
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Butyric acid is one molecule upstream of BTN1A1 binding partner, xanthine 
dehydrogenase (XDH, Figure 3A) (McManaman et al. 2002). The BTN1A1-XDH complex 
may be inhibited by butyric acid through the production of angiogenic- NADH and nitric 
oxide (Hewett et al. 1999; Park et al. 1998; Rinaldo et al. 1994; Thomsen and Miles 1998). 
Butyric acid decreases interleukin 1 beta (IL1b) expression (Joseph et al. 2004), which would 
also serve as negative feedback to the BTN1A1-XDH complex, normally stimulated by IL1b 
(Kocic et al. 1995). Because IL1b decreases inorganic pyrophosphate production, which 
synthesizes butyric acid, BTN1A1-XDH stimulus decreases butyric acid.  
Together, the feedback loop of Btn1a1 with butyric acid and the chromosomal 
associations of Btn1a1 are suggestive of a mechanistic relationship between HFD-induced 
obesity and mammary metastasis virulence.  Both BTN1A1 and butyric acid reside on the 
cell surface of mammary alveolar epithelial cells and are regulated by angiogenic Vegf 
(Figure 2) (McManaman et al. 2002; Rossiter et al. 2007). Butyric acid is currently thought to 
inhibit breast cancer through histone deacetylase (HDAC) inhibition (De los Santos et al. 
2007). There is little known about the biological activity of BTN1A1, however its binding 
partner XDH increases secretion of MMP2 (Figure 2), which has been shown to increase 
metastasis through the degradation of extracellular matrix (Galli et al. 2005). Elsewhere 
XDH activation of NFKB mediates angiogenesis (Shenkar et al. 1996). Thus the Btn1a1- 
butyric acid feedback loop may be influencing metastasis through epigenetic-, motility- and 
angiogenic- activity. 
Given the active chemotherapeutic research of butyric acid as a HDAC inhibitor, and 
the downregulation of Btn1a1 reported here, our findings indicate that high levels of Btn1a1 
expression may protect rather than promote of breast cancer. BTN1A1 protein was 
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successfully measured in human nipple aspirate fluid, but was not deemed a suitable 
biomarker of cancer risk because no studies demonstrated a correlation between BTN1A1 
and cancer at that time (Varnum et al. 2003). Consequently, Btn1a1 levels in cancer patients 
treated by HDAC inhibitors may merit monitoring. Investigation of the biological function of 
differential Btn1a1 expression in mouse models of mammary tumor metastasis is underway. 
Study limitations: 
 A role of decreased carbohydrates cannot be eliminated as an influencing factor of 
gene expression- and metastatic- effects of HFD seen here because HFD was formulated to 
have the same caloric density as MCD through a relative decrease in carbohydrates.  
However, diets matched for every nutrient besides fat would require differences in caloric 
density, another imperfect experimental design.  
 Similarly, HFD may have increased mammary tumor gene expression through subtle, 
undetectable changes in gene expression in molecules upstream of those altered by HFD. 
TNFa, PTEN, and butyric acid are examples of genes directly upstream of at least two genes 
that HFD upregulated, and are also associated with breast cancer.  However, the high R2 
value of identical, pooled, and normalized mammary tumor RNA ran across 11 microarray 
chips suggests minimal technical error. The strong influence of metastatic virulence on 
differential mammary tumor gene expression further indicates minimal technical error. As 
expected, these data indicate that HFD substantially altered liver gene transcription, and 
further suggest that cancer non-autonomous changes may contribute to the effects of HFD on 
mammary cancer in MMTV-PyMT transgenic mice. We also cannot exclude the possibility 
that the strong influence of HFD on metastasis seen in this mouse population was mediated 
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through gene expression changes in pulmonary metastasis that were not detectable in primary 
cancers. 
Conclusion: 
A diet high in fat is becoming a more prevalent occurrence. The resulting elevation in 
obesity prevalence is a substantial public health concern in part because of its association 
with breast cancer morbidity and mortality. Our data suggest that diet may increase breast 
cancer metastatic virulence through multifactoral cancer- autonomous and non- autonomous 
effects on cell migration, angiogenesis, and extracellular matrix breakdown.  Transcript 
changes due to HFD, to metastasis, and to their interaction illuminate the influence of the 
primary mammary tumor on pulmonary metastatic virulence. Yet transcript changes in the 
liver indicate that HFD influenced metastasis through systemic, non-autonomous 
mechanisms as well. Our data suggest that the complex relationships between diet, mammary 
carcinogenesis, and its metastasis will become clearer if greater focus is placed on 
understanding the role of extra- mammary sites in carcinogenesis and metastasis. 
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Figure 4.1. Top network depicting the influence of high fat diet on mammary tumor 
gene expression (Ingenuity Pathway Analysis Knowledge Base). Gene networks depict 
how the genes’ products directly and indirectly interact with each other, including those 
genes not identified as significant on the microarrays, and thus networks are ranked such that 
the highest ranked network contains the highest number of significantly expressed genes. 
Red nodes denote significant upregulation comparing high fat diet- relative to matched 
control diet- fed mice (Q = 0).  
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Figure 4.2. Top network of metastasis virulence biomarkers, depicting the genes of both 
AMD66 and MET66 that are expressed in human adipose or breast (Ingenuity Pathway 
Analysis Knowledge Base). Red nodes denote significant upregulation in high virulent 
mammary tumors relative to non- virulent mammary tumors (Q < 0.05). Green nodes denote 
significant downregulation in high virulent mammary tumors relative to non- virulent 
mammary tumors (Q < 0.05).  
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Figure 4.3. Btn1a1- gene expression network and quantitative trait locus in metastatic 
mammary cancer. A) Btn1a1, significantly downregulated by metastasis, and binding 
partner Xdh are regulated in a feedback loop with butyric acid, implicated in high fat diet 
effects on mammary tumors (Figure 1) through IL1B, also downregulated by metastasis (P < 
0.05).  B) Btn1a1 lies within the 95% confidence interval of a QTL associated with the trait 
average pulmonary metastatic density only among mice fed high fat diet. Variation in Btn1a1 
expression was partially explained by a significant expression quantitative trait locus also 
within the 95% confidence interval of the quantitative trait locus that describes the average 
pulmonary metastatic density x high fat diet interaction and near the physical location of the 
Btn1a1 gene. 
  
CHAPTER V 
Genetic architecture of tumor gene expression in dietary fat responsive mouse metastatic 
mammary cancer. 
 
Ryan R Gordon, Michele La Merrill, Kent W Hunter, David W Threadgill, Daniel Pomp 
 
Abstract 
 Breast cancer is the most common cancer type, and the second-leading cause 
of cancer-related deaths of women living in the United States. It has been estimated that in 
2009, nearly 200,000 women in the United States will be diagnosed with some form of breast 
cancer and that over 40,000 will die of this disease, typically from secondary metastasis. 
Breast cancer is a complex disease resulting from a combination of, and interaction between, 
environmental and genetic factors. However, the underlying genetic architecture that results 
in differential susceptibility to this disease is poorly understood. Additionally, links between 
diet and incidence of breast cancer have been reported for a broad spectrum of dietary 
components, including fat. 
We previously reported in an F2 mouse intercross, segregating for both obesity and 
metastatic mammary cancer polygenes, that animals fed a high-fat diet not only have shorter 
mammary cancer latency but also increased tumor growth and more pulmonary metastases 
over an equivalent time. Subsequent genetic analysis identified several modifiers of 
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metastatic mammary cancer along with widespread QTL by dietary fat interactions. To 
further investigate the genetic underpinnings that modify mammary cancer and metastasis, 
global expression profiles of axillary tumors were characterized in F2 mice, and expression 
QTL (eQTL), which are involved in the transcriptional networks of metastatic mammary 
cancer, were mapped. Several potential candidate genes colocalizing with previously 
detected metastatic cancer QTL were identified, while simultaneously accounting for copy 
number variation within the population. Additional analyses, such as eQTL by dietary fat 
interaction analysis, causality and database evaluations, helped to further refine the candidate 
loci to produce an enriched list of genes potentially involved in the pathogenesis of 
metastatic mammary cancer. 
 
Introduction: 
Breast cancer, a complex disease, results from a combination of environmental and 
genetic pressures. A substantial amount of effort has been expended to identify the many risk 
factors associated with breast cancer; however, the majority of underlying mechanisms that 
result in this altered disease state still remain unclear. Whereas some successful attempts to 
understand the genetic predisposition to mammary cancer have been achieved, such as 
identifying small-to-low effect familial risk factors (Rohan et al. 2006; Song et al. 2006; 
Walsh et al. 2006), the overall genetic architecture remains largely unknown. In addition, 
little success has been realized in understanding the interactions between genes and 
environmental components, such as diet, and the pathogenesis of metastatic mammary 
cancer. 
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Previously we generated an F2 intercross (Gordon et al. 2008b) between the M16i 
polygenic mouse model of obesity (Allan et al. 2004) and FVB/NJ-TgN(MMTV-
PyMT)634Mul (PyMT), a mouse model of metastatic mammary cancer (Guy et al. 1992). 
Results demonstrated that animals fed a high-fat diet not only have decreased mammary 
cancer latency, but also increased tumor growth and pulmonary metastases over an 
equivalent time. Several modifier loci (i.e. quantitative trait loci; QTL) for metastatic 
mammary cancer were detected along with widespread QTL by dietary fat interactions 
(Gordon et al. 2008a).  Subsequently, a subset of mammary tumors collected from F2 female 
mice were evaluated for whole genome expression using the Illumina mouse Sentrix array. 
Analyses of the gene expression data surprisingly revealed that, globally, only five genes 
were differentially expressed between mice on the two dietary fat treatments (la Merrill et al., 
2009). However, dietary fat was found to alter pulmonary metastasis of mammary cancers 
through cancer autonomous and non-autonomous changes in gene expression (la Merrill et 
al., 2009). 
Whereas QTL analysis and differential expression may reveal pathways, candidate 
regions and genes potentially linked to disease phenotypes, these methods are both 
independent assessments of the paradigm. As such, inferring a relationship between the 
results of the two methods is difficult. An approach that can bridge this disconnect is to treat 
the expression of each transcript identified through microarray analysis as a quantitative trait.  
The traits can then be tested for associations with genotypic data to map what is known as an 
expression QTL (eQTL) (Jansen and Nap 2001; Schadt et al. 2003a).  When running an 
eQTL analysis, two distinct classes of loci are detected. The first class is loci that map within 
close proximity to the actual physical location of the expressed gene (cis-acting), and the 
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second class is loci which map independently of the expressed genes physical location 
(trans-acting) (Pomp et al. 2008). Whereas trans-acting eQTL represent loci controlled by 
unknown regulators, cis-acting eQTL exhibit self-regulation (Alberts et al. 2005). Therefore, 
by overlaying these cis-acting eQTL with locations of traditional phenotypic QTL detected in 
the same mapping population, the potential exists to significantly narrow the pool of 
candidate genes that are both positional and functional in nature (Wang et al. 2007b). The 
field of research on metastatic breast cancer has produced only a few experiments utilizing 
this multifaceted approach (Crawford et al. 2008).  
Recently a new source of genetic variation, known as copy number variants (CNV), 
has been identified that can potentially impact on disease processes. CNV are described as 
segments of DNA that are over-or under-represented because of insertions/deletions 
occurring naturally over time or acutely due to tissue-specific somatic mutations (Feuk et al. 
2006). Approximately 12% of the human genome has been estimated to be affected by CNV 
(Beckmann et al. 2007) and this over/under-representation of chromosomal segments may 
have profound influences on the expression of the genes within these affected regions.  Many 
diseases, such as Crohn’s disease (Fellermann et al. 2006), lupus (Yang et al. 2007) and HIV 
(Gonzalez et al. 2005), have already been linked in part to CNV. CNV may also plausibly be 
linked to many common complex chronic diseases such as cancers (Shelling and Ferguson 
2007), yet currently our knowledge of the relationship between CNV and of chronic diseases 
remains limited. Further, the influence of CNV on detection of eQTL has been largely 
ignored. 
In this report, evaluation of our M16i x PyMT F2 cancer mapping population for 
tumor eQTL potentially involved in the transcriptional networks of metastatic mammary 
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cancer is described. The genetic regulation of expression profiles of metastatic mammary 
tumors through an eQTL analysis was established initially. Potential candidate genes for the 
previously detected phenotypic cancer QTL were then identified, while simultaneously 
accounting for CNV within our population and their impact upon mammary cancer 
susceptibility and progression. With the aid of other analyses, such as causality and database 
evaluations, these candidate genes were further refined to produce a short enriched list of 
genes potentially involved in the pathogenesis of metastatic mammary cancer in this mouse 
population. 
 
Materials and Methods: 
Population development: An F2 population (n = 615) was generated by crossing 
M16i, a polygenic obesity line (Allan et al. 2005), and FVB/NJ-TgN(MMTV-PyMT)634Mul 
(PyMT), a line transgenic for the Polyoma Middle T Oncoprotein leading to development of 
mammary tumors and subsequent pulmonary metastasis (Guy et al. 1992) (see (Gordon et al. 
2008b) for full details of population development). F2 mice were randomly assigned, within 
litter, gender, and genotype (PyMT or no PyMT), to receive one of two synthetic purified 
diets at 4 weeks of age, either a high-fat diet (HFD; Research Diets D12451) containing 45% 
of total calories from fat, 20% from protein, and 35% from carbohydrates, or a matched-
control-fat diet (MCD; Research Diets D12450B) containing 10% of total calories from fat, 
20% from protein, and 70% from carbohydrates. Mice were evaluated for various body 
weight, body composition and metastatic mammary cancer phenotypes as previously 
described (Gordon et al. 2008a; Gordon et al. 2008b). Axillary mammary tumors were 
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harvested from 131 F2 female PyMT carriers (HFD = 64 and MCD = 67) for microarray 
analysis. 
 
Microarray analysis of mouse mammary tumors:  For complete details refer to la 
Merrill et al (2009). Briefly, total RNA was isolated from axillary tumors using TRIzol 
(Invitrogen, Carlsbad, CA) and preprocessed for array hybridization using the Illumina® 
TotalPrep RNA Amplification kit (Ambion, Austin, TX). Expression profiles were generated 
using the Illumina Muse 6 Sentrix arrays (Kuhn et al. 2004) (Illumina, San Diego, CA) and 
the resulting data were transformed and normalized using the R-based evaluation program for 
Illumina expression data Lumi (Du et al. 2008) prior to filtering at an Illumina detection 
score of 0.95 and above. 
 
Correlation analyses: Pearson correlations were generated between all significantly 
expressed genes on the microarray and the metastatic cancer phenotypes previously 
measured in the F2 population (Gordon et al. 2008a). The correlations were generated as three 
separate data sets: one for the whole population and the other two for animals on either the 
HFD or the MCD. All resulting p-values were adjusted with the FDR multiple comparisons 
test. Transcripts were then sorted by their strength of correlation within each phenotype. 
 
Expression QTL (eQTL) analysis of mouse mammary tumors: eQTL were identified 
utilizing a customized bioconductor R-GUI based program. The eQTL models were fitted 
with the following effects: additive, dominance, breeding-replicate and diet. The resulting 
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eQTL were classified in one of two categories: “cis” if they mapped within 10 cM of the 
physical location of the gene they represent, and “trans” if they mapped elsewhere. Clusters 
containing 50 or more eQTL within a 5 cM interval (i.e. trans-bands) were designated as 
potential master regulatory regions. The significance threshold for all eQTL was set at a 
likelihood ratio statistic of 16.1 (LOD: 3.5). All eQTL classified as cis-acting were evaluated 
for the presence of eQTL x diet interactions by running an additional model which included 
all the aforementioned effects in addition to an eQTL x diet interaction term. The sum-of-
squares error and the degrees of freedom for the peak position for each eQTL in both the 
interaction and non-interaction models were then calculated and used to estimate an F 
statistic. Confidence intervals were calculated using the bootstrap method with 1000 
permutations in Grid QTL (Seaton et al. 2002) for cis-acting eQTL mapping in close 
proximity to master regulatory regions.  
 
Pathway evaluation: All eQTLwere evaluated using Ingenuity Pathway Analysis 
(IPA; Ingenuity Systems Inc., Redwood City, CA). Using the IPA core analysis function, 
reports containing information regarding the function, regulation, known mutations, tissue 
expression patterns, cellular location, and disease implication were generated for all genes of 
interest. IPA also provides rankings for biological functions based upon the number of genes 
from a reference set (a list of genes provided by the user) that participate in the particular 
function, while considering the total size of the reference set, the total number of genes from 
the reference set eligible for function analysis and the total number of molecules know to 
participate in the function in question.  
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The IPA core comparison function was used to generate the predicted transcriptional 
networks between the cis and trans-acting eQTL in master regulatory regions. Initially, both 
gene lists were analyzed separately to generate within-set transcriptional networks, 
containing each gene within the list as well as all other molecules and genes with which they 
are known to interact (based on the IPA database). Then both transcriptional network files 
(cis-acting, trans-acting) were evaluated with the comparison function of IPA, to determine if 
any interactions existed among the gene sets. 
 
Causality evaluation: Causality relationships between cis-acing eQTL and both 
cancer phenotypes and trans-acting eQTL were evaluated using the R-based package eQTL-
TF (Sun et al. 2007). When estimating the relationships between cis-acting eQTL and cancer 
phenotypes three models were considered (Figure 1). The causal model is where genetic 
alterations (G) result in changes in the expression of a cis-acting eQTL (C), which in turn 
result in modification of the phenotype (or change in gene expression of a trans-acting 
eQTL) (P/T). In the reactive model, variation in G directly impacts P/T resulting in altered 
gene expression of C. The third model evaluates whether variation in G can result in changes 
in both P/T and C independently. 
 
Oncomine evaluation: All cis-eQTL colocalizing with previously detected metastatic 
QTL (Gordon et al. 2008a) were entered into the Oncomine database (Rhodes et al. 2004) to 
determine if the genes they represent had been previously linked to metastatic cancer in 
humans. Specifically, all human breast cancer prognosis datasets in Oncomine were 
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evaluated at a p-value threshold of 0.01 for each gene. The prognosis category was evaluated 
because it best represents the possibility of having a metastatic cancer phenotype. If a gene 
was identified in any of the datasets in the prognosis category, it was further evaluated to 
determine if its expression is positively (no metastasis, alive, no disease) or negatively 
(metastasis, dead, relapse) associated with the clinical phenotype. 
 
 Evaluation of CNV in mouse mammary tumors: Copy number variation was evaluated 
using the NimbleGen mouse 385K whole genome tiling array  (NimbleGen Systems, Inc. 
Madison, WI) with a median probe spacing of 5.7 kb, in a subset of the F2 females selected to 
represent the largest spectrum of tumor mobilization capacity (propensity of the tumor to 
metastasize). This spectrum was achieved by selecting within each diet the 17 individuals 
with the highest number of observed pulmonary metastases and the 17 with the lowest 
number of observed pulmonary metastasis, for a total of 68 individuals. RNA-free genomic 
DNA was extracted using the Puregene Tissue Core Kit (Qiagen, Minneapolis, MN) from the 
axillary mammary tumors (test) and tails (reference) of all 68 individuals. DNA samples 
were fragmented and fluorescently labeled with either cy-3 (tumor DNA) or cy-5 (tail DNA). 
The labeled tumor samples were pooled with their reference and co-hybridized to a 
NimbleGen 385K CGH array. Arrays were evaluated for relative fluorescence to determine 
the copy number profile across the genome for each individual using the NimbleScan 
software (NimbleGen Systems, Inc. Madison, WI).  
Resulting data were evaluated using SignalMap software (NimbleGen Systems, Inc. 
Madison, WI), to determine if patterns of CNV could be identified within the population. To 
provide common settings across the population for analysis in SignalMap, the log2 ratio scale 
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was set at -2 and 2, while the track height was set at 120. Segments that deviated from 0.0 by 
± 0.2-0.4 indicated a single amplification or deletion. A segment that deviated from 0 by ± 
0.4-0.6 indicated a double amplification or deletion. If CNV was identified on chromosomes 
where we previously detected metastatic QTL, Proc Mixed in SAS (SAS Institute, Cary, NC) 
was used to determine whether significant associations were present between the copy 
number change and the phenotype the locus represented. The model evaluated included the 
fixed effects of diet and CNV, the interaction of diet x CNV, and the random effect of 
breeding replicate. If an association between the phenotype and copy number change was 
detected then cis-eQTL on the Chr in question were also evaluated to determine if its gene 
expression was altered by the amplification or deletion. 
 
Results: 
Correlation evaluations: Correlations amongst gene expression and metastatic 
phenotypes were analyzed in a three-step process, the first of which utilized the entire 
population regardless of diet. While many genes were weakly correlated with the metastatic 
phenotypes, no genes surpassed the significance threshold of p < 0.05 after adjustment for 
multiple testing. Given the design of our experiment we initially attributed the lack of 
correlation to the fact that the animals were fed two different diets that have been shown to 
have divergent effects on the metastatic potential. As such, the animals were separated 
according to diet and reevaluated for correlations. While the correlations between gene 
expression and metastatic virulence were slightly stronger in animals only fed the HFD 
compared to those detected in the whole population, they still were not significant after 
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adjusting for multiple comparisons. However, when the correlations were evaluated in 
animals fed the MCD, 14 genes were found to have significant correlations with the 
metastatic phenotype (Table 1). When these genes were evaluated with IPA, the major 
network functions included cancer, genetic disorders, cellular assembly and organization, and 
connective tissue disorders. IPA identified direct and indirect connections between several of 
these genes within this set and TP53, a well known oncogene. 
 
eQTL evaluation:  Totals of 220 cis-acting eQTL and 890 trans-acting eQTL (Figure 
2 A and B, and Supplemental Tables 1 and 2) were detected.  The cis-acting eQTL were 
found across all chromosomes with Chr 11 and 17 harboring the most, while Chr 2 and 16 
had the fewest. Trans-acting eQTL were likewise distributed across all the chromosomes 
with Chr 3, 8 and 19 containing the largest numbers. When averaged, the LRT score for all 
cis-acting eQTL was 45.9 with individual LRT scores ranging from 16.2 to 197.1.  The 
average LRT score for all trans-acting eQTL was significantly less at 23.9. However, the 
range for individual LRT scores amongst the trans-acting eQTL was similar to that observed 
amongst cis-acting eQTL. If the trans-acting eQTL were evaluated as two separate groups, 
those mapping to the same chromosome (but not within 10 cM) as the actual gene they 
represent and those mapping to different chromosomes, the average LRT scores were 37.5 
and 19.0 respectively.   
While the trans-acting eQTL represent loci controlled by unknown regulators, cis-
acting eQTL exhibit self-regulation (Alberts et al. 2005). As such, by comparing/overlaying 
these cis-acting eQTL with the phenotypic cancer QTL detected in this population, the 
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potential exists to reveal the unknown polygenes (or at least to provide gene candidates) that 
result in the metastatic mammary cancer phenotype. Utilization of this method enabled the 
detection of 76 potential candidates for the previously detected metastatic QTL and 95 
potential candidates for tumor growth and latency QTL (Supplemental Table 3 and 4). These 
candidates were further refined based on their proximity to the phenotypic QTLs. If genes 
only within 15 cM of the phenotypic QTL peaks are considered, then the number of 
candidates is reduced from 76 to 44 and from 95 to 33 for metastatic and tumor 
growth/latency QTL respectively (Tables 2 and 3). We had previously identified metastatic 
modifiers on Chr 1, 8, 11, 13 and 19 (Gordon et al. 2008a) and the distribution of eQTL-
based candidate genes relative to phenotypic QTL is portrayed in Figure 3. We has 
previously identified tumor growth and latency modifiers were identified on Chr 1, 5, 7, 9, 
13, 14 and 17 (Gordon et al. 2008a) and the distribution of eQTL-based candidate genes 
relative to phenotypic QTL is portrayed in Figure 4.  
To investigate the functions of all cis and trans-eQTL the two separate gene lists were 
entered into IPA and evaluated with the core analysis function. Of the 220 cis-eQTL, 206 
were found in the IPA database and of those eQTL, 117 were eligible for network and bio-
function analysis (Table 4). The top bio-functions as indicated by IPA in the cis-acting 
dataset were cancer and cellular movement. When the bio-functions were expanded to dissect 
more specifically the categories, it revealed that the genes in the cancer set fell into many 
subgroups, including apoptosis, tumor growth, migration, proliferation and invasion, along 
with categories representing a wide spectrum of specific cancer varieties. When the cellular 
movement group was expanded, the top functions were migration, invasion and localization. 
Additionally genes were partitioned into networks based on the known or predicted 
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interactions from the IPA database and ranked by IPA based on the number of candidate 
genes that appear within the dataset. Assessing the top functions of the highest ranked 
datasets revealed that many of these genes were involved in metabolism, cellular 
proliferation/death, and multiple processes of cancer. 
These same analyses were performed on the trans-acting eQTL and out of the 890 
eQTL, 808 were identified in the IPA database, and of those 515 were network and bio 
function eligible (Table 4). The top bio-functions represented in this dataset included 
carbohydrate metabolism, small molecule biochemistry and cancer. When the cancer bio-
function category was expanded to provide further insight, the top functions of genes within 
this category were revealed to be involved in tumorigenesis, apoptosis and cell death. The 
expansion of the carbohydrate metabolism set identified genes involved in the metabolism of 
fructose-6-phosphate, glycosaminoglycan and UDP-N-acetylglucosamine The networks with 
the highest scores in the trans-eQTL data shared similar functions to the top networks in the 
cis-eQTL, such as the processes involved in metabolism, small molecule biochemistry and 
cancer. DNA replication and repair, gene expression as well as endocrine disorders were 
represented as well. 
 
Diet interactions: Previously when evaluating this population for QTL we found that 
the majority of cancer related modifier loci exhibited interactions with dietary fat levels.  For 
example, the metastatic modifier we previously identified on Chr 8 resulted from the 
presence of a significant QTL in mice fed the high–fat diet but not the control-diet (Gordon 
et al. 2008a). As such it was possible that the cis-acting eQTL would likewise show dietary 
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interactions. These dietary interactions could potentially be used as a filter to predict which 
candidates within the phenotypic QTL confidence intervals may be responsible for the 
phenotypic variation observed. However, only ~7% of the cis-eQTL had diet interactions 
(Table 5). Of the interactions detected, four resulted from differential allelic effects within 
the two diets, the first, Slc43a3 mapped to Chr 2, the next, Basp1 was identified on Chr 15, 
while E4f1 was detected on Chr 17 and Frmd8 mapped to Chr 19.  All other eQTL by diet 
interactions resulted from the detection of a significant effect for animals fed one diet but not 
the other; the majority of significant effects were found in animals fed MCD. 
 
Causality evaluation: One way to further refine the candidate gene list is to evaluate 
the relationship between the cis-eQTL and the observed metastatic modifier loci. If eQTL 
have a causal relationship with these metastatic loci then they may in turn represent the 
actual underlying genetic modifier of the phenotype of interest (Schadt et al. 2005). The 
results revealed that very few significant causal relationships existed between cis-eQTL and 
metastatic virulence QTL. In only a few situations were weak independent associations 
detected between eQTL and phenotypic QTL such as those observed on Chr 1, 8 and 19 
(Table 6). In addition to the independent associations, one weak causal relationship, which 
bordered on the threshold of significance, was detected between H2afv and the metastatic 
modifier on chromosome 11 (Table 6). 
  
Oncomine evaluation: The evaluation of the Oncomine database revealed that 22 of 
the 45 candidates for the metastatic QTL have been previously reported in human breast 
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cancer prognosis datasets (Table 7). Of the 22 candidates detected, five were found to have 
an association between both increased and decreased gene expression and the clinical 
phenotype among the different datasets. Six of the candidates were found to have an increase 
in their expression associated with a better clinical outcome. In this category the candidates 
with the greatest number of human studies supporting their association were Dusp4 on Chr 8 
and Cxcl14 on Chr 13 with nine and five studies providing evidence, respectively. The final 
11 candidates were found to have an increase in their expression be associated with a poorer 
clinical prognosis. The candidate with the most compelling evidence in this group was H2afv 
on Chr 11 with seven studies supporting this link. 
 
 Master Regulator Analysis: Another observed phenomenon in large transcriptome 
mapping studies are chromosomal segments enriched with trans-acting genes forming what 
are commonly referred to as trans-bands or master regulatory regions. When the trans-eQTL 
detected in this intercross were evaluated in 5 cM windows, two potential master regulatory 
regions were identified on Chr 3 and 19 (Figure 2 B).  The region on Chr 3 contains 98 trans-
acting eQTL from 14 cM through 18 cM.  The region on Chr 19, from 13 cM through 17 cM, 
contains 60 trans-acting eQTL. To further evaluate these regions, the IPA comparison 
function was used to determine if any overlap exists between the co-localized cis and trans-
acting eQTL. This analysis failed to reveal any known connections. 
Given that IPA is limited to only identifying previously reported associations, the 
actual relationships between eQTL in the master regulatory regions may go undetected. As 
such, causality analysis was utilized to further investigate the relationships in master 
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regulatory regions between cis-eQTL and trans-eQTL. These analyses revealed potential 
candidates for the master regulators on Chrs 3 and 19.  On Chr 3 the cis-eQTL Pkia formed 
significant causal relationships with 93 trans-acting eQTL. The eQTL peak for Pkia did not 
map within the master regulatory region on Chr 3. However, the confidence interval for this 
eQTL extended from 4.4 cM to 17.4 cM, encompassing almost the entire master regulator 
region. In the master regulator region on Chr 19 Pkd2l1 was identified as being causally 
related to 54 trans-acting eQTL. Similar to Pika, the eQTL peak for Pkd2l1 was not located 
within the master regulatory region on Chr 19, but again the confidence interval, which 
extended form 8 cM to 45 cM, contained the entire master regulatory region.   
 
CNV evaluation: These results revealed that while situations of copy number 
variation did indeed exist (Figure 5), very few of these segments were shared among the 
animals tested. Four regions were identified that contained patterns of chromosomal 
rearrangements, the first of which was a short 0.5 Mb segment on Chr 8 at approximately 20 
Mb.  A 9 Mb segment at the distal end of Chr 11 was also detected at which 58% of the 
animals tested had an additional copy of this region. On Chr 13 a 1 Mb segment starting at 65 
Mb was identified where 11% of the population had a single amplification and 17% had a 
single deletion. The final region detected was a 0.25 Mb segment staring at 9.6 Mb on Chr 19 
where 8% had a single amplification and 20% of the animals had a single deletion. 
When these copy number changes were evaluated to determine if they were 
associated with metastatic development, no relationship was identified within the regions 
detected on Chrs 13 and 19, but significant associations within the regions of chromosome 8 
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(Figure 6 A) and 11 (Figure 6 B) were found. On Chr 8 individuals with a deletion of the 
region had significantly less pulmonary metastases compared to individuals with no CNV, 
while individuals with an amplification of the region had almost a threefold increase in the 
number of metastasis detected when compared to individuals with no CNV. On the other 
hand, individuals with the amplification of the segment on Chr 11 had a significant reduction 
in metastatic development. This evaluation was expanded to investigate whether the 
expression levels of the cis-eQTL on these two Chrs were associated with the detected 
CNVs. Only one cis-eQTL, Ascc2 which is located on Chr 11, was found to be associated 
with either of these copy number variations. A small but significant increase in expression of 
this gene was detected in animals that had amplification at the distal end of this chromosome 
(Figure 6 C). 
 
Discussion: 
Breast cancer is one of the most common cancer types diagnosed in the United States. 
In most cancer cases the primary tumor is considered nonfatal and if removed early enough, 
total remission should follow. Yet, in many instances as tumor growth progresses, abnormal 
cells invade the lymphatic system or other vasculature and metastasize to distant sites in the 
body, such as the brain, bones, and lungs. This advanced cancer is far more difficult to treat 
and typically results in mortality after a course of a few years or more (Murphy 2001). While 
the variability in the pathogenesis of breast cancer is most likely influenced by a combination 
of environmental elements (e.g. diet) and genetic predisposition, the underlying mechanisms 
resulting in the altered disease state still remain unclear. Since it has been estimated that 60-
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70% of patients have progressed to metastatic disease by the time of their diagnosis (Eccles 
et al. 1994), the elucidation of the genetic underpinnings influencing metastatic cancer is 
essential for decreasing cancer mortality.  
This pressing need to understand the genetic architecture of metastatic mammary 
cancer prompted the development of the F2 intercross between mice genetically predisposed 
to obesity and metastatic mammary cancer (Gordon et al. 2008b). Utilizing this population, 
we characterized several primary tumor phenotypes, such as tumor latency and growth, as 
well as the development of pulmonary metastasis (Gordon et al. 2008b). In addition, we 
found that the consumption of a high fat diet not only contributes to increased tumor growth, 
but increased metastatic virulence as well. These cancer phenotypes along with the genotypic 
data obtained from this F2 population facilitated the detection of multiple metastatic 
mammary cancer modifier loci, several of which exhibited QTL by diet interactions (Gordon 
et al. 2008b).  
Interestingly, subsequent differential expression analyses within F2 tumors revealed 
that very few genes were differentially expressed between the two dietary treatments (la 
Merrill et al, 2009). However, when the individuals were segregated based on metastatic 
tendencies, substantially more differentially expressed genes were identified (la Merrill et al, 
2009).  Given the wide range of metastatic phenotypes, the observed transcriptional 
differences in this genetically segregating population and the clinical importance of the 
metastatic process, further investigation into genetic architecture of metastatic mammary 
cancer was warranted. 
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Evaluation of candidates for metastatic QTL:  
Detection of strong correlations between transcript expression and metastatic 
phenotypes was expected. This was a reasonable assumption, given the findings of the 
previous studies evaluating transcriptional data in large mapping populations that reported 
significant correlations between their observed clinical phenotypes and gene expression 
(Ghazalpour et al. 2005). Yet, after evaluating our data, very few genes expressed above 
background on our arrays were significantly correlated with any of the metastatic traits. In 
retrospect, this result was not entirely surprising given that previous studies have had 
conflicting success with experiments utilizing mice harboring the PyMT transgene (Crawford 
et al. 2008; Qiu et al. 2004).  
One possibility for the limited correlations is that the metastatic process involves an 
intricate cascade of events (Carmeliet and Jain 2000; Howard et al. 2008; Kroemer and 
Pouyssegur 2008; Lunt et al. 2009), each of which may only require subtle changes in gene 
expression. If this were the case, then the combined network of genes could be significantly 
correlated with the clinical phenotype (Yvert et al. 2003), while the genes that comprise the 
network may individually be only weakly associated. The possibility also exists that genes 
expressed directly by the metastatic seed itself, or perhaps its host environment, could be 
more highly correlated with the metastatic phenotype than those expressed in the primary 
tumor tissue (Dong et al. 1999). However, Weigelt et al (2003), found that primary tumor 
cells and their matched distant metastatic cells had remarkably similar gene expression 
patterns. Weigelt et al findings suggest that tumors and metastasis are both relevant tissues 
for investigating the etiology of metastatic mammary cancer.  Furthermore, it is more 
clinically relevant to be able to predict a tumor’s ability to metastasize, prior to the event 
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actually occurring, and/or identify therapeutic targets which if perturbed may prevent the 
metastatic process altogether. 
 Relatively few studies have performed eQTL analyses utilizing cancer models in 
rodents. The populations that have been previously characterized evaluated models of skin 
tumors (Quigley et al. 2009), mammary cancer (Crawford et al. 2008) and prostate cancer 
(Yamashita et al. 2005). While the experiments by Crawford et al (2008) were successful in 
identifying a pathway altered in metastatic mammary cancer, they only focused on a select 
subset of genes which had been previously predicted to be important players in metastatic 
disease. Currently, no other full genome eQTL analysis for metastatic mammary cancer 
models has been reported. As such, we set out to expand this type of analysis on a larger 
scale by performing a whole genome eQTL analysis of metastatic mammary cancer, similar 
to analyses described previously in multiple other model species (Brem and Kruglyak 2005; 
Chesler et al. 2005; Schadt et al. 2003a; Yvert et al. 2003). 
One caveat that needs to be considered when performing an eQTL study is the degree 
of CNV within the mapping population. Taking into account CNV is especially important 
when analyzing tumor tissue, given the substantial amount of evidence linking the 
accumulation of CNV to cancer pathogenesis (de Tayrac et al. 2009; Fridlyand et al. 2006; 
Namba et al. 2006; Reis-Filho et al. 2005; van Beers and Nederlof 2006; Yusenko et al. 
2009). CNV can be classified into two categories, those that are inherited (germ-line) and 
those that are acquired during the replication of cells (somatic). In humans, germ-line CNVs 
are detected across all tissues in both healthy and diseased individuals (Shlien and Malkin 
2009). The presence of CNV in genomic regions encoding cancer modifiers can lead to 
increased risk for the development of cancer (Albertson et al. 2003). Somatic CNV are 
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acquired during DNA replication and are not found uniformly throughout all tissue types, and 
their presence can impart a growth advantage to cells harboring them, resulting in disease 
(Greenman et al. 2007). Tsafrir et al. (2006) article suggests that as cancer progresses it is 
possible for tumors to continue acquiring somatic CNV, which could potentially alter their 
metastatic tendencies. 
 Our experimental design, in which we evaluated the tumor tissues against a reference 
of matched tail tissues, only provided us the ability to evaluate somatic CNV. The primary 
objective was to evaluate the impact of somatic CNV on both metastatic development and the 
detection of eQTL. The influence of CNV upon transcriptional studies has not been well 
characterized, yet clearly duplications or deletions of chromosomal segments, which can 
result in altered expression of genes residing within those boundaries, could influence the 
detection of eQTL. It is possible that without accounting for perturbations in gene expression 
mediated by CNV, eQTL results could be incorrectly interpreted. Additionally, given the 
findings of Williams et al (2009) where the cis-eQTL identified for Glo1 was detected as a 
result of a duplicated region on CHR 17, CNV appears worth evaluating.  
In our population all but one of the cis-eQTL acted independently of somatic CNV. 
Ascc2, a gene physically located outside the genomic boundaries of the CNV on Chr 11, was 
shown to have its gene expression significantly modified by a CNV (Figure 6C). It is 
possible that CNV interval we detected on Chr 11 contains an enhancer element that impacts 
the expression Ascc2, but is not the primary source of transcriptional variation for this 
candidate observed in the F2 population. The presence of an enhancer element could 
potentially explain why the expression Ascc2 could be modified by a distant CNV and still be 
classified as a cis-acting eQTL. Other investigators have likewise detected relationships 
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between copy number changes and the expression of genes located outside the CNV regions 
(Henrichsen et al. 2009; Stranger et al. 2007). As suggested by Reymond et al. (2007), this 
type of relationship indicates that transcriptional variation of genes encoded outside the 
boundaries of a CNV can potentially occur if a key regulatory element for that particular 
gene is encoded within the CNV interval. While we detected very little connection between 
cis-eQTL and CNV in our population, the link identified between the CNV on Chr 11 and 
Ascc2, highlights the importance of evaluating CNV in transcriptional studies in order 
properly interpret the results.  
 While several cis and trans regulated eQTL were identified across all chromosomes, 
the cis-acting eQTL mapping in close proximity to our previously detected metastatic cancer 
QTL were of primary interest. Prior experiments have suggested that cis-eQTL colocalizing 
with metastatic mammary cancer modifiers may represent logical positional and functional 
candidate genes for theses loci (Wang et al. 2007b; Yamashita et al. 2005). This is further 
supported by the discovery of Rrp1b, a cis-eQTL that colocalized with a previously detected 
metastatic QTL, and was later predicted to be clinically important in metastatic disease 
(Crawford et al. 2007). Filtering the cis-eQTL based on their proximity to our previously 
detected phenotypic QTL enabled the detection of 44 candidates colocalizing with metastatic 
modifier loci. 
 Causality testing has been touted as having the potential to predict whether a 
transcript is associated with a clinical phenotype locus. A cis-eQTL causally associated with 
and physically located close to a QTL could provide a logical candidate for that particular 
locus (Farber et al. 2009; Schadt et al. 2005). Using this method we detected one cis-eQTL 
that was causally associated with a metastatic locus, H2afv on Chr 11, coding for a protein 
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that is a member of the histone H2a family. Histone modifications have been detected in 
human cancers (Fraga et al. 2005) and can be used to provide insight into clinical outcomes 
(Seligson et al. 2005). Currently, very little information regarding the function of H2afv 
exists, but other members of the histone family H2A (H2AX) (Liu et al. 2007b) and proteins 
they encode (Buforin IIb) (Lee et al. 2008) have been shown to be potent inhibitors of cancer. 
While a casual relationship between H2afv and a metastatic locus on Chr 11 was detected, 
the overall limited number of observed associations (casual, reactive and independent) may 
be highlighting the complexity of the metastatic mammary cancer paradigm. For any 
particular complex trait, the intricate architecture that gives rise to the disease may be 
difficult to elucidate, because several genes and the networks they comprise likely contribute 
to the development of an endpoint phenotype. Additionally, if the metastatic QTL we 
detected were driven by coding changes not resulting in transcriptional variation then we 
would likely fail to detect causal relationships between that particular metastatic locus and 
the colocalizing cis-eQTL. It is also possible that the limited number of associations we 
detected may simply be a result of a lack of power. However, a lack of power seems a less 
likely scenario given that several other studies have detected causal relationships in utilizing 
smaller populations (Schadt et al. 2005; Sun et al. 2007). Whereas causality testing is useful 
tool for detecting whether a transcript is associated with a phenotypic locus, caution is 
required when interpreting a lack of association.  
Given that previously QTL by diet interactions were identified in this F2 population 
(Gordon et al. 2008a) we anticipated seeing interactions reflected in eQTL as well. A cis-
acting eQTL interacting with diet and colocalizing with a metastatic QTL exhibiting a similar 
interaction may represent a likely candidate for that particular locus. However, only a small 
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number of interactions were detected in the transcriptome mapping population. Additionally, 
the eQTL for which we detected diet interactions colocalizing with a phenotypic QTL, such 
as Gdi3 on Chr 13, Frmd8 and Ms4a6c on Chr 19, resulted from significant eQTL effects in 
mice fed the MCD. The aforementioned results were not consistent with the interactions 
detected for the metastatic QTL that these eQTL colocalized with, which resulted from 
significant eQTL effects in mice fed the HFD. Whereas the limited number of interactions 
was initially surprising given our previous findings, this result seems consistent with the lack 
of differentially expressed genes between the two dietary treatments as we reported in la 
Merrill et al., (2009).  
The limited number of interactions detected may indicate that indirect effects of diet 
upon the tumors may have been responsible for the dietary effect upon tumor growth and 
metastatic development that we previously observed. These effects may be mediated through 
transcriptional changes in another tissue such as the liver, known to respond metabolically to 
lipid consumption (Morgan et al. 2008). Links between hepatic expression of genes involved 
in the regulation of estrogenic compounds and breast cancer pathogenesis have been 
previously reported (Gong et al. 2007). This appears to be supported by our findings that 36 
of the 211 genes differentially expressed in the liver between the two dietary treatments were 
involved in cancer processes (la Merrill et al 2009). It is also possible that the time point of 
tissue collection could be masking the diet effect. The axillary tumors were harvested at 11 
weeks of age, therefore only providing a transcriptional picture of the tumors after they had 
been growing for several weeks. It is feasible that dietary induced changes are programmed 
into the tumor as it is beginning to develop, in which case we would likely fail to detect the 
presence of eQTL by diet interactions in axillary tumor collected at 11 weeks. While having 
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expression profiles from several time points could possibly provide insight into the etiology 
of dietary fat effects upon the tumors, these would come at the expense of the number of 
arrays evaluated per time point, reducing our power to detect eQTL. 
The evaluation of the Oncomine database provides additional support for several of 
the candidates being involved in the development of metastatic mammary cancer. In addition 
the Oncomine results could potentially indicate which candidates might be clinically 
important in both humans and mice. Our analysis of this database yielded results that appear 
to support the link between H2afv and metastatic mammary cancer. Not only did we 
implicate H2afv as a candidate for the metastatic QTL on Chr 11 through causality analysis, 
the Oncomine evaluation supported a link between increased expression of this gene and a 
poorer clinical prognosis in humans. Another candidate, Dusp4 was implicated by Oncomine 
as a modifier of metastatic mammary cancer in humans as well. Dusp4, a member of the 
dual-specificity phosphatase family, has been previously implicated as a potential tumor 
suppressor in a variety of cancer types (Chitale et al. 2009; Sieben et al. 2005) and may be 
potentially a strong candidate for the metastatic modifier identified on Chr 8 in our prior 
QTL analysis.  
Whereas the evaluation of this database indentified several candidates that potentially 
influence the development of metastatic mammary cancer in both mice and humans, 
candidates not detected could also be modifiers of this disease in humans as well. One 
particular gene not identified in the Oncomine evaluation, which has been previously 
associated with metastatic mammary cancer in humans, is butyrophilin (Btn1a1) (Woelfle et 
al. 2003). Btn1a1 was previously reported as being expressed significantly lower in mice 
with tumors metastasizing versus those without metastasis (la Merrill et al 2009). Subsequent 
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eQTL analysis provided evidence that Btn1a1 is a potential modifier of the metastatic locus 
on Chr 13 (la Merrill et al. 2009).  
 
Evaluation of master regulatory regions: 
An additional use for causality testing is the ability to investigate genomic regions 
enriched with trans-eQTL. By applying the same methodologies used to detect H2AFV as a 
candidate for the metastatic locus on Chr 11 to these regions, we identified two cis-eQTL 
causally associated with a significant number of trans-eQTL. A cis-eQTL detected for Pkia, 
located at 5.4 cM on Chr 3, with a confidence interval extending from 4.4 cM to 17.4 cM, 
formed causal associations with 95% of the trans-eQTL located within this putative master 
regulator interval. The protein encoded by Pkia contributes to the inhibition of protein kinase 
A (PKA), a protein known to alter the functionality of numerous proteins via phosphorylation 
(Lum et al. 1999). The phosphorylation properties of PKA and the fact that it is a critical 
regulator of several metabolic pathways (Taylor et al. 2004) may provide the link between 
Pkia and the trans-eQTL mapping to Chr 3, which have top network functions that include 
several metabolic processes (Table 8) (as indicated by IPA) known to be regulated by PKA. 
On Chr 19 the peak of the cis-eQTL for Pkd2l1 mapped to 34.5 cM, well away from 
the master regulatory region at 13-17 cM. However, the master regulatory region was 
contained within the confidence interval detected for this eQTL. Results also indicated that it 
was casually associated with 90 % of the trans-eQTL in this master regulatory region. This 
gene encodes the protein TRPP2, a member of the transient receptor potential cation channel 
family. This protein is critical for the function of numerous biological processes across many 
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tissue types (Giamarchi et al. 2006). A link between this protein and the trans-eQTL appears 
to be supported by the fact that when the trans-eQTL are evaluated using IPA, several of the 
top functions are involved in the processes of the cell cycle, cellular growth and molecular 
transport (Table 8), all of which TRPP2 could impact.  
Confirmation of the relationship between both Pkia and Pkd2l1 and the trans-eQTL 
they are causally associated with has yet to be confirmed. However, our results suggest that 
causality testing might potentially be a useful tool for investigating the structure of master 
regulatory regions. Additionally, these results suggest that it is important to not only evaluate 
the relationship between the trans and cis-eQTL mapping within the master regulatory 
region, but to evaluate cis-eQTL with confidence intervals that encompass the master 
regulatory region of interest as well.  
 
Conclusions: 
 In conclusion, this work demonstrates the utility of using transcriptome mapping to 
identify candidates for previously detected QTL. This report represents is one of the most 
complete evaluations of metastatic mammary cancer to date, drawing upon on several 
techniques to provide insight into the genetic architecture of this disease. Utilizing CNV 
analysis we detected a somatic alteration on chromosome 11 that was associated with 
increased expression of Ascc2, a gene for which a cis-eQTL was detected as a potential 
candidate for a metastatic modifier on Chr 11. Additionally, to our knowledge this is the first 
eQTL analysis to report eQTL by diet interactions. Whereas only a few interactions were 
detected, their identification highlights the importance of accounting for eQTL by 
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environment interactions in transcriptional mapping studies in order to properly interpret the 
results. Furthermore, the use of causality testing provided insight into the relationship 
between the cis-eQTL detected for H2afv and the metastatic loci on Chr 11. The potential 
roles of H2afv and Dusp4 in metastatic mammary cancer were further supported by our 
evaluation of the Oncomine database. The use of causality analyses also provide an 
interesting look at the structure of our master regulator regions on Chr 3 and 19 and helped 
identify two potential master regulator candidates, Pika and Pkd2l1. Ultimately, these 
findings may provide additional insight into the intricate cascade of metastatic mammary 
cancer, which can be potentially applied in a clinical setting. The increased understanding of 
this disease could provide both, a predictive analysis of cancer pathogenesis, and possible 
targets for therapeutic interventions. 
 
 
 
 
 
 
 
 
 
 132 
 
Table 5.1: Significant correlations between gene expression and metastatic phenotype 
after adjustment for multiple test comparisons in animals fed the MCD 
Gene Chr Correlation Raw P-value Adjusted Function 
Ubc 5 -0.53 0.000005 0.041 Unknown 
S100a3 3 0.50 0.000014 0.041 
calcium ion binding, protein 
binding  
4933428G20Rik 11 -0.50 0.000017 0.041 Unknown 
Arhgap17 7 -0.49 0.000023 0.041 protein binding  
Nrm 17 -0.49 0.000029 0.041 Unknown 
Bscl2 19 -0.49 0.000031 0.041 Unknown 
Vps53 11 -0.49 0.000031 0.041 Unknown 
Psmd3 11 -0.48 0.000033 0.041 
protein binding , enzyme 
regulatory activity 
Slc25a39 11 -0.48 0.000039 0.041 Binding 
Sdhc 1 -0.48 0.000040 0.041 
succinate dehydrogenase 
activity 
Ctsk 3 -0.47 0.000051 0.042 
protein binding , peptidase 
activity 
Col1a1 11 -0.47 0.000056 0.042 ECM structure, protein binding  
Col5a1 2 -0.47 0.000056 0.042 ECM structure, integrin binding  
Sfpq 4 -0.47 0.000058 0.042 
nucleotide binding, protein 
binding  
Hist1h4m 13 0.46 0.000085 0.054 Unknown 
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Table 5.2: Candidate eQTL based on proximity to metastatic QTL  
Accession Symbol Chr LRT LOD 
eQTL peak 
(cM)a 
eQTL to Gene 
(cM)b 
eQTL to QTL 
(cM)c 
NM_183019.1 9330140K16Rik 1 23.3 5.1 19.9 2.0 12.9 
NM_133791.3 Wwc2 8 20.4 4.4 28.2 1.1 2.8 
NM_023312.2 Ndufa13 8 91.6 19.9 36.2 7.0 5.2 
NM_032544.2 Gtpbp3 8 24.9 5.4 36.2 8.0 5.2 
NM_028993.2 9130404D08Rik 8 24.4 5.3 38.2 5.0 7.2 
NM_176933.3 Dusp4 8 33.1 7.2 22.2 1.2 8.8 
 
9530006C21Rik 8 45.6 9.9 21.2 0.7 9.8 
NM_019733 Rbpms 8 77.6 16.9 21.2 0.8 9.8 
XM_109956 Wwc1 11 34.6 7.5 13.9 8.4 0.1 
NM_177364 Sh3pxd2b 11 47.4 10.3 15.9 4.3 1.9 
NM_029291.1 Ascc2 11 23.9 5.2 9.9 7.0 4.1 
NM_009288.1 Stk10 11 18.4 4.0 19.9 0.4 5.9 
NM_008698.1 Nipsnap1 11 22.4 4.9 7.9 4.9 6.1 
XM_109868 Tens1 11 77.1 16.8 6.9 1.6 7.1 
XM_488586 2210015D19Rik 11 93.6 20.3 6.9 3.4 7.1 
XM_126043.3 H2afv 11 110.0 23.9 5.9 1.9 8.1 
NM_134033.1 Ccdc117 11 67.6 14.7 3.9 0.5 10.1 
NM_178187.2 Hist1h2ae 13 40.3 8.8 13 1.4 0 
NM_024274.1 Fars1 13 61.4 13.3 15 7.5 2 
NM_015786 Hist1h1c 13 134.9 29.3 10 4.5 3 
NM_198093.2 Elmo1 13 16.7 3.6 9 3.6 4 
NM_025387.1 Tmem14c 13 155.0 33.7 17 8.4 4 
NM_026947.2 1810022C23Rik 13 18.6 4.0 18 3.5 5 
NM_175655.1 **Hist1h4f 13 28.2 6.1 18 3.6 5 
NM_013483.1 **Btn1a1 13 33.8 7.4 7 7.3 6 
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NM_178194.2 Hist1h2be 13 31.3 6.8 5 9.4 8 
NM_008112.2 Gdi3 13 129.4 28.1 4 1.8 9 
NM_009124.2 Sca1 13 49.0 10.6 25 3.2 12 
NM_019568 Cxcl14 13 16.5 3.6 25 9.3 12 
NM_173442.1 Gcnt1 19 23.5 5.1 14.5 4.2 1 
NM_173442.1 Gcnt1 19 45.0 9.8 14.5 4.2 1 
NM_026487.2 Atad1 19 16.2 3.5 13.5 6.5 2 
NM_009199.1 Slc1a1 19 27.9 6.1 19.5 1.9 4 
NM_028595 Ms4a6c 19 16.3 3.5 10.5 3.8 5 
NM_021890 Fads3 19 39.0 8.5 10.5 4.7 5 
NM_146097.1 Cbwd1 19 133.6 29.0 20.5 5.4 5 
NM_013754.1 Insl6 19 55.7 12.1 21.5 3.6 6 
NM_026169.3 Frmd8 19 20.3 4.4 8.5 5.0 7 
NM_134154.1 Slc25a45 19 30.6 6.6 5.5 2.0 10 
NM_021474.2 Efemp2 19 75.9 16.5 4.5 1.2 11 
NM_019861.1 Ctsf 19 45.8 10.0 4.5 1.6 11 
NM_016892.2 Ccs 19 16.8 3.7 4.5 1.6 11 
AK032179 Saps3 19 23.5 5.1 3.5 1.5 12 
NM_021460.1 Lip1 19 141.4 30.7 28.5 7.4 13 
 
aeQTL peak: The estimated peak position of the eQTL in cM 
beQTL to gene: The distance in cM from the peak eQTL position to the position of the gene it 
represents. 
ceQTL to QTL: The distance in cM from the peak eQTL position to the nearest metastatic 
QTL 
**
 Genes previously reported as differentially expressed between tumors of varying 
metastatic tendencies.   
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Table 5.3: Candidate eQTL based on proximity to tumor growth and latency QTL 
Accession Symbol Chr LRT LOD 
eQTL peak 
(cM)a 
eQTL to Gene 
(cM)b 
eQTL to QTL 
(cM)c 
NM_021099 Kit 5 48.7 10.6 43.6 3.0 4.1 
NM_175270.2 5730467H21Rik 5 54.2 11.8 48.6 9.1 9.1 
NM_007635.2 Ccng2 5 40.0 8.7 49.6 8.3 10.1 
NM_016974.1 Dbp 7 16.7 3.6 32 7.1 10.0 
AK030267 4933439J20Rik 7 18.4 4.0 54 6.1 12.0 
XM_135023.2 2610018I03Rik 9 55.0 12.0 45.2 9.0 10.8 
AK004616 Slc21a2 9 32.6 7.1 60.2 4.2 4.2 
NM_009275.2 Srprb 9 33.5 7.3 62.2 2.3 6.2 
NM_009153.1 Sema3b 9 69.3 15.1 60.2 7.1 4.2 
NM_199195.1 Bckdhb 9 54.0 11.7 46.2 6.6 9.8 
NM_008112.2 Gdi3 13 
129.
4 28.1 4 1.8 15.0 
NM_178194.2 Hist1h2be 13 31.3 6.8 5 9.4 14.0 
NM_013483.1 Btn1a1 13 33.8 7.4 7 7.3 12.0 
NM_198093.2 Elmo1 13 16.7 3.6 9 3.6 10.0 
NM_015786 Hist1h1c 13 
134.
9 29.3 10 4.5 9.0 
NM_178187.2 Hist1h2ae 13 40.3 8.8 13 1.4 6.0 
AK021333 Btn1a1 13 21.1 4.6 14 0.3 5.0 
NM_024274.1 Fars1 13 61.4 13.3 15 7.5 4.0 
NM_025387.1 Tmem14c 13 61.5 13.4 17 8.4 2.0 
NM_025387.1 Tmem14c 13 
155.
0 33.7 17 8.4 2.0 
NM_175655.1 Hist1h4f 13 28.2 6.1 18 3.6 1.0 
NM_026947.2 1810022C23Rik 13 18.6 4.0 18 3.5 1.0 
NM_009124.2 Sca1 13 49.0 10.6 25 3.2 6.0 
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NM_019568 Cxcl14 13 16.5 3.6 25 9.3 6.0 
NM_023879.1 Rpgrip1 14 38.7 8.4 27.9 1.6 12.1 
NM_027436.1 Mipep 14 91.4 19.9 27.9 6.7 12.1 
NM_009029.1 Rb1 14 24.6 5.4 33.9 8.3 6.1 
NM_016903.2 Esd 14 20.7 4.5 45.9 2.7 5.9 
320628 A130038J17Rik 14 20.9 4.5 45.9 0.1 5.9 
NM_008549.1 Man2a1 17 31.7 6.9 29.2 9.8 12.8 
78592 A330106M24Rik 17 35.8 7.8 39.2 5.9 2.8 
NM_152817.2 2610511O17Rik 17 18.0 3.9 44.2 1.2 2.2 
NM_144802.2 2810036L13Rik 17 29.3 6.4 46.2 2.5 4.2 
 
aeQTL peak: The estimated peak position of the eQTL in cM 
beQTL to gene: The distance in cM from the peak eQTL position to the position of the gene it 
represents. 
ceQTL to QTL: The distance in cM from the peak eQTL position to the nearest tumor 
growth/latency QTL 
 
 
 
 
 
 
 
 
 137 
 
Table 5.4: IPA Evaluation for cis/trans-eQTL 
 
Mapped 
Id'sa 
Eligible 
eQTLb Bio functions
c Networksd 
cis-acting 
eQTL 206 117 
Cancer  
(25) 
Cell death, Lipid metabolism, Small 
molecule biochemistry  
(22) 
   
Cellular 
movement  
(10) 
Lipid metabolism, Small molecule 
biochemistry, cell morphology  
(20) 
   
Gastrointestinal 
Disease  
(6) 
Genetic disorder, Neurological disease, 
Ophthalmic disease  
(14) 
   
Cell cycle  
(9) 
Amino acid metabolism, Cancer, 
Carbohydrate metabolism  
(14) 
     
trans-
acting 
eQTL 
808 515 
Carbohydrate 
metabolism  
(14) 
Gene expression, DNA replication and 
repair, Endocrine system disorders 
(32) 
   
Small molecule 
biochemistry  
(54) 
Drug metabolism, Cancer, Lipid 
metabolism 
(31) 
   
Gene expression  
(21) 
Carbohydrate metabolism, Small 
molecule biochemistry, immune 
response 
(31) 
   
Cancer  
(174) 
Gene expression, Cellular development, 
Nervous system development/function 
(29) 
 
a 
 The number of candidates that were found in the IPA database 
b 
 The number of candidates that had corresponding bio-function and network information in 
the IPA database 
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c 
 The top bio-functions as indicated by IPA . The number in () indicates how many of the 
candidates from the eligible list are involved in the function  
d
  The functions of the top networks as indicated by IPA. The number in () indicates how 
many of the candidates are in the particular network 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
Table 5.5: Significant cis-eQTL by diet interactions   
Symbol Chr Interactiona LRT 
eQTL 
peak 
E030013I19Rik 2 MCD 18.48 13.8 
Dnajc1 2 MC 23.40 7.8 
Slc43a3 2 B 42.13 46.8 
Accs 2 HFD 22.93 55.8 
Wfdc3 2 MCD 47.08 94.8 
Prdx2 8 MCD 16.70 52.2 
Bckdhb 9 MCD 54.01 46.2 
Gdi3 13 MCD 129.35 4 
D14Ertd449e 14 HFD 85.90 15.9 
Basp1 15 BD 23.16 16.4 
E4f1 17 BD 18.25 13.2 
Notch4 17 MCD 26.02 14.2 
Frmd8 19 BD 20.31 8.5 
Ms4a6c 19 MCD 16.26 10.5 
Pkd2l1 19 MCD 24.48 34.5 
 
aInteraction: (HFD) Significant effect in high-fat diet only; (MCD) Significant effect in the 
control diet only; (B) Differential effects in high-fat and control diets 
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Table 5.6: Causality results between cis-eQTL and metastatic phenotype   
Marker (cM)a Chr eQTL Phenotype Relationshipb P-value 
      
C1L10 (34.1) 1 3222401M22Rik Met  Independent 0.04 
      
C8L3 (20.5) 8 Afg3|1 Met Independent 0.05 
C8L6 (30.4) 8 Gtbp3 Met Independent 0.05 
      
C11L2 (2.9) 11 H2afv Met  Causal 0.05 
      
C19L6 (12.8) 19 6430407L02Rik Met  Independent 0.04 
C19L6 (12.8) 19 AW491445 Met  Independent 0.04 
C19L6 (12.8) 19 1200004M23Rik Met  Independent 0.04 
C19L6 (12.8) 19 Gcnt1 Met  Independent 0.05 
C19L9 (23.3) 19 1200004M23Rik Met  Independent 0.05 
 
a  Marker: The genetic marker (Gordon et al. 2008b)used as the anchor for the analysis 
b
 Relationship: Testing of the association between the marker, eQTL and phenotype 
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Table 5.7: Results from Oncomine database evaluation 
Symbol Chr NF a EE positive b EE negative c  
9330140K16Rik 1 x   
Wwc2 8   1 
Ndufa13 8  2 2 
Gtpbp3 8 x   
9130404D08Rik 8 x   
Dusp4 8  9  
9530006C21Rik 8 x   
Rbpms 8  4  
Wwc1 11   1 
Sh3pxd2b 11 x   
Ascc2 11 x   
Stk10 11  1 4 
Nipsnap1 11  1 1 
Tens1 11   1 
2210015D19Rik 11 x   
H2afv 11   7 
Ccdc117 11 x   
Hist1h2ae 13   4 
Btn1a1 13 x   
Fars1 13   1 
Hist1h1c 13   4 
Elmo1 13 x   
Tmem14c 13 x   
1810022C23Rik 13 x   
Hist1h4f 13 x   
Btn1a1 13 x   
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Hist1h2be 13   3 
Gdi3 13   1 
Sca1 13  4  
Cxcl14 13  5  
Gcnt1 19  1 2 
Gcnt1 19  1 2 
Atad1 19 x   
Slc1a1 19  4  
Ms4a6c 19 x   
Fads3 19 x   
Cbwd1 19  1  
Insl6 19 x   
Frmd8 19 x   
Slc25a45 19   1 
Efemp2 19   1 
Ctsf 19 x   
Ccs 19 x   
Saps3 19 x   
Lip1 19 x   
 
The 45 candidates for the Metastatic QTL were evaluated in the Oncomine database to 
determine if a potential association between their expression and formation of metastasis has 
been previously reported in humans. 
a  NF: An x indicates that the particular candidate was not found in the Oncomine human 
breast cancer prognosis datasets 
b
 EE positive: Indicates the number of studies reporting that increased expression is 
significantly associated with a positive (no metastasis, alive, disease free) clinical outcome. 
c
 EE negative: Indicates the number of studies reporting that increased expression is 
significantly associated with a negative (metastasis, dead, relapse) clinical outcome. 
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Table 5.8: IPA Evaluation for trans-eQTL in Master regulator intervals 
 Mapped 
Id'sa 
Eligible 
eQTLb 
Networksc 
MR  
Chr 3 
85 65 
Carbohydrate metabolism, Drug metabolism, Small 
molecule biochemistry 
(16) 
   
Cell cycle, cancer, Hematological disease 
(15) 
   
Carbohydrate metabolism, Small molecule 
biochemistry, Connective tissue development and 
function 
(14) 
   
Endocrine system development, Lipid metabolism, 
Small molecule biochemistry 
(14) 
    
MR  
Chr 19 
49 45 
Cancer, Cell-to-cell signaling and interaction, 
Cellular assembly and organization 
(13)  
   
Cancer, Reproductive system disease, Tumor 
morphology 
(11) 
   Cancer, Cellular function and maintenance, 
Respiratory disease 
(11) 
   Amino acid metabolism, Molecular transport, Small 
molecule biochemistry 
(1) 
a 
 The number of candidates that were found in the IPA database 
b 
 The number of candidates that had corresponding network information in the IPA database 
c
  The functions of the top networks as indicated by IPA. The number in () indicates how 
many of the candidates are in the particular network 
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Figure 5.1: Causality Evaluation Models: The three causality models tested. The causal 
model is where genetic alterations (G) result in changes in the expression of an cis-acting 
eQTL (C), which in turn result in modification of the phenotype or change in gene expression 
of a trans-acting eQTL (P/T). In the reactive model, variation in G directly impacts P/T 
resulting in altered gene expression of C. The third model evaluates whether variation in G 
can result in changes in both P/T and C independently. 
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A. Number of cis/trans on each chromosome  
 
B. Map of expression QTL (eQTL) 
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Figure 5.2: eQTL Mapping: The eQTL mapping results. A: The number of cis and trans-
eQTL detected on each chromosome at the significance LRT threshold of 16.1. B: Mapping 
of expression QTL (eQTL). Physical gene positions on the microarray are plotted along the 
y-axis and the genetic locations of the QTL are plotted along the x-axis. eQTL along the cis 
diagonal map within 10 cM of the transcript that they represent. eQTL acting in trans map to 
a different chromosome than the transcript they represent. ^Master regulators are eQTL 
acting in cis that map to a region associated with many trans-acting eQTL. 
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A.  cis-eQTL colocalizing with the metastatic locus on Chr 8 
 
B.  cis-eQTL colocalizing with the metastatic locus on Chr 11 
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C.  cis-eQTL colocalizing with the metastatic locus on Chr 13 
 
D.  cis-eQTL colocalizing with the metastatic locus on Chr 19 
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Figure 5.3: Metastatic QTL candidates: Metastatic QTL with colocalizing candidates. A: 
Cis-eQTL colocalizing with the metastatic locus on Chr 8. B: Cis-eQTL colocalizing with the 
metastatic locus on Chr 11. C: Cis-eQTL colocalizing with the metastatic locus on Chr 13. D: 
Cis-eQTL colocalizing with the metastatic locus on Chr 19. 
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A.  cis-eQTL colocalizing with the Inguinal tumor growth locus on Chr 5 
 
B.  cis-eQTL colocalizing with the Tumor Latency locus on Chr 7 
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C.  cis-eQTL colocalizing with the Tumor Latency locus on Chr 9 
 
D.  cis-eQTL colocalizing with the Tumor Latency locus on Chr 13 
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E. cis-eQTL colocalizing with the Latency and # of Tumors at Sacrifice loci on Chr 14 
 
F.  cis-eQTL colocalizing with the Axillary Tumor Growth locus on Chr 17 
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Figure 5.4: Primary Tumor QTL candidates: Primary Tumor QTL with colocalizing 
candidates. A: Cis-eQTL colocalizing with the inguinal tumor growth locus on Chr 5. B: Cis-
eQTL colocalizing with the tumor latency locus on Chr 7. C: Cis-eQTL colocalizing with the 
tumor latency locus on Chr 9. D: Cis-eQTL colocalizing with the tumor latency locus on Chr 
13. E: Cis-eQTL colocalizing with the tumor latency loci and total number of tumors at 
sacrifice loci on Chr 14. B: Cis-eQTL colocalizing with the axillary tumor growth locus on 
Chr 17. 
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Figure 5.5: Examples of Copy Number Variation (CNV) in the F2 Population: Examples 
of Copy Number Variation (CNV) found in the F2 Population. A snapshot of the CNV found 
within the F2 population. Examples from three separate chromosomes (8, 9 and 10) are 
shown. 
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A. 
 
B. 
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C. 
 
 
Figure 5.6: Evaluation of Copy Number Variation (CNV): Evaluation of Copy Number 
Variation (CNV). A: The impact of the Chr 8 CNV on the development of pulmonary 
metastasis. A duplication of this region was associated with a significant increase metastatic 
formation. B: The impact of the Chr 11 CNV on pulmonary metastasis development. The 
presence of an additional copy in this region was associated with a significant reduction in 
metastatic development. C: The impact of the Chr 11 CNV upon the expression of Ascc2. 
The presence of an additional copy in this region was associated with a significant increase in 
the expression of Ascc2. 
 
 
  
CHAPTER VI 
Synthesis 
Introduction 
Breast cancer is the most common cancer type, and the second-leading cause of 
cancer-related deaths in women (National-Cancer-Institute 2005). In 2008, over 180K 
women in the United States were diagnosed with some form of breast cancer and over 40K 
women died as a result of having this disease, typically from secondary metastatic 
malignancies (American-Cancer-Society 2009). Furthermore, it has been estimated that each 
year over $8B are spent on breast cancer treatment (National Cancer Institute 2007).  
A complex relationship exists between diet and the genetic architecture of metastatic 
mammary cancer. Genetic predisposition to breast cancer has been confirmed by 
identification of multiple, small to low effect familial risk factors, but the evidence linking 
dietary fat to breast cancer susceptibility is less consistent. Whereas some human studies 
have shown a link between increased breast cancer and increased fat intake (Cho et al. 2003; 
Lee et al. 2005; Thiebaut et al. 2007), others have failed to replicate these findings (Kim et 
al. 2006; Wakai et al. 2005). Given this lack of congruity and the large number of individuals 
afflicted with this disease, a need exists to clarify further the linkage between diet and cancer. 
Therefore, we tested the hypothesis that mice predisposed to mammary tumor development 
and challenged with either high or normal levels of dietary fat will experience variability in 
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the pathogenesis of mammary cancer as a result of variations in genetic predisposition and 
gene expression. A summary of our experiments and a synthesis of our findings follows. 
 
Population Development and Phenotype Characterization 
An F2 population (n = 615) was generated by crossing M16i, a polygenic obesity line 
(Allan et al. 2005), and FVB/NJ-TgN(MMTV-PyMT)634Mul (PyMT), a line transgenic for 
the Polyoma Middle T Oncoprotein, leading to the development of mammary tumors and 
subsequent pulmonary metastasis (Guy et al. 1992b). F2 mice were weaned at 3 weeks of age 
and randomly assigned, within litter, sex, and genotype (PyMT or no PyMT), to receive one 
of two synthetic purified diets at 4 weeks of age. Mice had ad libitum access to water and to 
their assigned feed, either a high-fat diet (Research Diets D12451) containing 45% of total 
calories from fat, 20% from protein, and 35% from carbohydrates or a matched-control-fat 
diet (Research Diets D12450B) containing 10% of total calories from fat, 20% from protein, 
and 70% from carbohydrates.  
The primary objective of our studies was to investigate the genetics of metastatic 
mammary cancer and the link between dietary fat and this disease. However, our 
experimental design also provided the opportunity to evaluate the effect of high-fat diet upon 
body weight and body composition in our genetically diverse F2 population. Body weight 
was measured for each mouse at 3, 6, and 9 wk of age and at sacrifice (~11 wk for females, 
~14 wk for males) and as expected the consumption of a high-fat diet resulted in increased 
weight gain at all time points regardless of gender and PyMT status, except for weight of 
both genders at 3 wk of age. Body composition measurements were collected at 7 wk of age 
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and at sacrifice using dual-energy X-ray absorptiometry. Similar to the results for body 
weight the animals fed the high-fat diet had significantly higher total body depositions of 
adipose tissue compared to animals fed the control-fat diet. 
In order to ascertain the impact of dietary fat on the metastatic cancer paradigm, each 
mouse was evaluated for age at mammary tumor onset, tumor progression, and pulmonary 
metastases development. Results demonstrated that female mice fed a high-fat diet 
experienced a shortened period of mammary cancer latency of approximately 7.15% 
compared to female mice fed the control-fat diet. While the total number of tumors detected 
at sacrifice did not differ between the two dietary treatments, the weights of the axillary and 
inguinal tumors were significantly heavier in animals fed the high-fat diets. Interestingly, the 
increased tumor mass detected in mice fed the high-fat diet was not the result of increased 
adipose in tumors, as the tumors per se in mice fed a high-fat diet actually had a lower 
percent fat content. This finding suggests that the tumor epithelial growth may be more 
aggressive as a result of consumption of a high-fat diet.  
In addition to the evaluation of the primary tumors, the pulmonary metastatic burden 
was evaluated at the time of sacrifice. Within the group of female mice that developed 
pulmonary metastases, a significant increase in metastatic load was observed in mice fed the 
high-fat diet relative to mice fed the control-fat diet. 
 
QTL Evaluations 
 To elucidate the genetic underpinnings controlling both the body composition and the 
metastatic mammary cancer traits, and evaluate a possible genetic basis for the dietary effects 
 161 
 
on cancer phenotypes, a large percentage of the F2 population was genotyped for 384 SNP 
markers. Genomic regions of interest for metastatic mammary cancer and body composition 
traits were localized by integrating SNP genotypes with the aforementioned phenotypes to 
identify quantitative trait loci (QTL). This analysis supported identification of 38 modifier 
loci for body composition and 25 modifier loci for mammary cancer and pulmonary 
metastasis, likely representing 9 and 13 unique loci after accounting for pleiotropy, 
respectively. While the majority of QTL detected were located in regions previously 
implicated in body composition or metastatic mammary cancer, a few of these loci 
represented novel discoveries, including a modifier of tumor onset on Chr 1 and a metastatic 
modifier on Chr 8.  
To evaluate the extent of overlap between obesity and metastatic cancer loci, the QTL 
positions from both phenotypes were compared and pleiotropy testing was performed. Only a 
small number of the cancer modifiers detected were in similar locations to obesity QTL that 
were mapped in the same population, and these cancer modifiers do not appear to result from 
pleiotropic effects of obesity loci. At first this seemed surprising, given the recent evidence 
that links obesity and cancer in humans (Hursting et al. 2007). Although this is only a single 
cross with limited power, it is possible that the obesity-cancer link has stronger 
environmental underpinnings relative to a genetic correlation. Our analyses were focused 
more on the effects of dietary fat on cancer, and the interaction between dietary fat and 
cancer modifiers, rather than the obesity-cancer linkage. 
The experimental design of this F2 population supported testing the hypothesis that 
animals fed a high-fat diet would have more advanced cancer phenotypes as a result of 
underlying QTL x diet interactions. This experiment revealed that 64% of all cancer 
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modifiers detected had significant diet interactions, and of these interactions, nine were 
caused by modifier effects being detected only in animals fed the high-fat diet, while three 
were detected only in mice fed the control-fat diet. These results implicate interactions of diet 
and modifier genes as a mechanism through which diet may affect breast cancer and 
metastasis. 
Gene Expression Analysis 
 To investigate the complex genetic architecture that underlies metastatic mammary 
cancer in greater depth, i.e.; factors that modify the mammary diet-cancer-metastasis linkage, 
expression profiles of axillary tumors were characterized for a subset of the F2 population 
with the Illumina Mouse-6 whole genome sentrix arrays. The differential expression analysis 
revealed an interesting primary result; at an False Discovery Rate (FDR) of p < 0.05, very 
few genes were differentially expressed in mice on the two diets. However, as the 
significance threshold was relaxed, a substantial number of differentially expressed genes, 
were identified. This finding suggests that dietary fat may modulate the expression of many 
genes in this paradigm, but only to a small extent.  
The relationship between genes expressed in the axillary tumors and the metastatic 
phenotype was investigated by comparing the expression profiles from mice with low and 
high metastatic tendencies. A total 690 genes was differentially expressed at an FDR of p < 
0.05. Entering the differentially expressed genes into the Ingenuity Pathway Analysis (IPA) 
revealed that the functions of many of these genes were involved in the processes of 
proliferation, inflammation, angiogenesis, and invasion. The multiple functions identified by 
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IPA provide a potential link between the genes identified by differential expression and 
metastatic mammary cancer. 
eQTL Evaluation 
Following differential expression analyses, the normalized data were entered into a 
systems-based analysis pipeline developed in R, facilitating a genome-wide expression QTL 
eQTL analysis as well as network and pathway QTL analyses. The resulting eQTL were 
classified in one of two categories: “cis” if they mapped within 10 cM of the physical 
location of the gene they represent, and “trans” if they mapped elsewhere. Clusters 
containing 50 or more eQTL within a 5 cM interval were designated as potential master 
regulatory regions. This analysis yielded the detection of 220 cis-acting eQTL and 890 trans-
acting eQTL. Additionally, two potential master regulatory regions were identified on Chr 3 
and 19. While the trans-acting eQTL represent loci controlled by unknown regulators, cis-
acting eQTL exhibit self-regulation (Alberts et al. 2005). As such, by comparing/overlaying 
these cis-acting eQTL with the phenotypic cancer QTL detected in this population, the 
capability exists to reveal potential unknown polygenes (or at least to provide candidates) 
that influence the metastatic mammary cancer phenotype. Utilizing this method enabled the 
detection of 76 potential candidates for the previously detected metastatic QTL.   
To further refine the candidate gene list of metastatic mammary cancer modifiers the 
relationship between the cis-eQTL and the observed metastatic loci was evaluated using 
causality analysis. An eQTL causally associated with a metastatic locus may represent the 
actual underlying genetic modifier of the phenotype of interest. The results revealed that very 
few significant relationships existed between cis-eQTL and metastatic virulence QTL. 
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However, one weak causal relationship bordering on the threshold of significance was 
detected between H2afv and the metastatic modifier on chromosome 11. 
When previously evaluating this population for QTL, we found that the majority of 
cancer related loci exhibited interactions with diet. As such it was possible that the cis-acting 
eQTL would likewise interact with dietary fat. A cis-acting eQTL interacting with diet and 
colocalizing with a metastatic QTL exhibiting a similar interaction may represent a likely 
candidate for that particular locus. Our results however, demonstrated that very few of the 
cis-eQTL had diet interactions. 
One caveat that needs to be considered when performing an eQTL study is the degree 
of copy number variation (CNV) within the mapping population. Taking CNV into account is 
especially important when analyzing tumor tissue, given the substantial amount of evidence 
linking the accumulation of CNV to cancer pathogenesis (Fridlyand et al. 2006; Reis-Filho et 
al. 2005; van Beers and Nederlof 2006). Additionally, it remains unclear how duplications or 
deletions of chromosomal segments that can result in altered expression of genes residing 
within those boundaries could influence the detection of eQTL. In our population all but one 
of the cis-eQTL acted independently of CNV. Ascc2, a gene physically located on Chr 11, 
was shown to have its gene expression significantly modified by a CNV. While we detected 
very little connection between cis-eQTL and CNV in our population, the link identified 
between the CNV on Chr 11 and Ascc2, highlights the importance of evaluating CNV in 
transcriptional studies in order properly interpret the results.  
The evaluation of the publically available databases such as Oncomine provided 
support for several of the candidates being involved in the development of metastatic 
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mammary cancer. For example, our analyses yielded results that appear to support the link 
between H2afv and metastatic mammary cancer. Not only did we implicate H2afv as a 
candidate for the metastatic QTL on Chr 11 through causality analysis, the Oncomine 
evaluation supported a link between increased expression of this gene and a poorer clinical 
prognosis in humans. Another candidate, Dusp4 was implicated by Oncomine as a modifier 
of metastatic mammary cancer in humans as well. Dusp4, a member of the dual-specificity 
phosphatase family, and a potential tumor suppressor, may be a strong candidate for the 
metastatic modifier we identified on Chr 8.  
 In addition to identifying a prioritized list of candidates for the metastatic modifiers 
detected through QTL analysis, the evaluations in Chapter V provided an interesting look at 
the master regulator regions on Chr 3 and 19. On Chr 3 98 trans-acting eQTL clustered 
within a 5 cM region at the proximal portion of the chromosome. Causality analysis revealed 
that a cis-eQTL detected for Pkia formed causal associations with 95% of the trans-eQTL 
located within this putative master regulator interval. This association between the trans-
eQTL and Pkia was further supported by the IPA evaluation of gene functions. In the other 
master regulatory region on Chr 19, 60 trans-acting eQTL clustered in the 5 cM window 
which started at 13 cM and went through 17 cM. Using analyses similar to those that 
identified Pika as a potential candidate for the master regulator on Chr 3, we identified 
Pkd2l1 as a potential candidate for the master regulator on Chr 19. 
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Future Directions 
 Several investigative approaches may be utilized in future experiments to gain a 
better understanding of the genetic architecture of metastatic breast cancer. These 
experiments should build upon the findings described in this dissertation. 
 
Validation of Candidates: As described in the previous section, we were able to 
indentify several candidate genes that can potentially alter the pathogenesis of metastatic 
mammary cancer in mice. A logical direction for future experiments would be to explore 
further the role that these genes play in the processes of metastatic mammary cancer. In 
pursuit of this validation, we attempted to ligate several of the top priority genes into the 
pEF6/V5-His TOPO® TA mammalian expression vector (Invitrogen, Carlsbad, CA) for 
transfection into the Mvt1 cell line (Pei et al. 2004). Whereas we were able to develop 
vectors that over-expressed particular candidates of interest, the transfection into the Mvt1 
cell line proved problematic. In culture, the Mvt1 cells were unable to survive with the 
increased expression of the candidate genes, and we were not able to characterize the effect 
of over-expressing these genes in-vivo. 
 While the over-expression of a candidate gene has the potential to be a viable 
technique for the validation of some genes, alternate approaches might be pursued as well. 
RNA interference (RNAi) could be used to induce the knockdown of candidate gene 
expression (Fire et al. 1998). A form of RNAi utilizing short hairpin RNA (shRNA) cassettes 
in a lentiviral-based vector has been shown to be effective in cell specific delivery, resulting 
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in permanent reduction of a targeted gene (Czauderna et al. 2003). This method could be 
potentially used to inhibit the expression of candidate genes in the Mvt1 cell line. 
If the expression of a particular gene could be altered in the Mvt1 without 
compromising the cells, then the Mvt1 cells could be subcutaneously injected into the 
mammary gland of 6-week old virgin FVB/NJ female mice. Similar to a protocol previously 
described (Park et al. 2005), these mice would be allowed to age for four weeks, at which 
point they would be sacrificed by anesthetic overdose. Tumors would then be dissected and 
weighed. The lungs could then be removed and evaluated under a dissecting microscope to 
determine the number of pulmonary metastases on the surface. Both tumor weights and 
number of metastases would be compared to mice injected with Mvt1 cells transfected with a 
control vector. This comparison would provide the opportunity to physically evaluate the 
impact that altered-expression of a gene of interest has had upon both the tumor’s growth and 
its metastatic potential. 
 
Investigation of Master Regulators: Similar methods as described above could be 
used to further investigate the master regulator regions identified on Chr 3 and 19. Pika and 
Pkd2l1 could be over-expressed or inhibited in a mammary cancer cell line via expression 
vectors or RNAi, respectively. If stable expression or knockdown of Pika and Pkd2l1 were 
achieved, then it would be possible to evaluate with RT PCR the impact of the altered 
expression of these potential master regulators upon the expression of the genes residing in 
the master regulatory interval.  
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Alternate Tissue Evaluation: Another possible experiment that might provide 
additional insight into the processes of pulmonary metastatic mammary cancer would be to 
evaluate the expression profiles of the lungs collected from mice that developed pulmonary 
metastases. These lungs have previously been collected and snap-frozen in liquid nitrogen. 
The RNA from these lungs could be extracted and transcriptional profiles generated with the 
Illumina mouse-6-arrays. The generation of transcriptional profiles of the lungs would allow 
for several analyses. Evaluation of whether the lungs and the tumors had common expression 
patterns would be possible; genes differentially expressed between the two tissue types 
would also be analyzed. In addition to the comparisons between the expression patterns of 
the two tissue types, the correlation between lung gene expression and the development of 
pulmonary metastases could be measured as well. This analysis would help determine if any 
gene expressed in the lungs had a significant impact on the formation of metastatic breast 
cancer cells.  
Furthermore, an eQTL analysis similar to one presented in chapter 5 could be carried 
out with the expression profiles of this tissue. An eQTL analysis of the lungs could help us 
identify additional candidates for the metastatic modifiers we identified in chapter 3. Several 
cis-eQTL colocalizing with the metastatic loci unique to the lungs could be identified, and 
this evaluation might detect cis-eQTL in common between the two datasets as well. If a cis-
eQTL colocalizing with metastatic loci were detected in both the lung and tumor evaluations, 
then it would potentially be a high priority candidate for validation. 
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Alternate Time-point Collection: Evaluation of the tumor gene expression at different 
stages of tumor development could provide additional insight into the connection between 
cancer pathogenesis and dietary-fat. In the mouse population described in this dissertation, 
tumors were collected from the female mice at ~11 weeks of age, several weeks after tumors 
were first detected. When the tumors were evaluated at this time-point very few genes were 
differentially expressed between the two dietary treatments. Diet-induced gene changes may 
be programmed into the tumor at the beginning of tumor development, in which case the 
dietary effect on the axillary tumor could remain undetected at 11 weeks. To evaluate the 
expression of mammary tumors at several time-points, tumors could be surgically removed at 
different stages of their growth for genetic analysis. This time-dependent approach would 
provide the opportunity to assess the expression difference of tumors from the same 
individual as metastatic cancer progresses. Additionally, the impact of dietary fat upon the 
expression of genes at these different stages could then also be evaluated.  
  
Overall Summary      
In conclusion, this dissertation represents an innovative approach to understanding 
the paradigm of metastatic mammary cancer by evaluating the growth and metastatic 
potential of mammary tumors under the influence of genetic and environmental pressures, 
specifically modifier loci and dietary fat, respectively. In utilizing an intercross of mice 
predisposed to both mammary cancer and obesity, fed diets varying in fat percentage, we had 
the opportunity to critically evaluate the genetic and genomic underpinnings of metastatic 
mammary cancer in a controlled setting. This approach yielded several important outcomes.  
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First, we generated a genome-wide map of QTL and QTL by diet interactions for 
metastatic mammary cancer in a mammalian intercross. Second, we thoroughly evaluated the 
transcriptional networks for metastatic mammary cancer in this population and in the 
presence of two levels of dietary fat. The impact of somatic chromosomal aberrations upon 
gene expression was also explored. Finally, we prioritized genes harboring genetic variation 
that may explain deviation in mammary cancer development, severity and metastatic 
potential. These candidate genes can now be investigated using both in vivo and in vitro 
techniques to determine their impact upon mammalian metastatic mammary cancer. 
Understanding the genetic architecture and environmental interactions of this disease are 
critical given the widespread physical and financial impact that breast cancer has in our 
society. Ultimately, our data may provide additional insight into the intricate cascade of 
metastatic mammary cancer, and our results can be potentially applied in a clinical setting. 
This advance could provide both a predictive analysis of cancer pathogenesis and possible 
targets for therapeutic interventions. 
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